Document:

EX-10.5

 Exhibit 10.5 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT 

by and between 

THE BROAD INSTITUTE, INC. 

and 

BLINK THERAPEUTICS INC. 

May 9, 2018 

 TABLE OF CONTENTS 

 

							
	 1.  Definitions.
	  	 	2	 
	 2.  License.
	  	 	23	 
	 2.1
	 	License Grants	  	 	23	 
	 2.2
	 	Reservation of Rights, Certain Restrictions	  	 	24	 
	 2.3
	 	Affiliates	  	 	25	 
	 2.4
	 	Sublicenses	  	 	26	 
	 2.5
	 	Inclusive Innovation Model	  	 	28	 
	 2.6
	 	No Other Grant of Rights	  	 	38	 
	 2.7
	 	Additional Limitations on Exercise of License Rights	  	 	39	 
	 3.  Development and Commercialization.
	  	 	39	 
	 3.1
	 	Diligence	  	 	39	 
	 3.2
	 	Adjustments of Development Plan	  	 	40	 
	 3.3
	 	Regulatory Filings	  	 	41	 
	 3.4
	 	Reporting	  	 	41	 
	 3.5
	 	Failure to Meet Development Milestone: Opportunity to Cure	  	 	41	 
	 3.6
	 	Activities of Others	  	 	47	 
	 4.  Consideration for Grant of License.
	  	 	47	 
	 4.1
	 	Equity	  	 	47	 
	 4.2
	 	Annual License Maintenance Fees	  	 	49	 
	 4.3
	 	Milestone Payments	  	 	50	 
	 4.4
	 	Royalty on Net Sales	  	 	54	 
	 4.5
	 	Patent Challenge	  	 	56	 
	 4.6
	 	Non-Royalty Sublicense Income	  	 	58	 
	 4.7
	 	Complex Consideration	  	 	59	 
	 4.8
	 	Success Payments	  	 	59	 
	 4.9
	 	Assumption of Obligations	  	 	59	 
	 5.  Reports; Payments; Records.
	  	 	59	 
	 5.1
	 	Reports and Payments	  	 	59	 
	 5.2
	 	Payment Currency	  	 	60	 
	 5.3
	 	Records	  	 	61	 
	 5.4
	 	Late Payments	  	 	62	 
	 5.5
	 	Payment Method	  	 	62	 
	 5.6
	 	Withholding and Similar Taxes	  	 	62	 
	 6.  Patent Filing, Prosecution and Maintenance.
	  	 	62	 
	 6.1
	 	Control	  	 	62	 
	 6.2
	 	Common Interest	  	 	64	 
	 6.3
	 	Expenses	  	 	64	 
	 6.4
	 	Abandonment	  	 	64	 
	 6.5
	 	Marking	  	 	65	 
	 6.6
	 	CREATE Act	  	 	65	 

  
 i 

							
	 7.  Enforcement of Patent Rights.
	  	 	65	 
	 7.1
	 	Notice	  	 	65	 
	 7.2
	 	Suit by Licensee	  	 	66	 
	 7.3
	 	Suit by Broad	  	 	67	 
	 7.4
	 	Own Counsel	  	 	68	 
	 7.5
	 	Cooperation	  	 	68	 
	 7.6
	 	Patent Validity Challenge	  	 	68	 
	 7.7
	 	Declaratory Judgment	  	 	68	 
	 7.8
	 	Actions Against Infringement Outside the Field	  	 	69	 
	 7.9
	 	Licensee Actions in Support of Affiliates and Sublicensees	  	 	69	 
	 8.  Warranties and Covenant: Limitation of Liability.
	  	 	69	 
	 8.1
	 	Compliance with Law	  	 	69	 
	 8.2
	 	Merger Agreement	  	 	70	 
	 8.3
	 	Services Agreement	  	 	70	 
	 8.4
	 	Representations and Warranties	  	 	70	 
	 8.5
	 	No Warranty	  	 	70	 
	 8.6
	 	Limitation of Liability	  	 	71	 
	 9.  Indemnification and Insurance.
	  	 	71	 
	 9.1
	 	Indemnity	  	 	71	 
	 9.2
	 	Insurance	  	 	73	 
	 10.
	 	Term and Termination.	  	 	73	 
	 10.1
	 	Term	  	 	73	 
	 10.2
	 	Termination	  	 	74	 
	 10.3
	 	Effect of Termination	  	 	75	 
	 10.4
	 	Survival	  	 	77	 
	 11.  Miscellaneous.
	  	 	77	 
	 11.1
	 	Confidentiality	  	 	77	 
	 11.2
	 	Additional Permitted Disclosure	  	 	80	 
	 11.3
	 	Preference for United States Industry	  	 	80	 
	 11.4
	 	No Security Interest	  	 	81	 
	 11.5
	 	Use of Names	  	 	81	 
	 11.6
	 	Entire Agreement	  	 	81	 
	 11.7
	 	Notices	  	 	81	 
	 11.8
	 	Dispute Resolution	  	 	82	 
	 11.9
	 	Governing Law and Jurisdiction	  	 	82	 
	 11.10
	 	Binding Effect	  	 	82	 
	 11.11
	 	Headings	  	 	82	 
	 11.12
	 	Counterparts	  	 	83	 
	 11.13
	 	Amendment; Waiver	  	 	83	 
	 11.14
	 	No Agency or Partnership	  	 	83	 
	 11.15
	 	Assignment and Successors	  	 	83	 
	 11.16
	 	Force Majeure	  	 	84	 
	 11.17
	 	Interpretation	  	 	84	 
	 11.18
	 	Severability	  	 	84	 
	 11.19
	 	Publicity	  	 	84	 

  
 ii 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of this 9th
day of May, 2018 (the “Effective Date”), by and between Blink Therapeutics Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 325 Vassar St., Suite 2A, Cambridge, Massachusetts 02139
(“Licensee”), and the Broad Institute, Inc., a non-profit corporation existing under the laws of Massachusetts, having a place of business at 415 Main Street, Cambridge, MA 02142
(“Broad”). 
 WHEREAS, the technology claimed in the Patent Rights (as defined below) was discovered and developed
by researchers at Broad and the Institutions (as defined below); 
 WHEREAS, Broad, the Massachusetts Institute of Technology
(“MIT”, a not-for-profit Massachusetts Corporation with a principal place of business at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139) and/or
the President and Fellows of Harvard College (“Harvard”, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center,
Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138) are co-owners of certain of the Patent Rights set forth on Exhibit 1.117. 

WHEREAS, pursuant to that certain Operating Agreement by and among Broad, MIT and Harvard, dated July 1, 2009, MIT and Harvard
have authorized Broad to act as their sole and exclusive agent for the purposes of licensing their interest in the co-owned Patent Rights, and MIT and Harvard have authorized Broad to enter into this Agreement
on their behalf with respect to such Patent Rights. 
 WHEREAS, the research was sponsored in part by the Federal Government of the
United States of America and as a consequence this license is subject to overriding obligations to the Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations; 

WHEREAS, Licensee wishes to obtain a license under the Patent Rights; 

WHEREAS, Broad and the Institutions desire to have products based on the inventions described in the Patent Rights developed and
commercialized to benefit the public; and 
 WHEREAS, such products may be applicable to the improvement of the health of individuals
throughout the world; and 
 WHEREAS, Licensee has represented to Broad, in order to induce Broad to enter into this Agreement, that
Licensee shall commit itself to commercially reasonable efforts to develop, obtain regulatory approval for and commercialize such products, and thereafter make them available to the public. 

  
 1 

 NOW, THEREFORE, the Parties hereto, intending to be legally bound, hereby agree as
follows: 
 1. Definitions. 
 As used
in this Agreement, the terms with initial letters capitalized, whether used in the singular or plural form, shall have the meanings set forth in this Article 1 or, if not listed below, the meaning designated in places throughout this
Agreement. 
 1.1 “Abandoned Patent Rights” shall have the meaning set forth in Section 6.4.1
(Abandonment by Licensee). 
 1.2 “Achieved Milestone” shall have the meaning set forth in
Section 4.3.5 (Milestone Payments). 
 1.3 “Acquirer” shall have the meaning set forth in
Section 4.9 (Assumption of Obligations). 
 1.4 “Actual Series B Valuation Multiple” means the
number, not to exceed [**], determined by dividing the Series B Pre-Money by the Series A Post-Money. 

1.5 “Additional National Stage Filings” shall have the meaning set forth in Section 6.1.4 (Control).

 1.6 “Additional Securities” means shares of capital stock, convertible securities or warrants, options, or other rights
to subscribe for, purchase or acquire from Licensee any capital stock of Licensee; provided that, “other rights to subscribe for, purchase or acquire” shall not include (i) preemptive or other rights to participate in new offerings of
securities by Licensee after the Effective Date, (ii) obligations under a purchase agreement for preferred stock of Licensee to acquire additional shares of such preferred stock on the same terms as those purchased at an initial closing upon
the passage of time or meeting (or waiver) of specified Licensee performance conditions or (iii) anti-dilution provisions that have not been triggered. 

1.7 “Affiliate” means, with respect to a Person, organization or entity, any Person, organization or entity
controlling, controlled by or under common control with, such Person, organization or entity. For purposes of this definition only, “control” of another Person, organization or entity will mean the possession, directly or indirectly, of
the power to direct or cause the direction of the activities, management or policies of such Person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, control will
be presumed to exist when a Person, organization or entity (a) owns or directly controls more than fifty percent (50%) of the outstanding voting stock or other ownership interest of the other organization or entity or (b) possesses,
directly or indirectly, the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the other organization or entity. The Parties acknowledge that in the case of certain entities organized under the laws of
certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage will be substituted in the preceding
sentence. 

  
 2 

 Notwithstanding the foregoing definition, until the earlier of the consummation of a Change of Control of
Licensee or [**] after the closing of the Initial Public Offering of securities of Licensee, (a) the Licensee’s investors shall not be considered to be Affiliates of the Licensee for purposes of this Agreement and (b) portfolio
companies owned in whole or in part by one or more of the Licensee’s investors that have no legal connection to nor contract with the Licensee, and would not otherwise be Affiliates of Licensee but for being owned in whole or in part by one or
more of the Licensee’s investors, shall not be considered to be Affiliates of the Licensee for purposes of this Agreement. A portfolio company owned in whole or in part by the Licensee’s investors or any of them that is not an Affiliate of
the Licensee under the foregoing sentence and enters into a Sublicense agreement with Licensee shall not become an Affiliate of Licensee solely as a result of entering into such Sublicense agreement. A portfolio company that was not an Affiliate
under the foregoing in this paragraph prior to [**] after the closing of the Initial Public Offering of securities of Licensee shall not become deemed an Affiliate of Licensee merely by the passage of time (i.e., they shall retain after such
time-point their previous non-Affiliate-of-Licensee status for purposes of this Agreement, unless and until a new control
relationship is formed (after such point in time) between Licensee and the applicable portfolio company). 
 1.8 “Ag
Product” means any product comprising a plant, plant tissue, plant cell, plant part or plant seed, including any organism in the microbiome used in association with such plant, plant tissue, plant cell, plant part or plant seed, that is
used for agricultural purposes. 
 1.9 “Agreement” shall have the meaning set forth in the preamble. 

1.10 “Alternative Agreement” shall have the meaning set forth in Section 8.2 (Option Agreement).

 1.11 “Anti-Dilution Shares” shall have the meaning set forth in Section 4.1.2 (Anti-Dilution
Issuances). 
 1.12 “Applicable Law” means (a) with respect to a given jurisdiction, all applicable laws, rules and
regulations (including any rules, regulations, guidelines or other requirements of any regulatory authorities) that may be in effect from time to time in such jurisdiction, and (b) with respect to any jurisdiction that does not have laws, rules
or regulations that govern genetically modified organisms, all applicable laws, rules and regulations (including any rules, regulations, guidelines or other requirements of any regulatory authorities) of the United States federal government that may
be in effect from time to time to the extent applicable to genetically modified organisms. 
 1.13 “Bankruptcy Event” means,
with respect to any Person, any of the following: 
 1.13.1 such Person shall commence a voluntary case or other proceeding seeking
liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other
similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of, or taking possession by, any such official in an involuntary case or other proceeding commenced against it, or shall make a
general assignment for the benefit of creditors, or shall take any corporate action to authorize any of the foregoing; 

  
 3 

 1.13.2 an involuntary case or other proceeding shall be commenced against such Person
seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other
similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60) days; or an order for relief shall be entered against such Person
under the United States federal bankruptcy laws as now or hereafter in effect; or 
 1.13.3 a receiver or trustee shall be appointed with
respect to such Person or all or substantially all of the assets of such Person. 
 1.14 “Base Editor” means [**]. 

1.15 “Base Editor Patent Rights” means any Patent Rights identified under the heading “Base Editor Patent
Rights” in Exhibit 1.117 (“Listed Base Editor Patent Rights”) and any Patent Rights that fall within any of clauses (b) through (f) of Section 1.117 (“Patent Rights”) with respect
to such Listed Base Editor Patent Rights. Certain Base Editor Patent Rights are further subcategorized as “REPAIR Base Editor Patent Rights” and “RESCUE Base Editor Patent Rights” in Exhibit 1.117 (each, a “Sub-category of Base Editor Patent Rights”). 
 1.16 “Base Editor Product” [**].

 1.17 “Beam” means Beam Therapeutics Inc., a Delaware corporation. 

1.18 “Beam Actual Series B Valuation Multiple” means the number, not to exceed [**], determined by dividing the Beam Series B Pre-Money by the Beam Series A Post-Money. 
 1.19 “Beam Change of Control” means, with
respect to Licensee, (a) a merger or consolidation of Licensee with Beam, (b) a transaction or series of related transactions in which Beam, together with its Affiliates (other than Licensee), becomes the owner of more than fifty percent
(50%) of the combined voting power of Licensee’s outstanding securities or (c) the sale, lease or other transfer to Beam of all or substantially all of Licensee’s assets or business to which this Agreement relates. 

1.20 “Beam Proceeds Factor” means a number, not more than [**], determined by dividing the gross proceeds to Beam from an
applicable sale of Beam Series B Preferred Stock by [**]. 
 1.21 “Beam Series A Investors” means F-Prime Capital Partners Healthcare Fund V, L.P. and ARCH Venture Fund IX, L.P., together with any other investors under common management with the foregoing. 

1.22 “Beam Series A Post-Money” means an amount determined by multiplying (a) the weighted average price per share of the
Beam Series A Preferred Stock sold by Beam to the Beam Series A Investors prior to the time of determination of the Beam Actual Series B Valuation Multiple by (b) the number of shares of outstanding capital stock of Beam on a Fully-Diluted
Basis immediately prior to the first sale and issuance of Beam Series B Preferred Stock 

  
 4 

 
(excluding for this purpose any securities issued in a bridge or similar financing that are convertible into, and are, at such first sale and issuance, converted into, Beam Series B Preferred
Stock). For purposes of the foregoing, any shares of Beam Series A Preferred Stock that are deemed Beam Series B Preferred Stock by operation of the definition of Beam Series B Preferred Stock shall be excluded from the calculation of the weighted
average price per share of the Beam Series A Preferred Stock for purposes of clause (a) and shall be deemed excluded from the number of shares of outstanding capital stock for purposes of clause (b). 

1.23 “Beam Series A Preferred Stock” means Beam’s Series A Preferred Stock, par value $0.0001 per share. 

1.24 “Beam Series B Pre-Money” means an amount determined by multiplying (a) the
weighted average price per share of Beam Series B Preferred Stock sold by Beam in a closing at the time of determination of the Beam Actual Series B Valuation Multiple (including in any such weighted average calculation any discount attributable to
the conversion of the first up-to-$[**] in principal amount of debt securities issued in a bridge or similar financing that converted into Beam Series B Preferred Stock
and excluding any other discount attributable to the conversion of such debt securities in excess of the first up-to-$[**] in principal amount) by (b) the number of
shares of outstanding capital stock of Beam on a Fully-Diluted Basis immediately prior to such closing (excluding for this purpose any securities issued in a bridge or similar financing that are convertible into, and are, at such closing, converted
into, Beam Series B Preferred Stock). 
 1.25 “Beam Series B Preferred Stock” means any series of preferred stock of Beam
sold by Beam in a financing transaction other than Beam Series A Preferred Stock, provided that if Beam has sold $[**] of Beam Series A Preferred Stock, the term “Beam Series B Preferred Stock” shall include any additional shares of Beam
Series A Preferred Stock sold by Beam. 
 1.26 “Beam Valuation Factor” means a number, not to exceed [**], determined by
dividing the Beam Actual Series B Valuation Multiple by [**]; provided, however, that if the Beam Series B Preferred Stock sold by Beam that gives rise to an obligation by Licensee to make a payment under
Section 4.3.2.3 (Series B Financing Following Beam Change of Control) is sold in a financing transaction in which the Beam Series A Investors, along with other investors who purchased Beam Series A Preferred Stock sold by
Licensee prior to the time of determination of the Beam Actual Series B Valuation Multiple, purchase more than [**] percent ([**]%) of the Beam Series B Preferred Stock sold in such financing transaction, the Beam Valuation Factor shall be [**].

 1.27 “Bona Fide Proposal” means a bona fide proposal for the research, development and commercialization of a [**]
Proposed Product. A Bona Fide Proposal shall include, at a minimum, [**]. 
 1.28 “Broad” shall have the meaning set
forth in the preamble. 
 1.29 “Broad Confidential Information” shall have the meaning set forth in
Section 11.1.1.1 (Definitions). 

  
 5 

 1.30 “Broad Designee” shall have the meaning set forth in
Section 4.1.1 (Initial Issuance). 
 1.31 “Calendar Quarter” means each of the periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 during the Term. 
 1.32
“Calendar Year” means any twelve (12) month period commencing on January 1. 
 1.33 “Cap Table” shall
have the meaning set forth in Section 4.1.4.1 (Representations and Warranties). 
 1.34 “Challenging
Party” shall have the meaning set forth in Section 4.5.1 (Patent Challenge). 
 1.35 “Change of
Control” means, with respect to Licensee, (a) a merger or consolidation of Licensee with a third party which results in the voting securities of Licensee outstanding immediately prior thereto ceasing to represent at least fifty percent
(50%) of the combined voting power of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a third party, together with its Affiliates, becomes the owner or beneficial
owner of more than fifty percent (50%) of the combined voting power of Licensee’s outstanding securities other than through issuances by Licensee of securities of Licensee in a bona fide financing transaction or series of related bona fide
financing transactions, or (c) the sale, lease or other transfer to a third party of all or substantially all of Licensee’s assets or business to which this Agreement relates; provided that in no event shall a Beam Change of Control
be deemed a Change of Control under this Agreement. 
 1.36 “Claims” shall have the meaning set forth in
Section 9.1.1 (Indemnity). 
 1.37 “Clinical Study” means a Phase 1 Clinical Study, Phase 2
Clinical Study, Phase 3 Clinical Study, or such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an NDA or other similar application for Regulatory
Approval (appropriate to the type of product candidate or product). 
 1.38 “Collaboration Period” shall have the meaning
set forth in Section 2.5.13.5 (Limited-Time Preclusion of [**]). 
 1.39 “Combination Product” shall have the
meaning set forth in Section 4.4.7 (Combination Products). 
 1.40 [**] 

1.41 “Common Stock” shall have the meaning set forth in Exhibit 4.1. 

  
 6 

 1.42 “Competitor” means any entity (a) listed in
Exhibit 1.42 and (b) that, subject to Section 2.5.4 (Exceptions), is an Affiliate of and controlled by, as that term is used in the definition of Affiliate, (and not merely under common control with) an entity
described under the foregoing clause (a). An entity that is a Competitor under the foregoing clause (b) shall only be deemed a Competitor for so long as such control exists. During the term, Licensee shall have the right to add up to
[**] additional entities to Exhibit 1.42 upon prior written notice to Broad if (a) such entities are competitors in Base Editing technology generally and such entity’s business is substantially dependent upon a Base Editing
technology platform that such competitor owns or controls, and (b) with respect to such Base Editing technology platform, such entity holds a blocking patent position with respect to such technology’s use for a particular class of Base
Editors (generally, and not merely with respect to a particular [**]). Such notice must include an explanation, to Broad’s reasonable satisfaction, as to how a proposed competitor meets the requirements set forth in the foregoing (a) and
(b). After Licensee has added such [**] additional entities, Licensee may propose that [**] or more additional entities that meet the requirements set forth in the foregoing (a) and (b) be added to Exhibit 1.42, and such entity(ies)
shall only be added to Exhibit 1.42 by mutual agreement of the Parties. 
 1.43 “Confidential Information” shall have
the meaning set forth in Section 11.1.1.3 (Definitions). 
 1.44 “Covered” means, with respect to
a given product, process, method or service, that a Valid Claim would (absent a license thereunder or ownership thereof) be infringed (whether directly infringed or indirectly by induced or contributory infringement) by the making, using, selling,
offering for sale, importation or other exploitation of such product, process, method or service. With respect to a claim of a pending patent application, “infringed” refers to activity that would infringe or be covered by such Valid Claim
if it were contained in an issued patent. Cognates of the word “Covered” shall have correlative meanings. 
 1.45 “Cross
Licenses” shall have the meaning set forth in Section 1.111 (“Non-Royalty Sublicense Income”). 

1.46 “Current Development Demonstration” means a demonstration by Licensee of the research, development
or commercialization of a Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product in the Field [**] by Licensee or through any of its Affiliates, or with respect to a Sublicensee, a demonstration of the research, development
or commercialization of a Royalty-Bearing Product in the [**]. Such demonstration shall require Licensee to [**]. 
 1.47 “Developing
Country” means any country identified as a low-income or lower-middle-income economy in the World Bank “Country and Lending Groups” classification. 

1.48 “Development Milestones” means the development and regulatory milestones set forth in Exhibit 3.1.1 hereto. 

1.49 “Development Plan” means the plan attached hereto as Exhibit 3.2.1 as such plan may be adjusted from time to time
pursuant to this Agreement. 
 1.50 “Direct License” shall have the meaning set forth in
Section 10.3.1 (Termination Rights). 

  
 7 

 1.51 “Dispute” shall have the meaning set forth in
Section 11.8 (Dispute Resolution). 
 1.52 “DNA Base Editor Product” [**]. 

1.53 “DNA Cleaver” means [**]. 

1.54 “DNA Cleaving Patent Rights” means any Patent Rights identified under the heading “DNA Cleaving Patent
Rights” in Exhibit 1.117 (“Listed DNA Cleaving Patent Rights”) and any Patent Rights that fall within any of clauses (b) through (f) of Section 1.117 (“Patent Rights”) with
respect to such Listed DNA Cleaving Patent Rights. 
 1.55 “DNA Cleaving Product” [**]. 

1.56 “Effective Date” shall have the meaning set forth in the preamble. 

1.57 “Enabled Product” means any product that (a) was made, discovered, developed or determined to have utility
(i) through the use of any of the Patent Rights, provided that the research or discovery program in which such Patent Rights are used has commenced within [**] years following the Effective Date, or (ii) through the use of Transferred
Materials and (b) is not a Licensed Product. 
 1.58 “EU” means the European Union. 

1.59 “EU Major Market Countries” means the United Kingdom, Germany, Italy, France and Spain. 

1.60 “Executive Officers” shall have the meaning set forth in Section 11.8 (Dispute Resolution).

 1.61 “Exempted Issuances” means: shares of common stock issued or issuable, and options, warrants or other
rights to purchase Common Stock sold, issued or issuable, by Licensee (i) to a corporation, partnership or other entity (other than a corporation, partnership or other entity that is an Affiliate (which definition for purposes of this
Section 1.61 (“Exempted Issuances”) shall be deemed to exclude the second paragraph of Section 1.7 (“Affiliate”)) of Licensee) or to the shareholders of such corporation,
partnership or other entity pursuant to the acquisition of such corporation, partnership or other entity by Licensee by merger, purchase of substantially all of the assets or similar transaction (but excluding any shares, options, warrants or other
rights issued or issuable as incentive compensation); and (ii) to an academic institution, inventor, biopharmaceutical company, or intellectual property holding company (in each case, other than a corporation, partnership or other entity that
is an Affiliate (which definition for purposes of this Section 1.61 (“Exempted Issuances”) shall be deemed to exclude the second paragraph of Section 1.7 (“Affiliate”)) of
Licensee) in consideration of such Person’s entering into a sponsored research, collaboration, technology or intellectual property license, development, OEM, marketing or other similar agreement with Licensee, including any such agreement
entered into in settlement of litigation (but excluding any shares, options, warrants or other rights issued or issuable as incentive compensation); provided, however, that shares issued or issuable to an investor in Licensee in connection with any
transaction contemplated under clause (i) or (ii) (other than shares issued to such investor as a shareholder of an entity as contemplated under clause (i)) shall not be Exempted Issuances. 

  
 8 

 1.62 “Explanation” shall have the meaning set forth in
Section 3.5.1 (Notice/Explanation/Plan). 
 1.63 “Failed
Sub-Category of Base Editor Patent Rights” shall have the meaning set forth in Section 3.1.2 (Sub-Categories of Patent Rights). 

1.64 “Failed Sub-Category of Patent Rights” shall have the meaning set forth in
Section 3.1.2.2 (Sub-Categories of Patent Rights). 
 1.65
“FDA” means the United States Food and Drug Administration. 
 1.66 “Field” means the
prevention or treatment of human diseases by [**]. 
 1.67 “Financing Threshold” means the earlier of
(a) an aggregate total investment of [**] U.S. Dollars [**] in cash since the date of incorporation or formation of Licensee, in one or a series of related or unrelated transactions, in each case, in exchange for Licensee’s capital stock
and (b) the date of the consummation of a Beam Change of Control transaction. 
 1.68 “First Commercial Sale” means the
date of the first sale by Licensee, its Affiliate or a Sublicensee of a Royalty-Bearing Product to a third party following receipt of any required Regulatory Approval in the country in which such Royalty-Bearing Product is sold, excluding, however,
any sale or other distribution for use in a Clinical Study, charitable purposes, compassionate use or similar limited purposes. 
 1.69
“FSFD” means, with respect to a clinical study, the first dose of the first subject dosed in such clinical study. 
 1.70
“Fully-Diluted Basis” means, as of a specified date, the number of shares of common stock of Licensee then-outstanding plus the number of shares of common stock of Licensee issuable upon exercise or conversion of then-outstanding
convertible securities or warrants, options, or other rights to subscribe for, purchase or acquire from Licensee any capital stock of Licensee (which shall be determined without regard to whether such securities or rights are then vested,
exercisable or convertible) plus, without duplication, the number of shares reserved and available for future grant under any then-existing equity incentive plan of Licensee; provided that, for clarity, “other rights to subscribe for, purchase
or acquire” shall not include (i) preemptive or other rights to participate in new offerings of securities by Licensee, (ii) obligations under a purchase agreement for preferred stock of Licensee to acquire additional shares of such
preferred stock on the same terms as those purchased at an initial closing upon the passage of time or meeting (or waiver) of specified Licensee performance conditions or (iii) anti-dilution provisions that have not been triggered. 

1.71 “[**]” shall have the meaning set forth in Section 2.5.13.2 ([**]). 

1.72 “[**] Inquiry” shall have the meaning set forth in Section 2.5.13.4 ([**] Inquiry). 

  
 9 

 1.73 “[**] Inquiry Date” shall have the meaning set forth in
Section 2.5.13.4 ([**] Inquiry). 
 1.74 “[**] Notice” shall have the meaning set forth in
Section 2.5.13.4 ([**] Inquiry). 
 1.75 “[**] Non-Performance
Notice” shall have the meaning set forth in Section 2.5.13.4 ([**] Inquiry). 
 1.76 “[**]
Selection Notice” shall have the meaning set forth in Section 2.5.13.2 ([**]). 
 1.77 [**] 

1.78 “Gene Targeting Patent Rights” means any Patent
Rights identified under the heading “Gene Targeting Patent Rights” in Exhibit 1.117 (“Listed Gene Targeting Patent Rights”) and any Patent Rights that fall within any of clauses (b) through (f) of
Section 1.117 (“Patent Rights”) with respect to such Listed Gene Targeting Patent Rights. 
 1.79
“Generic/Biosimilar Product” means, with respect to a Royalty-Bearing Product in a particular country, any pharmaceutical, biopharmaceutical (including gene therapies and cell therapies), or biologic product that:
(a) (i) contains the same active pharmaceutical ingredient(s) as such Royalty-Bearing Product, and is approved by the Regulatory Authority in such country with the same or substantially the same labeling as such Royalty-Bearing Product for at
least one indication in the Field or (ii) is approved by the Regulatory Authority in such country or jurisdiction as a substitutable generic or substitutable biosimilar for such Royalty-Bearing Product for an indication in the Field or
otherwise is approved in a manner that relied on or incorporated data submitted by Licensee, its Affiliates or Sublicensees, in connection with the regulatory filings for such Royalty-Bearing Product, including through an ANDA or 505(b)(2) NDA, or
any enabling legislation thereof, or any similar procedure provided for biosimilars or that may be applicable to gene therapy products in each case now or in the future; and (b) is sold in such country or jurisdiction by a third party that is
not a Sublicensee or an Affiliate of Licensee, or a distributor of any of them. Any product or component thereof (including any Royalty-Bearing Product or component thereof) licensed, marketed, sold, manufactured or produced by Licensee or its
Affiliates or Sublicensees, or any distributor of any of them, will not constitute a Generic/Biosimilar Product (but the identical product marketed by another third party is a Generic/Biosimilar Product if it falls within the definition
thereof as set forth herein). 
 1.80 “Harvard” shall have the meaning set forth in the Recitals. 

1.81 “Human Germline Modification” means human germline modification, including intentionally modifying the DNA of human
embryos or human reproductive cells. 
 1.82 “IND” means an FDA Investigational New Drug application, or equivalent
application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

1.83 “Indemnitees” shall have the meaning set forth in Section 9.1.1 (Indemnity). 

  
 10 

 1.84 “Indemnitor” shall have the meaning set forth in
Section 9.1.1 (Procedures). 
 1.85 “Ineligible Sublicensees” shall have the meaning set forth in
Section 10.3.1 (Termination of Rights). 
 1.86 “Infringement” shall have the meaning set forth in
Section 7.2 (Suit by Licensee). 
 1.87 “Initial Public Offering” or
“IPO” means a firm-commitment underwritten public offering of equity securities by Licensee (or an Acquirer) or its (or their) Affiliate pursuant to an effective registration statement under the Securities Act of 1933,
as amended (the “Securities Act”). 
 1.88 “Initiation of GLP Toxicology” means the first dose in a non-human animal of a Royalty-Bearing Product in toxicology testing conducted in accordance with Good Laboratory Practices under the guidelines of 21 U.S. CFR.§ 58.1 et seq. (or its successor regulation) with
the intention of using the results of toxicology testing in support of the filing of an IND for which other IND-enabling activities have been completed or are underway at the time of determination of
“achievement of Initiation of GLP Toxicology”. 
 1.89 “Institution” means each of Broad, Harvard
and MIT individually, and “Institutions” means Broad, Harvard and MIT collectively. 
 1.90 “Institution Names”
shall have the meaning set forth in Section 11.5 (Use of Name). 
 1.91 “Licensed
Product” means on a country-by-country basis, (a) any product candidate or product the making, using, selling, offering for sale, importing or
exporting of which in the country in question is Covered by at least one Valid Claim of the Base Editor Patent Rights or DNA Cleaving Patent Rights, or (b) any Base Editor Product the making, using, selling, offering for sale, importing or
exporting of which in the country in question is Covered by at least one Valid Claim of the Gene Targeting Patent Rights. 
 1.92
“Licensee” shall have the meaning set forth in the preamble. 
 1.93 “Licensee Confidential Information”
shall have the meaning set forth in Section 11.1.1.2 (Definitions). 
 1.94 “Licensee Patents”
shall have the meaning set forth in Section 1.116 (Patent Challenge). 
 1.95 “List of Countries”
shall have the meaning set forth in Section 6.1.4 (Control). 
 1.96 “Listed Base Editor Patent
Rights” shall have the meaning set forth in Section 1.15 (Base Editor Patent Rights). 

  
 11 

 1.97 “Listed DNA Cleaving Patent Rights” shall have the meaning set forth
in Section 1.54 (DNA Cleaving Patent Rights). 
 1.98 “Listed Gene Targeting Patent Rights” shall
have the meaning set forth in Section 1.78 (Gene Targeting Patent Rights). 
 1.99 “Litigation
Expenses” shall have the meaning set forth in Section 7.2.2 (Suit by Licensee). 
 1.100
“Livestock Applications” means (a) the modification or alteration of livestock, or of any products, cells or materials derived from livestock, or the use or provision of any processes, methods or services using livestock, or
the use of any products, cells or materials derived from livestock, for the purposes of (i) affecting the fitness of such livestock, including affecting their ability to survive or reproduce, (ii) creating, expressing, transmitting,
conferring, improving, or imparting a Trait of interest in such livestock, or (iii) bioproduction or bioprocessing, or (b) the use, production, alteration or modification of exotic animals, or of any products, cells, tissues or materials
derived from exotic animals (including biomaterials derived from such exotic animals) in or for consumer goods or products. For the purposes of this definition, (A) “livestock” means (1) cattle, sheep, goats, buffalo, llamas, camels,
swine, poultry and fowl (including egg-producing poultry and fowl), dogs, cats and equine animals, (2) animals used for food or in the production of food, (3) animals ordinarily raised or used on the
farm or for home use, consumption, or profit, and (4) fish used for food, and (B) “exotic animals” means snakes, alligators, elephants, camels and other exotic animals but specifically excludes all rodents. Notwithstanding anything in
this definition or elsewhere in this Agreement to the contrary, Livestock Applications does not include (i) the use of any animal or animal cell in preclinical research or (ii) the treatment of animal disease. 

1.101 “Loss of Market Exclusivity” means, on a Royalty-Bearing
Product-by-Royalty-Bearing Product, country-by-country, and Calendar Year-by-Calendar Year basis, that the following has occurred: 

(a) the Net Sales of such Royalty-Bearing Product in such country in such Calendar Year are less than [**] percent ([**]%) of the average Net
Sales of Royalty-Bearing Products in the [**] Calendar Quarters preceding the first marketing or sale of a Generic/Biosimilar Product to such Royalty-Bearing Product in such country; 

(b) the decline in such Net Sales is attributable in material part to the marketing or sale in such country of a Generic/Biosimilar Product
with respect to such Royalty-Bearing Product by a third party that is not a Sublicensee or a distributor of any of Licensee or its Affiliates or Sublicensees for the applicable Royalty-Bearing Product; and 

(c) Such Generic/Biosimilar Product is being marketed and sold by such third party in the Calendar Year for which a determination of Loss of
Market Exclusivity is being made. 
 1.102 “Maintenance Fees” shall have the meaning set forth in
Section 4.2 (Annual License Maintenance Fees). 
 1.103 “[**]” has the meaning set forth in
Section 2.5.12 ([**]). 

  
 12 

 1.104 “[**] License” has the meaning set forth in
Section 2.5.11 ([**] License). 
 1.105 “Milestone Deadline” shall have the meaning set forth in
Section 3.5.1 (Notice/Explanation/Plan). 
 1.106 “Milestone Event” means any milestone event indicated in
Section 4.3.1 (Product Milestone Payments) or 4.3.2 (Financing Milestone Payments). 
 1.107
“MIT” shall have the meaning set forth in the Recitals. 
 1.108 “Multi-Product Negotiation” means, with
respect to a [**] Proposed Product, a negotiation between Licensee and a Third Party involving [**] or more products that target [**] of which [**] such product targets the [**] as such [**] Proposed Product. 

1.109 “NDA” means a New Drug Application filed with the FDA or an equivalent application to any Regulatory Authority
(including a Biologics License Application, or BLA, or its foreign equivalent) requesting Regulatory Approval for a new product. 
 1.110
“Net Sales” means the gross amount billed or invoiced by or on behalf of Licensee, its Affiliates, and Sublicensees and any Affiliates of such Sublicensees (in each case, the “Invoicing Entity”) or if
not billed or invoiced the gross amount received by the Invoicing Entity, on sales, uses, leases or other transfers of Royalty-Bearing Products, less the following to the extent applicable with respect to such sales, leases or other transfers and
not previously deducted from the gross invoice price: (a) customary trade, quantity or cash discounts to the extent actually allowed and taken (including discounts in the form of inventory management fees and chargebacks); (b) amounts actually
repaid or credited by reason of rejection or return of any previously sold, leased or otherwise transferred Royalty-Bearing Products; (c) customer freight or insurance charges that are paid by or on behalf of the Invoicing Entity; (d) to
the extent separately stated on purchase orders, invoices or other documents of sale, any sales, value added or similar taxes, custom duties or other similar governmental charges levied directly on the production, sale, transportation, delivery or
use of a Royalty-Bearing Product that are paid by or on behalf of the Invoicing Entity, but not including any tax levied with respect to income; (e) rebates granted or given; and (f) a reasonable allowance for uncollectible accounts;
provided that: 
 1.110.1 in any transfers of Royalty-Bearing Products between an Invoicing Entity and an Affiliate of such Invoicing Entity
not for the purpose of resale by such Affiliate and not for use in a Clinical Study, charitable purposes, compassionate use or as free marketing samples provided in the customary course of the Invoicing Entity’s business, Net Sales will be
equal to the fair market value of the Royalty-Bearing Products so transferred, assuming an arm’s length transaction made in the ordinary course of business; 

1.110.2 in the event that (i) an Invoicing Entity receives non-cash consideration for any
Royalty-Bearing Products, (ii) an Invoicing Entity sells Royalty-Bearing Product in a transaction not at arm’s length with a non-Affiliate of an Invoicing Entity, or (iii) any Royalty-Bearing
Product is sold by an Invoicing Entity at a discounted price that is substantially lower than the customary prices charged by Invoicing Entity, then Net Sales will be calculated based on the fair market value of such consideration or transaction,
assuming an arm’s length transaction made in the ordinary course of business, not to exceed the list price of the Royalty-Bearing Products in any event; and 

  
 13 

 1.110.3 with respect to any provision hereof requiring a calculation of fair market value,
assuming an arm’s length transaction made in the ordinary course of business, the Invoicing Entity may use the average price of the relevant Royalty-Bearing Product sold for cash during the relevant period in the relevant country. 

Transfers of Royalty-Bearing Products by an Invoicing Entity to its Affiliate or a Sublicensee for resale by such Affiliate or Sublicensee or
use in Clinical Studies, for compassionate use, or use as free marketing samples, will not be deemed Net Sales. Instead, if applicable, Net Sales will be determined based on the gross amount billed or invoiced by such Affiliate or Sublicensee upon
resale of such Royalty-Bearing Products to a third party purchaser. Transfers of Royalty-Bearing Products by an Invoicing Entity for use in Clinical Studies, for compassionate use, or use as free marketing samples will not be deemed Net Sales unless
such Invoicing Entity bills or invoices for such Royalty-Bearing Products, in which case, Net Sales will be determined based on the gross amount billed or invoiced by such Invoicing Entity upon transfer for such use. 

In the event that Licensee enters into a Sublicense pursuant to which running royalties based on the net sales of a Royalty-Bearing Product
are payable to Licensee and Licensee is unable to incorporate into such Sublicense the Net Sales definition hereunder, then Licensee may submit a request to Broad that the definition of net sales agreed upon in such Sublicense be deemed to apply to
any amounts billed or invoiced by such Sublicensee under such Sublicense with respect to such Royalty-Bearing Products. In addition to such proposal, Licensee shall demonstrate to Broad’s satisfaction, in Broad’s sole discretion, that
Broad would receive an amount of running royalties under such Sublicense applying such net sales definition equal to or greater than the amount of running royalties that Broad would otherwise receive under the definition of Net Sales hereunder. If
Licensee makes such demonstration to Broad’s satisfaction, then the net sales definition under such Sublicense shall be deemed to apply to royalty payments on Royalty-Bearing Products owed by Licensee to Broad with respect to such Sublicensee.

 1.111 “Non-Royalty Sublicense Income” means all consideration
received by Licensee or its Affiliates for a Sublicense such as license or distribution fees, milestone or option payments, or license maintenance fees, including any consideration received by Licensee under a Sublicense. Non-Royalty Sublicense Income specifically excludes the following: 
 1.111.1 payments to Licensee or an
Affiliate by a Sublicensee under a Sublicense under the Patent Rights for the purpose of funding the costs of bona fide research and development or manufacture of Royalty-Bearing Products by the Licensee or its Affiliates to be conducted on or
following the Effective Date of this Agreement and the effective date of such Sublicense, as specifically allocated in a research and development plan or manufacturing or commercial plan, as applicable, between Licensee or its Affiliate and the
Sublicensee or as specifically described as such in the Sublicense; 

  
 14 

 1.111.2 if (i) Licensee enters into a Sublicense prior to the [**] anniversary of the
Effective Date and (ii) no bona fide research, development or manufacturing costs of Royalty-Bearing Products under such Sublicense are specifically allocated as contemplated in Section 1.111.1 (“Non-Royalty Sublicense Income”), then Licensee may elect to exclude up to [**] percent ([**]%) of the upfront payment (or any series of payments that are intended to serve as an upfront (and not as an
event-based milestone) and are only conditioned upon the passage of time and the Sublicense remaining in effect) received by Licensee or its Affiliates under such Sublicense from Non-Royalty Sublicense Income
for the purpose of funding the costs of bona fide research, development or manufacturing by the Licensee or its Affiliates on or following the effective date of such Sublicense of Royalty-Bearing Products which are the subject of such Sublicense,
provided that in such event (A) Licensee has until the [**] anniversary of the effective date of such Sublicense to use any such amounts excluded from the upfront payment for the research, development and manufacture of Royalty-Bearing Products
under such Sublicense, (B) Licensee shall provide to Broad (x) promptly following the execution of such Sublicense, a proposed budget for its future research, development and manufacturing expenses for Royalty-Bearing Products under such
Sublicense (as amended from time to time in accordance with this Agreement, the “Proposed Budget”) and (y) within [**] days following each anniversary of the effective date of such Sublicense until the [**] anniversary of such
Sublicense, a written report with a reasonably detailed accounting of all such research, development and manufacturing expenses for Royalty-Bearing Products under the Sublicense since the later of the effective date of such Sublicense and the last
such report, and (C) if the amount excluded from Non-Royalty Sublicense Income exceeds Licensee’s or its Affiliates’ cumulative research, development and manufacturing expenses for
Royalty-Bearing Products under such Sublicense as of the earlier of (x) the [**] anniversary of the effective date of such Sublicense and (y) the [**] date of the Proposed Budget, then the difference between the two (2) amounts shall
be deemed Non-Royalty Sublicense Income as of such date, provided that if such difference is greater than [**] percent ([**]%) of such cumulative research, development and manufacturing expenses, then the
difference shall be deemed Non-Royalty Sublicense Income as of the effective date of the applicable Sublicense and the late payment provisions of Section 5.4 (Late Payments) shall
apply, and provided further that, prior to the [**] anniversary of the effective date of any Sublicense, Licensee may amend the Proposed Budget for such Sublicense by written notice to Broad, except that any extension of the term of the Proposed
Budget past the [**] anniversary of the effective date of such Sublicense will not lengthen the period of time in which Licensee must, for the purposes of this Section 1.111.2 use any amounts excluded from the upfront
payment for the research, development and manufacture of Royalty-Bearing Products under such Sublicense. 
 1.111.3 reimbursement for patent
expenses as specifically allocated or specifically described as such in the Sublicense (including prosecution and enforcement expenses) paid to third parties at
out-of-pocket cost to Licensee; 
 1.111.4 reimbursement of
commercialization expenses, as specifically allocated or as specifically described as such in the Sublicense, of Licensee under a co-promotion arrangement at Licensee’s cost (determined in accordance with
U.S. generally accepted accounting principles consistently applied); 
 1.111.5 reimbursement of license, option, or other fees as
specifically allocated or as specifically described as such in the Sublicense paid to third parties at out-of-pocket cost to Licensee; 

  
 15 

 1.111.6 proceeds from equity investments to the extent at fair market value, principal
amount of loans to the extent not forgiven, and royalties on Net Sales of Royalty-Bearing Products; and 
 1.111.7 a percentage of any
profit share for any product, to the extent such percentage does not exceed Licensee’s and its Affiliates’ percentage share contribution of the research, development and commercialization costs of such product following the effective date
of the Sublicense (taking into consideration the geography for which the profit share is applicable and including share contributions by Licensee or its Affiliates in kind or through a reduction of future payments owed to Licensee or its
Affiliates), and provided that for net sales on which such profit share is based running royalties are paid to Broad to the extent required in accordance with the terms of this Agreement. 

To avoid doubt as to the calculation of Non-Royalty Sublicense Income, “equity investments to the
extent at fair market value” means that only a premium over the fair market value of the security received for the equity investment (such fair market value being determined by reference to the price paid by a
non-Sublicensee Third Party for the equivalent Licensee security (equal to such price wherever available) or by a reasonable methodology where such non-Sublicensee Third
Party price is not available) would be included in Non-Royalty Sublicense Income, and if a loan is partially forgiven, then only the forgiven portion of the loan would be included in the Non-Royalty Sublicense Income. 
 In the event that non-cash
consideration is received as Sublicense Income, Sublicense Income shall be calculated based on the fair market value of such non-cash consideration at the time of the transaction assuming an arm’s length
transaction made in the ordinary course of business. For clarity, a license of intellectual property rights that are necessary for Licensee to make, have made, use, have used, sell, offer for sale, have sold, export and import Royalty-Bearing
Products, and other routine contractual covenants that do not involve the payment of any monetary consideration and are customary in the type of deal that the Sublicense is included in (including covenants providing for the research, development,
supply, and commercialization responsibilities of the Sublicensee, confidentiality provisions, licenses or other rights or forbearances with respect to improvements and other technologies and intellectual property, retention of co-promotion rights or options to obtain co-promotion rights to the Royalty-Bearing Product(s) covered by such Sublicense, and indemnification) shall not be deemed non-cash consideration. For purposes of this Section 1.111.7 (“Non-Royalty Sublicense Income”), “all consideration received by
Licensee or its Affiliates for a Sublicense” shall include all consideration received by Licensee or any of its Affiliates for any option, license, sublicense, standstill, covenant not to sue or other right granted under any other rights owned
or controlled (for example, by virtue of a license granted by a third party) by Licensee or its Affiliate, or other agreement or arrangement entered into by Licensee or its Affiliate, in connection with a Sublicense. All rights relevant to making,
using, selling, offering to sell or importing particular Royalty-Bearing Products to which a Sublicense relates shall be included in or deemed to be granted in connection with the Sublicense under which the rights granted to Licensee hereunder are
sublicensed with respect to such Royalty-Bearing Products. 

  
 16 

 In addition, to the extent that Licensee enters into a cross-license with a Third Party to
achieve freedom-to-operate for Royalty-Bearing Products while providing the Third Party with
freedom-to-operate with respect to all or some portion of the Patent Rights (“Cross Licenses”), the non-economic
value of the licenses to Licensee as part of such Cross License, and the other routine contractual covenants by other parties to such Cross License, shall not be deemed to give rise to Non-Royalty Sublicense
Income for purposes of this Agreement. For clarity, any financial consideration that Licensee receives under such a Cross License shall be treated as Non-Royalty Sublicense Income under this Agreement. 

In addition, no Beam Change of Control transaction, Change of Control transaction or other transaction giving rise to potential payments under
Section 4.6 (Non-Royalty Sublicense Income) of this Agreement shall be deemed to be a Sublicense nor to give rise to Non-Royalty Sublicense
Income. 
 1.112 “Option Agreement” shall have the meaning set forth in Section 8.2 (Option
Agreement). 
 1.113 “Other IP” shall have the meaning set forth in Section 7.2 (Suit by
Licensee). 
 1.114 “Ownership Threshold” shall have the meaning set forth in Section 4.1.2
(Anti-Dilution Issuances). 
 1.115 “Party” means Broad or Licensee and “Parties” means both of them. 

1.116 “Patent Challenge” means any direct, or indirect through the actions of another acting on Licensee’s,
its Affiliate’s, or a Sublicensee’s behalf or upon its or their instruction, dispute or challenge, or any knowing, willful, or reckless assistance in the dispute or challenge by another, of the validity, patentability, scope, priority,
construction, non-infringement, inventorship, ownership or enforceability of any Patent Right or any claim thereof, or opposition or assistance in the opposition of the grant of any letters patent within the
Patent Rights, in any legal or administrative proceedings in a court of law, before the United States Patent and Trademark Office or other similar agency or tribunal in any jurisdiction, or in arbitration including, without limitation, by
reexamination, inter partes review, opposition, interference, post-grant review, nullity proceeding, preissuance submission, third party submission, derivation proceeding or declaratory judgment action. For clarity, a Patent Challenge shall
not include (1) arguments made by Licensee that (a) distinguish the inventions claimed in patents or patent applications owned or controlled by Licensee (“Licensee Patents”) from those claimed in the Patent Rights but
(b) do not disparage the Patent Rights or challenge the validity, scope, or enforceability of the Patent Rights’ claims (excluding any claims that have been abandoned, lapsed, expired, or are otherwise no longer in force) under applicable
patent laws, regulations or administrative rules, in each case (i) in the ordinary course of ex parte prosecution of the Licensee Patents or (ii) in inter partes proceedings before the United States Patent and Trademark Office or
other agency or tribunal in any jurisdiction (excluding interferences or derivation proceedings), or in arbitration, wherein the Licensee Patents have been challenged; (2) arguments or assertions as to whether the Patent Rights Cover a given
product, to the extent arising in a Suit brought by Broad; (3) Licensee payments of patent costs to another licensor or assignor of Licensee Patent Rights as required by the agreement under which the Licensee obtained rights to such patent
rights, even if the licensor or assignor is engaging in behavior or presenting arguments that would themselves be considered a Patent Challenge if done by the Licensee; nor (4) Licensee being named as an essential party, real party in interest
or other status similar to either of the foregoing, in an interference between Patent Rights and Licensee Patents or other adversarial proceeding similar to an interference. 

  
 17 

 1.117 “Patent Rights” means, in each case to the extent owned
or controlled by Broad: (a) the patents and patent applications listed in Exhibit 1.117 (including the PCT or original direct national filing in any country, in each case, claiming priority to such application(s) listed in Exhibit
1.117 that are filed on such application(s)); (b) provisional applications not listed in Exhibit 1.117 but to which a nonprovisional application identified in (a) claims priority; (c) any patent or patent application that is a
continuation or divisional (excluding continuation-in-part patents or patent applications except to the extent described in (e) below), or that is a reissue,
renewal, reexamination, substitution or extension of any patent application identified in (a); (d) any patents issuing on any patent application identified in (a) or (c), including any reissues, renewals, reexaminations, substitutions or
extensions thereof; (e) any claim of a continuation-in-part application or resulting patent (including any reissues, renewals, reexaminations, substitutions or
extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a); (f) any foreign counterpart (including
PCTs) of any patent or patent application identified in (a) or (c) or of the claims identified in (e); and (g) any supplementary protection certificates, pediatric exclusivity periods, and other patent term extensions and exclusivity
periods and the like of or based on any patents and patent applications identified in any of (a) through (f). For the avoidance of doubt, the Parties agree to amend this Agreement to add to Exhibit 1.117 such patents and applications
identified in (b); provided, however, that any patent or patent application not so added to Exhibit 1.117 shall still be considered a Patent Right hereunder if it falls within (b). 

1.118 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a
government. 
 1.119 “Phase 1 Clinical Study” means a clinical study in any country involving the initial introduction of an
investigational new drug into humans, typically designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In
the United States, “Phase 1 Clinical Study” means a human clinical study that satisfies the requirements of 21 C.F.R. § 312.21(a). 

1.120 “Phase 2 Clinical Study” means a human clinical study in any country conducted to evaluate the effectiveness of a drug
for a particular indication or indications in patients with the disease or condition under study and, possibly, to determine the common short-term side effects and risks associated with the drug. In the United
States, “Phase 2 Clinical Study” means a human clinical study that satisfies the requirements of 21 C.F.R. § 312.21 (b). 

  
 18 

 1.121 “Phase 3 Clinical Study” means a human clinical study in any country,
whether controlled or uncontrolled, that is performed after preliminary evidence suggesting effectiveness of the drug under evaluation has been obtained, and intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. In the United States, “Phase 3 Clinical Study” means a human clinical study that satisfies the requirements of 21
C.F.R. § 312.21 (c). 
 1.122 “Plan” shall have the meaning set forth in Section 3.5.1
(Notice/Explanation/Plan). 
 1.123 “[**] Period” shall have the meaning set forth in
Section 2.5.13 ([**]). 
 1.124 “[**]” shall have the meaning set forth in
Section 2.5.13 ([**]). 
 1.125 “Proceeds Factor” means a number, not more than [**], determined
by dividing the gross proceeds to Licensee from an applicable sale of Series B Preferred Stock by [**]. 
 1.126 “Process”
shall have the meaning set forth in Section 2.5.14 (Processing of Proposed Product Notices). 
 1.127
“Product-Specific Base Editor Patent Rights” means any Base Editor Patent Rights subcategorized as “Product-Specific Base Editor Patent Rights” in Exhibit 1.117. 

1.128 “Proposed Budget” shall have the meaning set forth in Section 1.111.2 (“Non-Royalty Sublicense Income”). 
 1.129 “[**]” shall have the meaning set
forth in Section 2.5.13.2 ([**]). 
 1.130 “Proposed Product Development Period” shall have the
meaning set forth in Section 2.5.5.2 (Proposed Product Development Period). 
 1.131 “Proposed Product
Extension Period” shall have the meaning set forth in Section 2.5.14 (Processing of Proposed Product Notices). 

1.132 “Proposed Product Notice” shall have the meaning set forth in Section 2.5.3 (Notice of [**]
Proposed Product). 
 1.133 “Proposed Product Notice Date” shall have the meaning set forth in
Section 2.5.3 (Notice of [**] Proposed Product). 
 1.134 “Proposing Party” shall have the meaning
set forth in Section 2.5.3 (Notice of [**] Proposed Product). 
 1.135 “Prosecution” shall have
the meaning set forth in Section 6.1 (Control). 
 1.136 “Record Retention Period” shall have the
meaning set forth in Section 5.3 (Records). 

  
 19 

 1.137 “Regulatory Approval” means, with respect to a particular product or
service, receipt of all regulatory clearances or approvals (which in the case of the EU may be through the centralized procedure) required in the jurisdiction in question for the sale of the applicable product or service in such jurisdiction,
including receipt of pricing approval, if any, legally required for such sale. 
 1.138 “Regulatory Authority” means, in a
particular country or jurisdiction, any applicable government regulatory authority involved in granting approvals for the clinical testing, manufacturing and marketing of a Royalty-Bearing Product in such country or jurisdiction, including, in the
United States, the FDA. 
 1.139 “Related Product” means with respect to a Royalty-Bearing Product (the “reference
Royalty-Bearing Product”), a Royalty-Bearing Product targeting (a) [**] and (b) (i) [**] or (ii) [**] whose alteration would have the same intended clinical outcome in the same intended patient population, in each case of clause (a), (b)(i) and
(b)(ii) as the reference Royalty-Bearing Product. 
 1.140 “REPAIR Base Editor Patent Rights” means those Base Editor Patent
Rights subcategorized as “REPAIR Base Editor Patent Rights” in Exhibit 1.117. 
 1.141 “RESCUE Base Editor Patent
Rights” means those Base Editor Patent Rights subcategorized as “RESCUE Base Editor Patent Rights” in Exhibit 1.117. 

1.142 “Restored Licenses” shall have the meaning set forth in Section 3.5.7 (Failure to Meet
Development Milestone; Opportunity to Cure). 
 1.143 “Restored Product” shall have the meaning set forth in
Section 3.5.7 (Failure to Meet Development Milestone; Opportunity to Cure). 
 1.144 “Retained
Product” shall have the meaning set forth in Section 3.5.6.3 (Unmet Deadline). 
 1.145 “Retained
Product List” shall have the meaning set forth in Section 3.5.6.3 (Unmet Deadline). 
 1.146 “RNA
Base Editor Product” [**]. 
 1.147 “Royalty Term” shall have the meaning set forth in
Section 4.4.3 (Royalty Term). 
 1.148 “Royalty-Bearing Product” means any Licensed Product or
Enabled Product. 
 1.149 “Securities Act” shall have the meaning set forth in Section 1.87
(“Initial Public Offering” or “IPO”). 
 1.150 [**] 

1.151 [**] 

  
 20 

 1.152 “Selection Date” shall have the meaning set forth in
Section 2.5.13 ([**]). 
 1.153 “Series A Investors” means
F-Prime Capital Partners Healthcare Fund V, L.P. and ARCH Venture Fund IX, L.P., together with any other investors under common management with the foregoing. 

1.154 “Series A Post-Money” means an amount determined by multiplying (a) the weighted average price per
share of the Series A Preferred Stock sold by Licensee to the Series A Investors prior to the time of determination of the Actual Series B Valuation Multiple by (b) the number of shares of outstanding capital stock of Licensee on a
Fully-Diluted Basis immediately prior to the first sale and issuance of Series B Preferred Stock (excluding for this purpose any securities issued in a bridge or similar financing that are convertible into, and are, at such first sale and issuance,
converted into, Series B Preferred Stock). For purposes of the foregoing, any shares of Series A Preferred Stock that are deemed Series B Preferred Stock by operation of the definition of Series B Preferred Stock shall be excluded from the
calculation of the weighted average price per share of the Series A Preferred Stock for purposes of clause (a) and shall be deemed excluded from the number of shares of outstanding capital stock for purposes of clause (b). 

1.155 “Series A Preferred Stock” means Licensee’s Series A Preferred Stock, par value $0.0001 per share. 

1.156 “Series B Pre-Money” means an amount determined by multiplying (a) the
weighted average price per share of Series B Preferred Stock sold by Licensee in a closing at the time of determination of the Actual Series B Valuation Multiple (including in any such weighted average calculation any discount attributable to the
conversion of the first up-to-$[**] in principal amount of debt securities issued in a bridge or similar financing that converted into Series B Preferred Stock and
excluding any other discount attributable to the conversion of such debt securities in excess of the first up-to-$[**] in principal amount) by (b) the number of
shares of outstanding capital stock of Licensee on a Fully-Diluted Basis immediately prior to such closing (excluding for this purpose any securities issued in a bridge or similar financing that are convertible into, and are, at such closing,
converted into, Series B Preferred Stock). 
 1.157 “Series B Preferred Stock” means any series of preferred stock of
Licensee sold by Licensee in a financing transaction other than Series A Preferred Stock, provided that if Licensee has sold $[**] of Series A Preferred Stock, the term “Series B Preferred Stock” shall include any additional shares of
Series A Preferred Stock sold by Licensee. 
 1.158 “Services Agreement” shall have the meaning set forth in
Section 8.3 (Services Agreement). 
 1.159 “Shares” shall have the meaning set forth in
Section 4.1.1 (Initial Issuance). 
 1.160 “Skipped Milestone” shall have the meaning set forth in
Section 4.3.5 (Milestone Payments). 
 1.161 “Start Date” means the period commencing on the
Effective Date and ending on the second anniversary thereof. 

  
 21 

 1.162 “Sub-Category Product
Milestones” means the Development Milestones identified under the heading “Sub-Category Product Milestones” in Exhibit 3.1.1. 

1.163 “Sub-Category of Base Editor Patent Rights” shall have the meaning set forth in
Section 1.15 (“Base Editor Patent Rights”). 
 1.164
“Sub-Category of Patent Rights” means each Sub-Category of Base Editor Patent Rights and the DNA Cleaver Patent Rights. 

1.165 “Sublicense” means: (a) any right (including any sublicense or covenant not to sue) granted by Licensee or any
Sublicensee to any third party, under or with respect to or permitting any use or exploitation of any of the Patent Rights or otherwise permitting the development, manufacture, marketing, distribution, use or sale of Royalty-Bearing Products;
(b) any option or other right granted by Licensee or any Sublicensee to any third party to negotiate for or receive any of the rights described under clause (a); or (c) any standstill or similar obligation undertaken by Licensee or any
Sublicensee toward any third party not to grant any of the rights described in clause (a) or (b) to any other third party; in each case regardless of whether such grant of rights, option, standstill, or similar undertaking is referred to or is
described as a sublicense. 
 1.166 “Sublicensee” means any Person or entity granted a Sublicense. 

1.167 “Subscription Agreement” means a Subscription Agreement in the form attached hereto as Exhibit 4.1. 

1.168 “Suit” shall have the meaning set forth in Section 11.9 (Governing Law and Jurisdiction). 

1.169 “[**]” shall have the meaning set forth in Section 2.5.13 ([**]). 

1.170 “[**]” shall have the meaning set forth in Section 2.5.13 ([**]). 

1.171 “Term” means the term of this Agreement as set forth in Section 10.1 (Term). 

1.172 “Third Party” or “third party” means an entity that is not Broad, an Institution, Licensee, or an
Affiliate of Licensee. 
 1.173 “[**] Proposed Product” means an actual or potential Licensed Product for use
in the Field [**]. 
 1.174 “Transferred Materials” means any protocols, data, materials or other information provided by or
on behalf of Broad to Licensee or its Affiliates under an agreement between Licensee (or its Affiliate) and Broad (or its Affiliate) pursuant to which such protocols, data, materials or other information is specifically intended to be deemed
“Transferred Materials” under this Agreement. 
 1.175 “United States” means the United States of America. 

  
 22 

 1.176 “Valid Claim” means: (a) a claim of an issued and unexpired
patent within the Patent Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, (ii) rendered unenforceable through disclaimer, or (iii) permanently lost through an interference or opposition proceeding without any right of appeal or review, or not appealed or put in for review within the applicable
statutory or regulatory period; or (b) a pending claim of a pending patent application within the Patent Rights that has not been (i) abandoned or finally rejected without the possibility of appeal or refiling or (ii) pending more
than [**] years from the date of the first substantive office action on such pending patent application, provided such patent application is not pending more than [**] years from its earliest priority date. A pending claim that ceases to be a Valid
Claim due to the foregoing time limit shall, if it later issues, qualify again as a Valid Claim, provided that it meets the requirements of clauses (a)(i)-(iii) of the foregoing definition. 

1.177 “Valuation Factor” means a number, not to exceed [**], determined by dividing the Actual Series B Valuation Multiple by
[**]; provided, however, that if the Series B Preferred Stock sold by Licensee that gives rise to an obligation by Licensee to make a payment under Section 4.3.2.2 (Series B Financing prior to Beam Change of Control) is
sold in a financing transaction in which the Series A Investors, along with other investors who purchased Series A Preferred Stock sold by Licensee prior to the time of determination of the Actual Series B Valuation Multiple, purchase more than [**]
percent ([**]%) of the Series B Preferred Stock sold in such financing transaction, the Valuation Factor shall be [**]. 
 1.178
“[**]” shall have the meaning set forth in Section 4.8 (Success Payments). 
 2. License. 

2.1 License Grants 
 2.1.1
Subject to the terms and conditions set forth in this Agreement, Broad hereby grants to Licensee (a) an exclusive, worldwide, royalty-bearing license, sublicensable solely in accordance with Section 2.4 (Sublicenses)
below, under the Institutions’ interests in (i) the Base Editor Patent Rights (other than the Product-Specific Base Editor Patent Rights) and DNA Cleaving Patent Rights, solely to make, have made, offer for sale, sell, have sold, and
import Licensed Products, solely for use within the Field and (ii) the Product-Specific Base Editor Patent Rights solely to make, have made, offer for sale, sell, have sold, and import Licensed Products that are Base Editor Products, solely for
use within the Field, and (b) a non-exclusive, royalty-bearing license, sublicensable solely in accordance with Section 2.4 (Sublicenses) below, under the Institutions’
interests in (i) the Base Editor Patent Rights (other than the Product-Specific Base Editor Patent Rights) and DNA Cleaving Patent Rights, solely to make, have made, offer for sale, sell, have sold, and import Enabled Products solely for use
within the Field and (ii) the Product-Specific Base Editor Patent Rights solely to make, have made, offer for sale, sell, have sold, and import Enabled Products that are Base Editor Products, solely for use within the Field. 

  
 23 

 2.1.2 Subject to the terms and conditions set forth in this Agreement, Broad hereby grants
to Licensee an exclusive, worldwide, royalty-bearing license, sublicensable solely in accordance with Section 2.4 (Sublicenses) below, under the Institutions’ interests in the Gene Targeting Patent Rights, solely to
make, have made, offer for sale, sell, have sold, and import Licensed Products that are Base Editor Products, solely for use within the Field, and a non-exclusive, worldwide, royalty-bearing license,
sublicensable solely in accordance with Section 2.4 (Sublicenses) below, under the Institutions’ interests in the Gene Targeting Patent Rights solely to make, have made, offer for sale, sell, have sold, and import
Enabled Products that are Base Editor Products solely for use within the Field. 
 2.1.3 Subject to the terms and conditions set forth in
this Agreement, Broad hereby grants to Licensee a non-exclusive, worldwide, royalty-bearing license, sublicensable (through a single tier) solely in accordance with Section 2.4
(Sublicenses) below, under the Institutions’ interest in the Patent Rights solely for internal research purposes; provided that, notwithstanding the foregoing, the license granted under this Section 2.1.3 (License
Grants) excludes (a) Human Germline Modification (b) the stimulation of biased inheritance of particular genes or traits within a population of plants or animals and (c) the modification of the tobacco plan (including any plant part,
plant cell, plant tissue or plant seed), except for modifications that (i) are related to the use of the tobacco plant as a manufacturing system or as a model system for research purposes but (ii) are not related to any use or application
in the cultivation, growth, manufacture, exportation or production of any tobacco product. Notwithstanding the foregoing, in the event that Licensee has granted both a Sublicense of its
rights under Section 2.1.1 (License Grants) or Section 2.1.2 (License Grants) and an internal research Sublicense under this Section 2.1.3 (License Grants), then such
internal research Sublicense shall be sublicenseable through the same number of tiers as the Sublicense granted by Licensee pursuant to Section 2.1.1 (License Grants) or Section 2.1.2 (License
Grants). 
 2.2 Reservation of Rights, Certain Restrictions. Notwithstanding anything herein to the contrary: 

2.2.1 The Institutions retain the right for themselves and for other
not-for-profit research organizations and government agencies to make, use, perform and practice the subject matter described or claimed in the Patent Rights for
research, teaching, educational and scholarly purposes (including, but not limited to, the right to enter into projects permitted under 15 U.S.C. 3710a (the CRADA statute) or other sponsored research projects or collaborations whether or not such
collaborations are formal or informal), in all fields in all territories at any time without restriction; provided, however, that sponsored research funded by a commercial entity shall be considered research for purposes of this
Section 2.2.1 (Reservation of Rights, Certain Restrictions); 
 2.2.2 The Institutions and the United States
federal government retain rights in the Patent Rights pursuant to 35 U.S.C. §§ 200-212 and 37 C.F.R. § 401 et seq., and any right granted in this Agreement greater than that permitted under 35
U.S.C. §§ 200-212 or 37 C.F.R. § 401 et seq. shall be subject to modification as may be required to conform to the provisions of those statutes and regulations. Licensee acknowledges that the
United States federal government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded invention claimed in any Patent Right
as set forth in 35 U.S.C. §§ 200-211 and the regulations promulgated thereunder, as amended, or any successor statutes or regulations. 

  
 24 

 2.2.3 In addition to the reservation of rights under Section 2.2.1
(Reservation of Rights, Certain Restrictions), the Institutions reserve the right for themselves and for any Third Party (including non-profit and for-profit entities),
to research, develop, make, have made, use, offer for sale, sell, have sold, import or otherwise exploit the Patent Rights and Royalty-Bearing Products as research products or research tools, or for research purposes in the Field; 

2.2.4 Licensee agrees that any Royalty-Bearing Products used or sold in the United States that are subject to 35 U.S.C. §§ 201-211 and the regulations promulgated thereunder, as amended, or any successor statutes or regulations thereto shall, to the extent required by law, be manufactured substantially in the United States; and 

2.2.5 Broad retains the rights, for itself, and for the Institutions, where applicable, set forth in Section 2.5
(Inclusive Innovation Model), Section 3.5.1 (Notice/Explanation/Plan), Section 6.1.4 (Control), and Section 6.4 (Abandonment). 

2.2.6 RESERVED 
 2.3
Affiliates. The licenses granted to Licensee under Section 2.1 (License Grants) include the right to have some or all of Licensee’s rights or obligations under this Agreement exercised or performed by one or
more of Licensee’s Affiliates, solely on Licensee’s behalf; provided, however, that: 
 2.3.1 Licensee shall notify Broad in
writing in advance of any delegation to an Affiliate to exercise or perform any of Licensee’s rights or obligations under this Agreement, and shall use reasonable efforts to so notify Broad within [**] days in advance of any such delegation;

 2.3.2 prior to any Affiliate exercising or performing any of Licensee’s rights or obligations under this Agreement, such Affiliate
shall agree in writing with Licensee to be bound by the terms and conditions of this Agreement as if it were Licensee hereunder, including specific written agreement (a) to indemnify, defend and hold Indemnitees harmless, and carry insurance,
under the same terms as Article 9 of this Agreement, and (b) that the Institutions are express third party beneficiaries of such writing; provided that nothing in this Section 2.3.2 (Affiliates) is intended to
increase the payments (or the number of payments) to Broad under this Agreement (for non-limiting examples, an Affiliate agreeing to the terms and conditions of this Agreement as if it were Licensee hereunder
shall not increase the number of times the milestone tables in Article 4 can be run and shall not give rise to additional Win State Payments); 

2.3.3 no such Affiliate shall be entitled to grant, directly or indirectly, to any third party any right of whatever nature under, or with
respect to, or permitting any use or exploitation of, any of the Patent Rights, including any right to develop, manufacture, market or sell Royalty-Bearing Products; 

2.3.4 prior to any Affiliate exercising or performing any of Licensee’s rights or obligations under this Agreement, such Affiliate shall
agree in writing that it shall not practice the license under the Patent Rights for any uses prohibited by Section 2.7 (Additional Limitations on Exercise of License Rights) (except to the extent that the Licensee would
have the right to do so after notice from Broad of a permitted application of such use); 

  
 25 

 2.3.5 any act or omission taken or made by an Affiliate of Licensee under this Agreement
will be deemed an act or omission by Licensee hereunder, and Licensee shall be responsible for each of its Affiliates complying with all obligations of Licensee under this Agreement (including without limitation all restrictions placed on Licensee
herein), to the extent applicable to such Affiliate; and 
 2.3.6 any assumption of rights or obligations by Affiliates of Licensee under
this Agreement shall not relieve Licensee of any of its obligations under this Agreement. 
 2.4 Sublicenses. 

2.4.1 Sublicense Grant. Licensee will be entitled to grant Sublicenses to third parties under the licenses granted pursuant to
Section 2.1 (License Grants) subject to the terms of this Section 2.4 (Sublicenses). Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of
this Agreement. Notwithstanding any Sublicense, Licensee shall remain primarily liable to Broad for all of Licensee’s duties and obligations contained in this Agreement and any act or omission of a Sublicensee which would be a breach of this
Agreement if performed by Licensee shall be deemed to be a breach by Licensee of this Agreement. 
 2.4.2 Sublicense Agreements.
Licensee shall grant sublicenses pursuant to written agreements, which will be subject and subordinate to the terms and conditions of this Agreement. Such Sublicense agreements will contain, among other things, the following: 

2.4.2.1 all provisions necessary to ensure Licensee’s ability to perform its obligations under this Agreement; 

2.4.2.2 a provision requiring the Sublicensee to comply with all terms and conditions of the Agreement applicable to
Sublicensees under this Agreement, including Article 2 (License), 4.5 (Patent Challenge), 5.3 (Records), 5.3.2 (Audit of Sublicensees), 6.5 (Marking), 8.1 (Compliance with Law), Article 9
(Indemnification and Insurance), Sections 10.3.1 (Termination of Rights), 10.3.2 (Accruing Obligations), 11.1 (Confidentiality), 11.3 (Preference for United States Industry) and 11.5 (Use of Name); 

2.4.2.3 a section requiring Sublicensee to indemnify, defend and hold Indemnitees harmless, and carry insurance, under the same
terms set forth in Article 9 (Indemnification and Insurance) of this Agreement (which obligation to indemnify, defend, and hold harmless, to avoid doubt, may be limited to the activities under the Sublicense (e.g., the Sublicensee
shall not be required to indemnify for activities arising under other unrelated Sublicenses to unrelated Third Parties)), which also will state that the Indemnitees are intended third party beneficiaries of such Sublicense agreement for the purpose
of enforcing such indemnification; 
 2.4.2.4 a statement that Broad is an intended third party beneficiary of such
Sublicense to the extent such Sublicense relates to the sublicense of Patent Rights, solely for the purpose of enforcing all patent challenge, intellectual property ownership, indemnification and insurance and compliance with law provisions of such
Sublicense, in each case applicable to the Patent Rights (or the practice thereof) and, with respect to 

  
 26 

 
such indemnification and insurance provisions, Royalty-Bearing Products; and enforcing the right to terminate such Sublicense for breach of the patent challenge, indemnification (solely with
respect to such Sublicensee’s obligation to indemnify Broad) and insurance provisions of such Sublicense with respect to the Patent Rights (or the practice thereof) and, with respect to such indemnification and insurance provisions,
Royalty-Bearing Products; and a statement that (a) each other Institution is an intended third party beneficiary of such Sublicense for the purpose of enforcing such Institution’s rights, including indemnification and insurance provisions
that relate to the Patent Rights (or the practice thereof) or Royalty-Bearing Products under such Sublicense, and (b) (1) that the rights of Broad or any Institution may be enforced by any Institution in any court of competent jurisdiction and,
without limiting the generality of the foregoing, Sublicensee consents to jurisdiction in Massachusetts courts, and (2) notwithstanding the governing law selected for such Sublicense, the Sublicensee agrees that, in the event of any difference
in interpretation or result as between the laws of the jurisdiction of such Sublicense and the laws of Massachusetts, the laws of Massachusetts shall control in any action in which Broad or any Institution is enforcing its rights under such
Sublicense; 
 2.4.2.5 a provision stating that in the event Sublicensee or its Affiliate directly or indirectly brings,
assumes, or participates in, or knowingly, willfully or recklessly assists in bringing, a Patent Challenge then Licensee shall be entitled to terminate the Sublicense; 

2.4.2.6 a provision clarifying that, subject to Section 10.3.1 (Termination of Rights), in the event
of termination of the licenses set forth in Section 2.1 (License Grants) (in whole or in part (e.g., as to one license or the other, or termination in a particular country)), any existing Sublicense agreement shall
terminate to the extent of such terminated license; 
 2.4.2.7 a provision prohibiting the Sublicensee from sublicensing its
rights under such Sublicense agreement through more than [**] additional tiers, provided that such further Sublicense also shall comply with the terms of this Section 2.4 (Sublicenses); 

2.4.2.8 a provision requiring the Sublicensee to notify Licensee of the achievement of each milestone described in
Section 4.3.1 (Product Milestone Payments) in accordance with the timeframes set forth in Section 4.3.3 (Milestone Payments); 

2.4.2.9 a provision requiring the Sublicensee to comply with Section 8.1 (Compliance with Laws) and
Section 11.5 (Use of Names) of this Agreement; 
 2.4.2.10 a provision requiring the Sublicensee to
agree that it shall not use the Patent Rights for Human Germline Modification; and 
 2.4.2.11 a provision prohibiting the
Sublicensee from assigning the Sublicense agreement without the prior written consent of Broad, except that Sublicensee may assign the Sublicense agreement to (a) its Affiliate or (b) a successor in connection with the merger,
consolidation or sale, lease or other transfer of all or substantially all of its assets or that portion of its business to which the Sublicense agreement relates; provided, however, that any permitted assignee agrees in writing to be bound by the
terms of such Sublicense agreement. 

  
 27 

 2.4.3 Delivery of Sublicense Agreement. Licensee shall furnish Broad with a fully
executed copy of any Sublicense agreement promptly after its execution, provided that Licensee shall have no obligation to provide Broad with a copy of a Sublicense agreement between Licensee or a Sublicensee, on the one hand, and an Affiliate of
Licensee or such Sublicensee or a contract research organization or contract manufacturing organization (solely for the provision of services under such Sublicense), on behalf of Licensee or such Sublicensee under this Agreement, on the other hand.
All Sublicenses shall be the Confidential Information of Licensee. Broad shall keep all such copies in its confidential files and shall use them solely for the purpose of monitoring Licensee’s and Sublicensees’ compliance with their
obligations hereunder and enforcing Broad’s rights under this Agreement. Licensee shall be entitled to redact proprietary non-public information of Licensee or the applicable Sublicensee or research plans
under the Sublicense to the extent not reasonably required for Broad to monitor Licensee’s and Sublicensee’s compliance with their obligations under the applicable Sublicense and this Agreement and for Broad to enforce its rights under
this Agreement. Licensee shall not redact any information [**] for Broad to evaluate and confirm compliance of such Sublicense with the terms and conditions of this Agreement. 

2.4.4 Termination for Breach by Sublicensee. Any act or omission of a Sublicensee which would be a breach of this Agreement if performed
by Licensee shall be deemed to be a breach by Licensee of this Agreement. Without limiting any other rights or remedies available to Broad, it is understood that if (a) Licensee cures such breach in accordance with
Section 10.2.2 (Termination for Default) or (b) Licensee uses commercially reasonable efforts to cure such breach in accordance with Section 10.2.2 (Termination for Default) and terminates the
applicable Sublicense, then Broad shall not be entitled to terminate this Agreement for the breach by the Sublicensee even if it resulted in a material breach of this Agreement. 

2.5 Inclusive Innovation Model. 

2.5.1 General. If a Third Party inquires with Broad for a license under the Base Editor Patent Rights (other than Product-Specific Base
Editor Patent Rights) or DNA Cleaving Patent Rights with respect to products for use in the Field or for a license under the Gene Targeting Patent Rights or Product-Specific Base Editor Patent Rights with respect to Base Editor Products for use in
the Field, in each case while this Agreement is in effect, Broad may refer such Third Party to Licensee to seek a potential Sublicense. 

2.5.2 Start Date. Notwithstanding anything to the contrary in this Agreement, Sections 2.5.3 (Proposed Product Notice) through
2.5.13 ([**]) shall apply only from and after the second (2nd) anniversary of the Effective Date (“Start Date”). Prior to Start Date, Broad shall have no right to invoke
such Sections. 

  
 28 

 2.5.3 Proposed Product Notice. If after the Start Date a Third Party that is not a
Competitor (a “Proposing Party”) makes a Bona Fide Proposal to Broad for developing what Broad reasonably believes is a [**] Proposed Product that is Covered by the Base Editor Patent Rights (other than the Product-Specific Base
Editor Patent Rights) or DNA Cleaving Patent Rights or, to the extent such [**] Proposed Product is a Base Editor Product, is additionally or alternatively Covered by the Gene Targeting Patent Rights or Product-Specific Base Editor Patent Rights,
and Broad is interested in having such [**] Proposed Product developed and commercialized, Broad may notify Licensee of the Third Party’s Bona Fide Proposal and shall include in such notification the identity of the Proposing Party and the
identity of the applicable [**] to which the [**] Proposed Product is directed (such notice, the “Proposed Product Notice,” and the effective date of such notice in accordance with Section 11.7, the
“Proposed Product Notice Date”). [**]. 
 2.5.4 Exceptions. If the Proposing Party’s proposal does not meet the
definition of Bona Fide Proposal or the proposed product is not a [**] Proposed Product, each as determined in Broad’s reasonable discretion, or the Third Party is a Competitor or becomes a Competitor during the Proposed Product Development
Period, then Sections 2.5.5 ([**] Proposed Product Options) through 2.5.13 ([**]) shall not apply (and without limiting the generality of the foregoing Broad shall have no right to grant a [**] License to such Third Party with respect
to such [**] Proposed Product nor to require that Licensee grant a Sublicense or provide a development plan and development milestones in relation thereto). Notwithstanding the foregoing, if Licensee reasonably believes such Third Party is a
Competitor under Section 1.42(b) (Competitor), then, promptly after the Proposed Product Notice Date, Licensee shall notify Broad and such notice shall include an explanation, to Broad’s reasonable satisfaction,
as to how such Third Party is an Affiliate controlled by (and not merely under common control with) an entity described under Section 1.42(a) (Competitor). If Licensee provides such notice to Broad’s reasonable
satisfaction, then Sections 2.5.5 ([**] Proposed Product Options) through 2.5.13 ([**]) shall not apply. For clarity, if a Third Party becomes a Competitor after the Proposed Product Development Period for a given [**]
Proposed Product, Broad’s right to grant or have granted a [**] License, and any [**] License already granted by Broad, to such Third Party with respect to such [**] Proposed Product will not be affected, provided that, going forward, if such
Third Party remains a Competitor, then such Third Party will be ineligible to be considered a Proposing Party under Section 2.5.3 (Proposed Product Notice). 

2.5.5 [**] Proposed Product Options. 

2.5.5.1 Notice to Broad. Within [**] days of the Proposed Product Notice Date, Licensee may either (a) provide a
Current Development Demonstration to Broad in accordance with Section 2.5.6 (Existing Development or Commercialization), or (b) notify Broad as to whether it (i) has a good faith interest in researching,
developing and commercializing the [**] Proposed Product itself in accordance with Section 2.5.7 (Intended Development or Commercialization), (ii) has a good faith interest in entering into a Sublicense with the Proposing
Party to research, develop and commercialize the [**] Proposed Product in accordance with Section 2.5.8 (Proposing Party Development or Commercialization), (iii) has a good faith interest in entering into a Sublicense with
another Third Party to research, develop and commercialize the [**] Proposed Product in accordance with Section 2.5.9 (Third Party Development or Commercialization), or (iv) does not wish to pursue the foregoing (a),
(b)(i), (b)(ii) or (b)(iii). For clarity, Licensee may notify Broad at any time that it is no longer interested in developing such [**] 

  
 29 

 
Proposed Product under either (a), (b)(i), (b)(ii) or (b)(iii). As part of the notice to Broad under this Section 2.5.5.1 (Notice to Broad), Licensee shall also confirm
whether, in the [**] months prior to the Proposed Product Notice Date, Licensee (or an Affiliate of Licensee) is already negotiating or has already negotiated with the Proposing Party to research, develop or commercialize the applicable [**]
Proposed Product, and the length of time and nature of such negotiations (e.g., whether there has been active and consistent dialogue with the applicable counter-party, the exchange of terms and conditions, etc.). 

2.5.5.2 Proposed Product Development Period. If Licensee so notifies Broad under (b)(i), (b)(ii) or (b)(iii) of
Section 2.5.5.1 (Notice to Broad), Licensee shall have [**] months from the Proposed Product Notice Date to prepare a development plan and commence activities thereunder with respect to such [**] Proposed Product in
accordance with Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or Commercialization), or 2.5.9 (Third Party Development or Commercialization), as applicable, (such [**] month
period, the “Proposed Product Development Period”). [**] months into the Proposed Product Development Period, Licensee shall provide to Broad a good faith update as to the progress of such plan, including whether Licensee intends to
use the remaining [**] months of the Proposed Product Development Period to continue to develop such plan and commence activities thereunder. The Proposed Product Development Period for a given [**] Proposed Product shall be reduced by the length of
time of active negotiations between Licensee and the Proposing Party in the [**] months prior to the Proposed Product Notice Date to research, develop or commercialize the applicable [**] Proposed Product, provided that such reduction shall not be
greater than [**] months and provided further that only active negotiations regarding a transaction specific to such [**] Proposed Product (and not a class or type of products generally or a Multi-Product Negotiation) shall be offset from
Licensee’s Proposed Product Development Period. In the event that the Parties are unable to agree as to whether Licensee has been engaged in active negotiations, or the length of time of such active negotiations, then the matter shall be
resolved in accordance with Exhibit 4.4.7, provided that any final determination of the applicable arbitrator(s) shall not be deemed to extend (a) the Proposed Product Development Period beyond [**] months, or (b) the
reduction to such Proposed Product Development Period for active negotiations beyond [**] months. Further, the Proposed Product Development Period shall apply on a Proposed Product
Notice-by-Proposed Product Notice basis, and shall be no longer than [**] months (subject to the foregoing sentence with respect to a reduction of up to [**] months for
prior negotiations by Licensee). By way of example, if Licensee has actively negotiated for [**] months with a Proposing Party pursuant to Section 2.5.8 (Proposing Party Development or Commercialization) prior to the
applicable Proposed Product Notice Date, then the applicable Proposed Product Development Period shall be reduced by [**] months, and Licensee shall have [**] months remaining in which to develop a plan pursuant to
Section 2.5.7 (Intended Development or Commercialization) or negotiate a Sublicense pursuant to Section 2.5.8 (Proposing Party Development or Commercialization) or
Section 2.5.9 (Third Party Development or Commercialization). By way of further example, if Licensee has [**] months remaining of the applicable Proposed Product Development Period but Licensee ceases its ongoing
negotiations with [**] months remaining to negotiate a Sublicense with an alternative Third Party, then Licensee shall have no more than [**] months within which to negotiate such Sublicense pursuant to Section 2.5.8
(Proposing Party Development or Commercialization) or Section 2.5.9 (Third Party Development or Commercialization). 

  
 30 

 2.5.6 Existing Development or Commercialization. If the [**] Proposed Product is
directed to a [**] for which the Licensee, directly or through any of its Affiliates or Sublicensees, is currently researching, developing or commercializing a Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product in the
Field, then Licensee may, within [**] days of the Proposed Product Notice Date, provide a Current Development Demonstration to Broad. Thereafter, Licensee shall continue to use commercially reasonable efforts, itself or through its
Affiliate or Sublicensee to continue to implement such plan. Licensee shall provide a written report to Broad describing Licensee’s progress under the applicable plan at least [**] until the First Commercial Sale of such Licensed Product,
Enabled Product, Base Editor Product or DNA Cleaving Product. Licensee may, on an [**] basis concurrently with the delivery of each [**] diligence report to be provided by Licensee to Broad under Section 3.4 (Reporting)
hereof, make commercially reasonable adjustments to the applicable research, development or commercialization plan as necessary to improve Licensee’s ability to meet its obligations under such plan; provided that, such adjustments shall be
subject to review and approval by Broad, such approval not to be unreasonably withheld, conditioned or delayed. 
 2.5.7 Intended
Development or Commercialization. If Licensee notifies Broad within [**] days of the Proposed Product Notice Date that Licensee or its Affiliate is interested in developing a Licensed Product, Enabled Product, Base Editor Product
or DNA Cleaving Product directed to the [**] as such [**] Proposed Product in the Field, then within the Proposed Product Development Period, Licensee shall be required to (a) prepare, or have prepared, a commercially reasonable research,
development or commercialization plan, similar to the Development Plan with respect to other Licensed Products developed by Licensee in the Field, subject to necessary adjustments and including reasonable development milestones, at
least [**] preclinical development milestone and associated timelines, and including evidence that Licensee or its applicable Affiliate or Sublicensee has, or reasonably expects to have, access to any intellectual property (other than
any intellectual property owned or controlled by the Proposing Party) that would be necessary to develop and commercialize such Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product and has, or reasonably expects to have,
funding available to advance such plan and (b) commence, or have commenced on its behalf, research or development activities for such Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product in the Field pursuant to such
plan. Licensee’s failure to prepare or have prepared a plan as described in clause (a) of the preceding sentence or to commence or have commenced research or development activities as described in clause (b) of the preceding sentence
shall, in each case, not constitute a material breach of this Agreement; provided, however that, in addition to Broad having the right to grant a [**] License to the extent permitted in Section 2.5.11 ([**] License),
following each such failure and solely for the subsequent [**] Proposed Product which Licensee elects to develop under Section 2.5.7 (Intended Development or Commercialization), Section 2.5.8
(Proposing Party Development or Commercialization), or Section 2.5.9 (Third Party Development or Commercialization), and for which at least [**] months of the Proposed Product Development Period for such [**] Proposed
Product remain following any applicable reductions pursuant to Section 2.5.5.2 (Proposed Product Development Period), Broad shall be entitled to reduce by [**] months the Proposed

  
 31 

 
Product Development Period; provided further that, for clarity, the right to reduce the applicable Proposed Product Development Period pursuant to this sentence shall apply following each such
failure to prepare such a plan or commence or have commenced such research or development activities. Broad’s rights with respect to a [**] License set forth in Section 2.5.11 ([**] License), [**] for a failure under
the foregoing sentence that results in a diligence failure pursuant to Section 3.5.6.2 (Unmet Deadline), as applicable, and Broad’s right to reduce a Proposed Product Development Period pursuant to the preceding
sentence shall be Broad’s sole and exclusive remedies under law and this Agreement for any failure by Licensee to prepare such a plan or commence or have commenced such research or development activities as described in the preceding sentence.
In the discussion of such development plan and development milestones, Broad shall not unreasonably withhold its consent to Licensee’s proposed plan. If the Parties agree on such development plan and milestones and Licensee or its Affiliate
commences research or development activities thereunder within the Proposed Product Development Period, Licensee shall maintain its exclusive license(s) hereunder with respect to such [**] Proposed Product in the Field, but shall be obligated
(i) to, itself or through its Affiliate or Sublicensee, use commercially reasonable efforts to develop and commercialize the Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product in the Field in accordance with such new
development plan (which shall be incorporated into and be part of the “Development Plan” for all purposes hereunder) and (ii) to, itself or through its Affiliate or Sublicensee, meet the development milestones on the timeline
associated therewith with respect to the Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product in the Field (which shall be a “Development Milestone” for all purposes hereunder) in the Field (subject to extension
in the same manner as provided in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions) applied mutatis mutandis), and (iii) provide a written report to Broad describing Licensee’s progress under
such plan at least [**] until the First Commercial Sale of such Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product. Exhibit 3.1.1 shall be amended to reflect such development milestones and timeline with respect to
such Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product. Licensee may, on an [**] basis concurrently with the delivery of each [**] diligence report to be provided by Licensee to Broad under
Section 3.4 (Reporting) hereof, make such commercially reasonable adjustments to the applicable plan as necessary to improve Licensee’s ability to meet its research, development or commercialization obligations under
such plan; provided that such adjustments shall be subject to review and approval by Broad, such approval not to be unreasonably withheld, conditioned or delayed. 

2.5.8 Proposing Party Development or Commercialization. If, within [**] days of the Proposed Product Notice Date, Licensee
notifies Broad that Licensee is not interested in developing such [**] Proposed Product in the Field but that it wishes to grant a Sublicense to the Proposing Party to develop a Royalty-Bearing Product directed to the [**] as such [**] Proposed
Product in the Field, Licensee will have until the end of the Proposed Product Development Period to (a) negotiate and enter into such a Sublicense agreement with such Proposing Party, (b) prepare, or have prepared, together with the
Proposing Party, a commercially reasonable research, development or commercialization plan similar to the Development Plan with respect to other Licensed Products developed by Licensee in the Field, subject to necessary adjustments and including
reasonable development milestones, at least [**] preclinical development milestone and associated timelines, and including evidence that Licensee or its applicable Affiliate or Sublicensee or the Proposing Party have, or reasonably

  
 32 

 
expects to have, access to any intellectual property that would be necessary to develop and commercialize such Royalty-Bearing Product in the Field and has, or reasonably expects to have, funding
available to advance such plan and (c) commence research or development activities with the Proposing Party for such Royalty-Bearing Product pursuant to such plan. In the discussion of such development plan and development milestones, Broad
shall not unreasonably withhold its consent to Licensee’s proposed plan. If the Parties agree on such development plan and milestones and research or development activities thereunder are commenced by or on behalf of the Licensee or the
Proposing Party within the Proposed Product Development Period, Licensee shall maintain its exclusive license(s) hereunder with respect to such [**] Proposed Product in the Field, but shall be obligated (i) to, itself or through its Affiliate
or Sublicensee (including the Proposing Party), use commercially reasonable efforts to develop and commercialize the Royalty-Bearing Product in the Field in accordance with such new development plan (which shall be incorporated into and be part of
the “Development Plan” for all purposes hereunder) and (ii) to, itself or through its Affiliate or Sublicensee (including the Proposing Party) meet the development milestones on the timeline associated therewith with respect to the
Royalty-Bearing Product (which shall be a “Development Milestone” for all purposes hereunder) in the Field (subject to extension in the same manner as provided in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan
Discussions) applied mutatis mutandis), and (iii) provide a written report to Broad describing Licensee’s and the Proposing Party’s progress under such plan at least [**] until the First Commercial Sale of such Royalty-Bearing
Product. Exhibit 3.1.1 shall be amended to reflect such development milestones and timeline with respect to such Royalty-Bearing Product. Licensee may, on an [**] basis concurrently with the delivery of each [**] diligence report to be
provided by Licensee to Broad under Section 3.4 (Reporting) hereof, make such commercially reasonable adjustments to the applicable plan as necessary to improve Licensee’s ability to meet its research, development or
commercialization obligations under such plan; provided that such adjustments shall be subject to review and approval by Broad, such approval not to be unreasonably withheld, conditioned or delayed. 

2.5.9 Third Party Development or Commercialization. In parallel with, or in lieu of, seeking to Sublicense a Royalty-Bearing Product to
the Proposing Party, the Licensee may seek to enter into a Sublicense with another Third Party. In such event, Section 2.5.8 (Proposing Party Development or Commercialization) shall apply to Licensee with such Third Party
as the Proposing Party thereunder. If the Licensee enters into such a Sublicense with another Third Party within the Proposed Product Development Period, then Licensee shall have the right to discontinue any discussions under
Section 2.5.8 (Proposing Party Development or Commercialization) without consequence and as long as the Sublicense with the Third Party that Licensee entered into remains in effect, Broad shall have no right to grant
a [**] License for the applicable [**] Proposed Product. In the event that such Sublicense terminates, then Licensee shall promptly notify Broad and then [**] ([**] License) shall govern regarding any right of Broad to [**] License with
respect to the relevant [**] Proposed Product.  
 2.5.10 Proposed Product
Development Period Obligations. Throughout the Proposed Product Development Period set forth in Sections 2.5.7 (Intended Development or Commercialization) through Section 2.5.9 (Third Party Development or
Commercialization), Licensee shall continuously use commercially reasonable efforts to, as applicable, (a) prepare, or have prepared, the research, development or commercialization plan and thereafter, commence

  
 33 

 
research or development activities pursuant to such plan, as required by Section 2.5.7 (Intended Development or Commercialization), or (b) enter into a Sublicense
agreement and thereafter, commence (or have commenced) research and development activities under the research, development or commercialization plan, as required by Section 2.5.8 (Proposing Party Development or
Commercialization) or 2.5.9 (Third Party Development or Commercialization). 
 2.5.11 [**] License. If, with respect to
a [**] Proposed Product, (a) within [**] days of the Proposed Product Notice Date (or at any other time during the Proposed Product Development Period), Licensee notifies Broad that [**] in (i) [**], (b) Licensee [**], (c) Licensee [**], (d)
Licensee [**], or (e) Licensee otherwise [**], as applicable, then, in each case (a) through (e), Broad will be entitled, [**] ([**]), to grant, in its sole discretion, to such Proposing Party [**] license under the Patent Rights to
make, have made, offer for sale, sell, have sold and import such [**] Proposed Product or a Related Product to such [**] Proposed Product (a “[**] License”), and Licensee’s rights to such Patent Rights shall, [**]; provided
that each [**] License will require the Proposing Party to [**], provided further that [**]. 
 2.5.12 [**]. All consideration to
Broad (or its designee) under a [**] License (other than reimbursement for patent expenses paid to third parties equal to the out-of-pocket cost to Broad of such patent
expenses) is “[**].” Broad shall be entitled to [**]. Unless otherwise agreed by the Parties, [**] will be paid [**] on an [**] basis in accordance with Broad’s usual and customary practices for its distributions, except to the
extent [**] under this Agreement in which case Broad may elect to [**]. [**] License [**] received by Broad or its designee, whether zero or a positive number, on an [**] basis in accordance with Broad’s usual and customary
practices for its distributions. Such reports and any related records shall be subject to audit by the Licensee on terms equivalent to those set forth in Section 5.3 (Records), applied mutatis mutandis, provided,
however, that such audit shall be limited to an audit of Broad’s records and shall not extend to any licensee under a [**] License (either directly or by causing Broad to exercise any audit rights it may have under the [**] License), and such
audit shall be limited in scope to a determination that Broad’s report of [**] is true and complete. 
 2.5.13 [**]. Licensee shall not
be required to provide a Current Development Demonstration in accordance with Section 2.5.6 (Existing Development or Commercialization) hereof, or elect a [**] Proposed Product option in accordance with
Section 2.5.5 ([**] Proposed Product Options) hereof, [**] License, for [**] Proposed Products [**] that have been selected for research, development or commercialization of a Licensed Product in the Field pursuant to a
collaboration agreement between Licensee or its Affiliates and [**] (such collaboration agreement, a “[**],” such [**], in accordance with, and subject to, the following terms and conditions: 

2.5.13.1 [**]. A [**] that has been selected for research, development or commercialization of a Licensed Product in the Field
pursuant to a [**] may be [**] by Licensee, on a [**] basis, at the time of execution of such [**] or at any time within [**] years thereafter, up to that number of [**] specified in Section 2.5.13.3 (Permitted Number of
[**]), to a list of [**] (“[**]”) generated by Licensee and provided to and maintained by Broad or [**], as applicable. In the event there is [**], the compensation, costs and expenses for [**] shall be incurred and paid
solely by Licensee. A [**] shall be deemed a “[**]” for the purposes of this Section 2.5.13 ([**]) and only 

  
 34 

 
those [**] that are included on the [**] shall be deemed [**] for the purposes of this Section 2.5.13 ([**]). For the avoidance of doubt, a [**] shall not by itself
constitute a [**]. Except as noted below with respect to [**], the effective date of addition of any [**] (“Selection Date”) shall be [three (3)] business days prior to the date on which Broad or the [**] receives written notice
from Licensee that a given [**] is to be added to the [**]. Except as noted below in connection with [**], a [**] shall be deemed a [**] for a period of [**] years from the date such [**] is added to the [**] unless removed in accordance with
Section 2.5.13.6 (Other Limitations on [**]). In addition to the foregoing, Licensee may add to the [**] the [**] that are the subject of a [**] from a [**] at any time and from time to time between Licensee and such [**]
regarding a [**]. A [**] that is included on the [**] shall be deemed a “[**]” for the purposes of this Section 2.5.13 ([**]) during the [**] Period (as defined below) and the date on which Broad or the
[**] receives written notice from Licensee that a given [**] is to be added to the [**] List shall be deemed the “Selection Date” for such [**]. The number of [**] that Licensee may add to the [**] in connection with any such [**]
shall not exceed the number of [**] as Licensee would be eligible to add to the [**] if Licensee and such Third Party entered into such [**] Collaboration, as determined based on a [**] by such prospective [**] Collaborator in connection with such
active discussions. Licensee shall clearly identify in its notice to Broad [**] those [**]. Licensee shall notify Broad [**] promptly if any [**] should be removed from the [**] because Licensee determines that the circumstances of the discussions
with the [**] have changed and that such [**] is no longer the subject of [**], in which case such [**] shall be deemed not to have been nominated as a [**] for the purposes of this Section 2.5.13 ([**]). A [**] shall
remain a [**], a [**] for [**] months (the “[**] Period”) from the Selection Date for such [**], subject to up to [**] [**] of an additional [**] months by Licensee upon notice to Broad or the [**] if Licensee determines in good
faith that such [**] remains the subject of [**] between Licensee and the relevant [**] regarding a [**] Collaboration at the time of such [**]. Licensee (or the [**], as applicable) shall notify Broad that Licensee has [**] that a [**] shall remain
on the [**]. Such notice shall not identify the [**] by name nor include any other identifiable information but shall include a [**] for such [**] which shall enable Broad to track and monitor the status of such [**]. The purpose of such notice is
to permit Broad to initiate communications with Licensee and to monitor compliance by Licensee with the terms of this Agreement. If Licensee enters into a [**] with respect to a [**], Licensee shall notify Broad within [three (3)] business days
thereof, and such [**] shall remain a [**] and the Selection Date for such [**] shall remain the date on which Broad or the [**] received written notice from Licensee that such [**] was to be added to the [**]. If there is a [**], the [**] shall
notify Licensee within [**] business day if any [**] that Licensee notifies [**] to add to the [**] is already, at the time of such notice, the subject of a [**] Inquiry having a [**] Inquiry Date that is more than [**] business days prior to such
notice from Licensee. A [**] shall not become a [**] or be added to the [**] if such [**] is the subject of a [**] Inquiry having a [**] Inquiry Date that is more than [**] business days prior to the time at which Licensee notifies the [**] that
Licensee is designating such [**] for inclusion on the [**]. 

  
 35 

 2.5.13.2 [**]. If no [**] has been selected at the time of
Licensee’s selection of the first [**], Broad shall maintain the [**]. If at any time during the Term, (a) Licensee wishes to select a [**] or (b) Licensee no longer wishes for Broad to retain the [**], then Licensee shall provide Broad with written notice thereof (the “[**]”) and shall include in such notice a list of at least [**] independent attorneys registered to practice
before the United States Patent and Trademark Office of whom neither Licensee nor Broad is a client, who are experienced in intellectual property matters in the biopharmaceutical industry and who are able to take on an obligation of confidentiality
to both Parties. Within [**] days after the date of the [**], Broad shall select by written notice to Licensee (the “[**] Selection Notice”) one of the individuals named in the [**]. Such individual selected by Broad shall be the
“[**].” If Broad does not select such individual in a [**] Selection Notice within such [**] day period, then the individual selected by Licensee from among the individuals named in the [**] and identified by Licensee in writing to
Broad shall be the [**]. The [**] shall be bound by confidentiality obligations to both Parties. In the event a [**] is no longer able or willing to serve in such role, the Parties shall appoint a new [**] by again following the procedures set forth
in this Section 2.5.13.2. Notwithstanding anything in this Section 2.5.13, in the event that Licensee does not provide a [**] to Broad, there will be no [**] and, unless the context otherwise
requires or unless otherwise expressly set forth in this Agreement, all references to “the [**]” under this Agreement will refer to Broad. 

2.5.13.3 Permitted Number of [**]. The number of [**] that may be selected as [**] for a given [**] is dependent
on the amount of [**] under the [**], in accordance with the following provisions of this Section 2.5.13.3 (Permitted Number of [**]). On a [**] basis, Licensee may select as [**] up to that number of [**] that is
proportionate to the total amount of [**] under a given [**] at a rate of no less than [**] per [**]; provided, however, that such rate shall be [**] per [**] in effect as of the Effective Date. By way of example, (a) if the [**] under the [**]
is [**], Licensee may add up to [**] to the [**], (b) if the [**] under the [**] is [**], Licensee may add up to [**] to the [**], and (c) if the [**] under the [**] is [**], Licensee may add up to [**] to the [**], in each case
(a) through (c) which [**] shall be deemed [**]. If at any point during the Collaboration Period, there is a reduction in the levels of [**] under a given [**], Licensee shall notify Broad of such reduction and the [**] shall be adjusted
accordingly to reflect such reduction in [**]. Promptly after the date of execution of any [**] are to be selected, Licensee shall notify Broad and, if applicable, the [**] thereof, and shall include in such notice the amount of [**] under such
[**]. 
 2.5.13.4 [**] Inquiry. Notwithstanding anything to the contrary in this Agreement, this
Section 2.5.13.4 ([**] Inquiry) shall only apply if a [**] has been appointed under Section 2.5.13.2 ([**]). For any Proposed Product for which a Bona Fide Proposal has been provided to Broad,
prior to providing a Proposed Product Notice with respect to such Proposed Product to Licensee in accordance with Section 2.5.3 (Proposed Product Notice), Broad shall inquire of the [**] in writing whether or not the [**]
to which the applicable Proposed Product is directed is a [**] (such inquiry, the “[**] Inquiry,” the date of such inquiry, the “[**] Inquiry Date”). The [**] shall, within the period beginning on the [**] business
day and ending on the [**] business day following Broad’s request, notify Broad in writing whether or not such [**] is a [**] (such notice, the “[**] Notice”). The [**] Notice shall note if a [**]. If such [**], the [**] Notice
shall include the Selection Date for such [**], and the provisions of Section 2.5.13.5 (Time-Limited Preclusion of [**]) and Section 2.5.13.6 (Other Limitations on

  
 36 

 
[**]) shall apply. If such [**] is not a [**], then Broad may provide Licensee with a Proposed Product Notice with respect to the Proposed Product that is directed to the applicable [**] under
Section 2.5.3 (Proposed Product Notice). If the [**] does not [**] provide a [**] Notice to Broad, then Broad may notify Licensee in writing thereof (“[**] Non-Performance
Notice”) and Licensee may notify the [**] of such non-performance. If Broad does not receive a [**] Notice within [**] business days of the date of the [**]
Non-Performance Notice, then Broad may provide a Proposed Product Notice directly to Licensee under Section 2.5.3 (Proposed Product Notice). [**] shall not disclose the existence or
nature of a [**] Inquiry to Licensee until after the [**] business day following such [**] Inquiry, at which time [**] shall notify Licensee of each [**] that is the subject of such [**] Inquiry. Broad shall not disclose to any Third Party whether a
[**] is a [**] reserved by Licensee or otherwise is under research, development and/or commercialization by Licensee or its Affiliate or Sublicensee; provided, however, that for any [**] that is the subject of a [**] Inquiry during the Collaboration
Period for such [**], Broad shall be entitled to inform the Proposing Party that provided the Bona Fide Proposal for the [**] Proposed Product directed at the applicable [**] of the date on which such [**] that is a [**] may become available for a
renewed Bona Fide Proposal, such date to correspond with the expiration of the Collaboration Period for the applicable [**]. If such Proposing Party provides such renewed Bona Fide Proposal, and Broad provides to Licensee a corresponding Proposed
Product Notice based on such Bona Fide Proposal, then the provisions of Section 2.5.13.5 (Time-Limited Preclusion of [**]) shall apply to such Proposed Product Notice. 

2.5.13.5 Time-Limited Preclusion of [**]. For a period of [**] years from the Selection Date (the
“Collaboration Period”), Licensee shall not be required to provide a Current Development Demonstration in accordance with Section 2.5.6 (Existing Development or Commercialization) hereof, or elect a [**]
Proposed Product option in accordance with Section 2.5.5 ([**] Product Options) hereof, and Broad shall have no right to grant a [**] License, for any [**] Proposed Product directed to a [**], provided that the Selection
Date for such [**] is within [**] years from the execution date of the [**] under which the [**] has been selected. Following expiration of the Collaboration Period for a given [**], if Broad receives a Bona Fide Proposal for a [**] Proposed Product
directed to such [**] and provides such Proposed Product Notice to Licensee, Licensee shall be required to provide to Broad a Current Development Demonstration for such [**] Proposed Product. If Licensee fails to provide a Current Development
Demonstration for such [**] Proposed Product, then Broad shall be entitled to grant the Proposing Party a [**] License for such [**] Proposed Product. 

2.5.13.6 Other Limitations on [**]. The Collaboration Period shall apply in lieu of, and not in addition to, the
Proposed Product Development Period set forth in Sections 2.5.7 (Intended Development or Commercialization) through 2.5.9 (Third Party Development and Commercialization). Once a given [**] has been selected as a [**]
under a given [**], the [**] Proposed Product options set forth in Section 2.5.5 ([**] Proposed Product Options) shall not apply to [**] Proposed Products directed to such [**]. [**] may be dropped from the [**] upon notice
by Licensee to Broad; provided that, once a [**] has been dropped from the [**] for a given [**] (other than a [**] that is a [**] at the time it is dropped), it may not again be selected to the [**] for such [**]. 

  
 37 

 2.5.14 Processing of Proposed Product Notices. Licensee shall not be required to
simultaneously prepare or carry-out a plan under Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or Commercialization), or 2.5.9 (Third Party
Development or Commercialization) in accordance with the timing requirements set forth therein or with Section 2.5.10 (Proposed Product Development Period Obligations) (to “Process”) for more than [**]
Proposed Product Notices at any one time. If Broad provides a Proposed Product Notice for which Licensee fails to make a Current Development Demonstration and Licensee is currently Processing [**] other Proposed Product Notices on the Proposed
Product Notice Date for such Proposed Notice, then the time periods set forth in Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or Commercialization), 2.5.9 (Third Party
Development or Commercialization), as applicable, for Processing of any such additional Proposed Notice by Licensee shall each be extended (and the obligation in Section 2.5.10 (Proposed Product Development Period
Obligations) shall be tolled) by a period equal to the result of multiplying (a) [**] months times (b) (i) [**] if the number of Proposed Product Notices being Processed by Licensee on the relevant Proposed Product Notice Date is more than [**] and
less than or equal to [**], [**] if the number of Proposed Product Notices being Processed by Licensee on the relevant Proposed Product Notice Date is more than [**] and less than or equal to [**], (iii) [**] if the number of Proposed Product
Notices being Processed by Licensee on the relevant Proposed Product Notice Date is more than [**] and less than or equal to [**], and (iv) [**] if the number of Proposed Product Notices being Processed by Licensee on the relevant Proposed Product
Notice Date is more than [**] (“Proposed Product Extension Period”). During such Proposed Product Extension Period for a given Proposed Product Notice, Broad shall not be permitted to grant a [**] License to any [**] Proposed
Product that is the subject of such Proposed Notice. If the number of Proposed Product Notices being Processed by Licensee on the relevant Proposed Product Notice Date is more than [**], Licensee shall have no obligation to Process additional
Proposed Notices until the number of Proposed Notices being Processed by Licensee is fewer than [**], and the Proposed Product Extension Period shall be extended until, and shall be recalculated at, such time. 

2.6 No Other Grant of Rights. Except as expressly provided herein, nothing in this Agreement will be construed to confer any ownership
interest, license or other rights upon Licensee or its Affiliates or Sublicensees by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of Broad, or any other entity, regardless of
whether such technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Patent Rights. By way of example and not of limitation, nothing contained herein shall restrict Broad from
granting licenses under (a) the Patent Rights outside the Field or (b) the Product-Specific Base Editor Patent Rights and the Gene Targeting Patent Rights inside or outside the Field, provided such rights in the foregoing clause
(b) are not granted to make, have made, offer for sale, sell, have sold, and import Base Editor Products for use in the Field (other than as permitted under Section 2.2 (Reservation of Rights, Certain Restrictions))
for so long as and to the extent that Licensee is granted exclusive licenses hereunder to such Patent Rights for such Base Editor Products in the Field. 

  
 38 

 2.7 Additional Limitations on Exercise of License Rights. 

2.7.1 Germline Modification. Licensee will not use the Patent Rights for Human Germline Modification. 

2.7.2 Gene-Drive Applications. Licensee will not use the Patent Rights for the stimulation of biased inheritance of particular genes or
traits within a population of plants or animals. 
 2.7.3 Tobacco. Licensee will not use the Patent Rights for modifying the tobacco
plant (including any plant part, plant cell, plant tissue or plant seed), except for modifications that (a) are related to the use of the tobacco plant as a manufacturing system or as a model system for research purposes but (b) are not
related to any use or application in the cultivation, growth, manufacture, exportation or production of any tobacco product. 
 3. Development and
Commercialization. 
 3.1 Diligence. 

3.1.1 Licensee shall use commercially reasonable efforts: (a) to develop Licensed Products within the Field in accordance with the
Development Plan; (b) to introduce any Licensed Products within the Field that gain Regulatory Approval into the commercial market; (c) to market Licensed Products within the Field that have gained Regulatory Approval following such
introduction into the market; and (d) to make such Licensed Products that have gained Regulatory Approval reasonably available to the public. In addition, Licensee, by itself or through its Affiliates or Sublicensees, shall achieve each of the
Development Milestones within the time periods specified in Exhibit 3.1.1, as they may be extended in accordance with this Agreement. 

3.1.2 Sub-Categories of Patent Rights. 

3.1.2.1 During the first [**] years following the Effective Date, Licensee shall devote commercially reasonable resources to
determining the viability of the technology covered, claimed or otherwise disclosed in each Sub-Category of Patent Rights to exploit Licensed Products in the Field. In the event that Licensee makes a final
determination that it will not pursue the research or development of any Licensed Product Covered by a Valid Claim of, or otherwise made, discovered, developed or determined to have utility, in whole or in part, by the use of, a Sub-Category of Patent Rights, it shall so notify Broad in writing and, unless otherwise agreed upon by the Parties in writing, Licensee’s rights to such Sub-Category of
Patent Rights shall be terminated under this Agreement upon Broad’s receipt of such notice. 
 3.1.2.2 If, with respect
to a Sub-Category of Patent Rights, either (a) Licensee has failed to devote commercially reasonable resources to determining the viability of the technology covered, claimed or otherwise disclosed in
such Sub-Category of Patent Rights to exploit Licensed Products in the Field as set forth in Section 3.1.2.1 (Sub-Categories of Patent Rights)
or (b) within [**] years after the Effective Date, Licensee has not (i) initiated a discovery program for the development of a Licensed Product covered by a Valid Claim of, or otherwise made, discovered, developed or determined to have
utility, in whole or in part, by the use of, such Sub-Category of Patent 

  
 39 

 
Rights and (ii) submitted an updated Development Plan and Development Milestones to Broad for such Sub-Category of Patent Rights as set forth in
Section 3.2.2 (Adjustments of Development Plan), then the license to such Sub-Category of Patent Rights will terminate (such Sub-Category of
Patent Rights subject to license termination, a “Failed Sub-Category of Patent Rights”). If the Failed Sub-Category of Patent Rights is a Sub-Category of Base Editor Patent Rights, then Licensee’s license to the Gene Targeting Patent Rights shall be deemed to be non-exclusive with respect to such Failed Sub-Category of Patent Rights. Notwithstanding the foregoing, if Licensee is developing a Licensed Product that is Covered by both the Failed Sub-Category of Patent Rights and
a separate Sub-Category of Patent Rights, then Licensee may, within [**)] days of such Sub-Category of Patent Rights becoming a Failed
Sub-Category of Patent Rights, provide a list to Broad of all such Licensed Products and a reasonably detailed written explanation of how such products are Covered by such separate Sub-Category of Patent Rights. If Broad agrees, in its reasonable discretion, that such Licensed Product is Covered by such separate Sub-Category of Patent Rights, then
Licensee will retain a non-exclusive license to the Failed Sub-Category of Patent Rights solely to the extent necessary to develop such Licensed Product. Subject to the
foregoing sentence, Broad shall have the right in its sole discretion to grant exclusive or non-exclusive licenses to any Third Party under such Failed Sub-Category of
Patent Rights. Additionally, Broad shall have the right to grant to third party licensees of any Failed Sub-Category of Patent Rights, a non-exclusive license under the
Patent Rights other than such Failed Sub-Category of Patent Rights solely to make, have made, offer for sale, sell, have sold and import products Covered by such Failed
Sub-Category of Patent Rights in the Field, which non-exclusive license shall not extend to components of such product that are, (x) if the Failed Sub-Category of Patent Rights is a Failed Sub-Category of Base Editor Patent Rights, a different category of Base Editor than the category of Base Editor that is the subject
matter of such Failed Sub-Category of Base Editor Patent Rights or a DNA Cleaver and (y) if the Failed Sub-Category of Patent Rights is the DNA Cleaving Patent
Rights, a Base Editor. As a non-limiting example of the foregoing exclusion, if [**] under this paragraph, then the foregoing non-exclusive license under the remaining
patent rights would [**]. Broad’s rights under this Section 3.1.2.2 (Sub-Categories of Patent Rights) shall be its exclusive termination rights under this Agreement for any
breach by Licensee of Section 3.1.2.1 (Sub-Categories of Patent Rights) or failure of Licensee described in clause (a) or (b) of this Section 3.1.2.2 (Sub-Categories of Patent Rights). 
 The foregoing paragraph may apply to multiple
Sub-Categories of Patent Rights, if there are multiple Failed Sub-Categories of Patent Rights. 

3.2 Adjustments of Development Plan. 

3.2.1 Within [**] months after the Effective Date, Licensee shall submit to Broad a written plan for the development and commercialization of
Licensed Products, which shall be attached hereto as Exhibit 3.2.1. Such plan shall be designed to meet the Development Milestones attached in Exhibit 3.1.1, on the timeline provided in Exhibit 3.1.1. Broad shall have the right
to approve Licensee’s submitted Development Plan, such approval not to be unreasonably withheld, delayed, or conditioned. Broad shall be reasonably available to meet and discuss with Licensee as Licensee is preparing the Development Plan, to
help ensure consensus as to the Development Plan that Licensee will submit. In addition, an abbreviated plan outlining the high-level anticipated development actions and timelines for DNA Base Editor Products, RNA Base Editor Products and DNA
Cleaving Products is attached hereto as Exhibit 3.2.1-1. 

  
 40 

 3.2.2 Within [**] years after the Effective Date, Licensee shall update its Development Plan
and Development Milestones to include the elements required by the Sub-Category Product Milestones. Broad shall have the right to approve Licensee’s submitted, updated Development Plan, such approval not
to be unreasonably withheld, delayed, or conditioned. Broad shall be reasonably available to meet and discuss with Licensee as Licensee is preparing the updated Development Plan, to help ensure consensus as to the Development Plan that Licensee will
submit. 
 3.2.3 Licensee will be entitled, from time to time, upon providing prior written notice to Broad, to make such adjustments to the
then applicable Development Plan as Licensee believes, in its good faith judgment, are needed in order to improve Licensee’s ability to meet the Development Milestones, provided that such adjustment right shall not include the right to adjust
the timelines for the Milestone Deadlines except as set forth in Section 3.5.1 (Notice/Explanation/Plan). 
 3.3
Regulatory Filings. As between Broad and Licensee, and subject to Section 2.5 (Inclusive Innovation Model) Licensee shall have the right to prepare and present all regulatory filings necessary or appropriate to
obtain Regulatory Approval for Licensed Products in the Field in any country and to obtain and maintain any Regulatory Approval required to market Licensed Products in the Field in any such country. Licensee shall solely own all right, title and
interest in and to all such Regulatory Approvals and filings. 
 3.4 Reporting. Within [**] days after the end of each Calendar Year,
Licensee shall furnish Broad with a written report summarizing its, its Affiliates’ and its Sublicensees’ efforts during the prior year to develop and commercialize Licensed Products within the Field, including: (a) research and
development activities, including information regarding specific Royalty-Bearing Products in development and their therapeutic applications; (b) the status of applications for Regulatory Approvals; (c) commercialization or other
distribution efforts; and (d) marketing efforts. Each report must contain a sufficient level of detail for Broad to assess whether Licensee is in compliance with its obligations under Section 3.1 (Diligence) and a
discussion of intended efforts for the then current year. Together with each report, Licensee shall provide Broad with a copy of the then current Development Plan, which shall include sufficient detail to enable Broad to assess what Royalty-Bearing
Products are in development and the status of such development. 
 3.5 Failure to Meet Development Milestone: Opportunity to Cure.

 3.5.1 Notice/Explanation/Plan. If Licensee believes that it will not achieve a Development Milestone by the then-applicable
deadline (i.e., the original timeline therefor in Exhibit 3.1.1, or any extension thereto in accordance with this Agreement) (“Milestone Deadline”) or that such then-applicable Milestone Deadline needs to be or should be
extended, it may notify Broad in writing in advance of the relevant deadline, explicitly referencing this Section 3.5.1 (Notice/Explanation/Plan). Licensee shall include with such notice (a) a

  
 41 

 
reasonable explanation of the reasons for such failure or need for extension (and lack of finances or development preference for a non-Royalty-Bearing
Product will not constitute reasonable basis for such failure or need for extension) in sufficient detail to enable Broad to assess Licensee’s compliance with Section 3.1.1 (Diligence) (“Explanation”)
and (b) a reasonable, detailed, written plan for promptly achieving a reasonable extended or amended milestone (“Plan”). 

3.5.2 Missing Plan or Explanation. If Licensee notifies Broad in accordance with Section 3.5.1
(Notice/Explanation/Plan), but fails to provide Broad with both an Explanation and Plan, then Licensee will have an additional [**] days or until the original deadline of the relevant Development Milestone, whichever is later, to meet such
milestone. Licensee’s failure to do so shall constitute a material breach of this Agreement, and Broad shall have the right to terminate this Agreement solely to the extent described in the applicable provision of
Section 3.5.6 (Unmet Deadline). 
 3.5.3 Sufficient Notice/Explanation/Plan. If Licensee notifies Broad as
provided in Section 3.5.1 (Notice/Explanation/Plan) and provides Broad with an Explanation and Plan, then the applicable Milestone Deadline set forth on Exhibit 3.1.1 will be amended automatically to incorporate such
extension to such Milestone Deadline; provided such extension does not extend the applicable Milestone Deadline by an amount greater than [**] years beyond the applicable Milestone Deadline as provided in Exhibit 3.1.1 hereto as of the
Effective Date of this Agreement. Any request by Licensee to extend a Milestone Deadline by an amount greater than [**] years beyond the applicable Milestone Deadline as provided in Exhibit 3.1.1 hereto as of the Effective Date of this
Agreement (whether as an initial request or through multiple extensions to such Milestone Deadline) shall only apply, and the applicable Milestone Deadline shall only be extended, if both such Explanation and Plan are acceptable to Broad in its
reasonable discretion. 
 3.5.4 Explanation Discussions. If Licensee so notifies Broad and provides Broad with an explanation for such
failure or need for extension and Plan, but such explanation is not an Explanation, then Licensee will have an additional [**] days or until the original deadline of the relevant Development Milestone, whichever is later, to meet such milestone.
Licensee’s failure to do so shall constitute a material breach of this Agreement, and Broad shall have the right to terminate this Agreement solely to the extent described in the applicable provision of Section 3.5.6
(Unmet Deadline). 
 3.5.5 Plan Discussions. If Licensee notifies Broad in accordance with Section 3.5.1
(Notice/Explanation/Plan) and Licensee submits an Explanation and Plan to Broad that requests to extend a Milestone Deadline by an amount greater than [**] years beyond the applicable Milestone Deadline as provided in Exhibit 3.1.1 hereto as
of the Effective Date of this Agreement (whether as an initial request or through multiple extensions to such Milestone Deadline), and the Plan provided by Licensee is not acceptable to Broad in its reasonable discretion, then Broad will explain in
writing to Licensee why the Plan is not acceptable and provide Licensee with written suggestions for an acceptable Plan. Licensee will have [**] opportunity to provide Broad with an acceptable Plan within [**] days, during which time Broad agrees to
work with Licensee in good faith in Licensee’s effort to develop a reasonably acceptable Plan. If, within such [**] days, Licensee provides Broad with an acceptable Plan, then, Exhibit 3.1.1 will be amended automatically to incorporate
the extended or amended milestone set forth in the Plan. If, within such [**] days, Licensee fails to provide an acceptable Plan, then Licensee will have an additional [**] days or until the original deadline of the relevant Development Milestone,
whichever is later, to meet such milestone. 

  
 42 

 3.5.6 Unmet Deadline. Licensee’s failure to meet the then-current Milestone
Deadline for any Development Milestone (taking into account any extension or modification thereof as a result of the applicable procedures set forth in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions)) shall
constitute a material breach of this Agreement, and Broad shall have the following rights as its exclusive termination rights for such material breach of this Agreement: 

3.5.6.1 If such failure is a failure to meet the first Development Milestone (“Initiate a discovery program ...”)
with respect to [**] Royalty-Bearing Products within the timeframe set forth on Exhibit 3.1.1, then Broad shall have the right to terminate this Agreement forthwith, immediately upon written notice to Licensee under
Section 10.2.2.4 (Termination for Default). 
 3.5.6.2 If such failure relates to (a) a
Licensed Product, Enabled Product, Base Editor Product or DNA Cleaving Product for which Licensee exercised its rights under Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or
Commercialization), or 2.5.9 (Third Party Development or Commercialization) following receipt of a Proposed Product Notice with respect to a [**] Proposed Product, (b) a Licensed Product that was a Retained Product for which Licensee
retained the licenses under Section 2.1 (License Grants) in accordance with the terms of Section 3.5.6.3 (Unmet Deadline) or (c) a Licensed Product that was a Restored Product for which
Licensee was granted the licenses under Section 2.1 (License Grants) in accordance with the terms of Section 3.5.7.3 (Failure to Meet Development Milestone: Opportunity to Cure), then Broad will be
entitled, without any compensation or accounting to Licensee, to terminate forthwith, immediately upon written notice to Licensee, the licenses granted under Section 2.1 (License Grants) with respect to the applicable [**]
to which the [**] Proposed Product (or in the cases of clauses (b) and (c), such relevant Licensed Product) is directed. Upon such termination, Broad shall be entitled to grant to any third party(ies) an exclusive or non-exclusive license(s) under the Patent Rights to make, have made, offer for sale, sell, have sold and import such Licensed Product for use within the Field or outside the Field. 

3.5.6.3 If such failure is not a failure provided for under Section 3.5.6.1 (Unmet Deadline) or
Section 3.5.6.2 (Unmet Deadline) and is a failure to meet the then-current Milestone Deadline for any Development Milestone (taking into account any extension or modification thereof as a result of the applicable procedures
set forth in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions)) that is not a Sub-Category Product Milestone, Broad shall be entitled, without any compensation or
accounting to Licensee, to terminate forthwith, immediately upon written notice to Licensee, the licenses granted under Section 2.1 (License Grants) with respect to all Royalty-Bearing Products for which Licensee has not
achieved Initiation of GLP Toxicology prior to the date of such notice (other than any such Royalty-Bearing 

  
 43 

 
Products that are Related Products to a Royalty-Bearing Product for which Licensee has achieved Initiation of GLP Toxicology prior to the date of such notice). If such failure is not a failure
provided for under Section 3.5.6.1 (Unmet Deadline) or Section 3.5.6.2 (Unmet Deadline) and is a failure to meet the then-current Milestone Deadline for any Development Milestone (taking into
account any extension or modification thereof as a result of the applicable procedures set forth in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions)) that is a
Sub-Category Product Milestone, Broad shall be entitled, without any compensation or accounting to Licensee, to terminate forthwith, immediately upon written notice to Licensee, the licenses granted under
Section 2.1 (License Grants) with respect to such Sub-Category of Patent Rights except with respect to Royalty-Bearing Products for which Licensee has achieved Initiation of GLP
Toxicology prior to the date of such notice and any Royalty-Bearing Products that are Related Products to a Royalty-Bearing Product for which Licensee has achieved Initiation of GLP Toxicology prior to the date of such notice. 

(a) Promptly after receipt of such notice (and in any event within [**] days thereof), Licensee shall deliver to Broad a true,
correct and complete list of all Royalty-Bearing Products for which Licensee has achieved Initiation of GLP Toxicology prior to the date of such notice and that, if applicable, are covered by a Valid Claim within, or otherwise made, discovered,
developed or determined to have utility, in whole or in part, by the use of, the terminated Sub-Category of Patent Rights (the “Retained Product List”) and sufficient information for Broad to
identify Related Products (i.e., [**], splicing variant or mutation, intended patient population and intended clinical outcome) to such Royalty-Bearing Products. For each such Royalty-Bearing Product (each, a “Retained Product”),
Licensee shall follow the following procedure: 
 (b) For each Retained Product, the Parties will negotiate in good faith and
agree, during the [**] days following the date Licensee provided the Retained Product List to Broad, upon a development plan with respect to such Retained Product, which development plan will be similar to the Development Plan with respect to
Licensed Products that were being developed by Licensee, subject to necessary adjustments, and will include reasonable development milestones, including at least [**] preclinical development milestone if such Retained Product is a preclinical
product, and associated timelines. In the discussion of such development plan and development milestones, Broad shall not unreasonably withhold its consent to Licensee’s proposed plan. If the Parties agree in writing on such development plan
and development milestones within such [**] day period, Broad shall grant to Licensee, and shall be deemed to have granted to Licensee, the licenses under Section 2.1.1 (License Grants) to make, have made, offer for sale,
sell, have sold and import such Retained Product and Related Products to such Retained Product for use within the Field, and under Section 2.1.2 (License Grants) to make, have made, offer for sale, sell, have sold and
import such Retained Product and Related Products that are Base Editor Products, but Licensee shall be obligated (a) to use commercially reasonable efforts to develop and commercialize the Retained Product in accordance with such new
development plan (which shall be incorporated into and be part of the 

  
 44 

 
“Development Plan” for all purposes hereunder) and (b) to meet the development milestones on the timeline associated therewith with respect to the Retained Product (which shall be
a “Development Milestone”, which shall not be subject to extension in the manner provided in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions), but shall only be subject to extension in Broad’s
sole discretion). Exhibit 3.1.1 shall be amended to reflect such development milestones and timeline with respect to such Retained Product. If the Parties do not agree in writing on such development plan and milestones for such Retained
Product within such [**] day period, the licenses under Section 2.1 (License Grants) to make, have made, offer for sale, sell, have sold and import such Retained Product and Related Products to such Retained Product shall
be deemed terminated as of 11:59 p.m. Eastern Time on the last day of such period. 
 (c) Notwithstanding anything in this
Agreement to the contrary, the procedure set forth in Sections 3.5.1 (Notice/Explanation/Plan) through 3.5.5 (Plan Discussions) shall not be applicable to extend the Development Milestones for a Licensed Product that was a Retained
Product (although the Development Plan may still be updated with respect thereto without modifying the Development Milestones, and the Development Milestones may still be modified with Broad’s consent in its sole discretion). 

(d) Notwithstanding anything in this Section 3.5.6 (Unmet Deadline) to the contrary, for any Retained
Product for which a Retained Product or a Related Product to such Retained Product already had a Development Plan and Development Milestones in place, and such Retained Product or a Related Product to such Retained Product that already had a
Development Plan and Development Milestones in place has not missed such Development Milestones, such Development Plan and Development Milestones shall remain in place, with no requirement to negotiate a new Development Plan and new Development
Milestones with respect thereto for such Retained Product or a Related Products to such Retained Product. 
 3.5.7 If Broad has terminated
any licenses granted under Section 2.1 (License Grants) in accordance with the terms of Section 3.5.6.3 (Unmet Deadline) and during the Term, Licensee wishes to obtain the licenses under
Section 2.1 (License Grants) with respect to a product for which Licensee does not have a license under Section 2.1 (License Grants) and that was, prior to such termination, within the definition
of Royalty-Bearing Product (each, a “Restored Product” and such licenses, “Restored Licenses”), Licensee shall notify Broad, and Broad and Licensee shall follow the procedures below: 

3.5.7.1 Licensee shall make a proposal to Broad equivalent in all material respects to a Bona Fide Proposal to Broad for
developing such Restored Product in the Field, including with such proposal a statement of the extent such Restored Product is Covered by the Base Editor Patent Rights, DNA Cleaving Patent Rights or Gene Targeting Patent Rights and sufficient
information for Broad to identify Related Products (i.e., [**], splicing variant or mutation, indicated patient population and clinical outcome) to such Restored Product. If Broad is interested in having such Restored Product

  
 45 

 
developed and commercialized, Broad has not granted to any third party (such third parties to include, for purposes of this Section 3.5.7.1 (Failure to Meet Development
Milestone: Opportunity to Cure), Affiliates of Licensee) any rights or licenses that would be breached by the grant of the Restored Licenses and the grant by Broad of the Restored Licenses would not otherwise be in conflict with any contract,
agreement, arrangement or understanding between Broad and a third party, Broad shall notify Licensee. 
 3.5.7.2 If the
proposal does not meet the definition of Bona Fide Proposal (as applied to the Restored Product and not a [**] Proposed Product), then Section 3.5.7.3 (Failure to Meet Development Milestone: Opportunity to Cure) shall not
apply. 
 3.5.7.3 If Licensee notifies Broad within [**] days after Broad has notified Licensee pursuant to the last sentence
of Section 3.5.7.1 (Failure to Meet Development Milestone: Opportunity to Cure), the Parties will negotiate, during the [**] days following such notification by Licensee, a development plan with respect to such Restored
Product, which development plan will be similar to the Development Plan with respect to Licensed Products developed by Licensee, subject to necessary adjustments, and will include reasonable development milestones, including at least one preclinical
development milestone if such Restored Product is a preclinical product, and associated timelines. Broad may withhold its consent to Licensee’s proposed development plan and development milestones in Broad’s sole discretion. If the Parties
agree in writing on such development plan and milestones within such [**] day period, Broad shall grant to Licensee, and shall be deemed to have granted to Licensee, the licenses under Section 2.1 (License Grants) to make,
have made, offer for sale, sell, have sold and import such Restored Product and Related Products to such Restored Product for use within the Field, but Licensee shall be obligated (a) to use commercially reasonable efforts to develop and
commercialize the Restored Product in the Field in accordance with such new development plan (which shall be incorporated into and be part of the “Development Plan” for all purposes hereunder) and (b) to meet the development
milestones on the timeline associated therewith with respect to the Restored Product (which shall be a “Development Milestone” (for all purposes hereunder) (subject to extension in the same manner as provided in Sections 3.5.1
(Notice/Explanation/Plan) through 3.5.5 (Plan Discussions), applied mutatis mutandis). Exhibit 3.1.1 shall be amended to reflect such development milestones and timeline with respect to such Restored Product. If the Parties do
not agree in writing on such development plan and development milestones for such Restored Product within such [**] day period, Broad shall have no obligations to Licensee with respect to such Restored Product hereunder. 

3.5.7.4 For clarity, the provisions of this Section 3.5.7 (Failure to Meet Development Milestone:
Opportunity to Cure) shall not apply to any product with respect to which Broad exercised its rights under Section 3.5.6.2 (Unmet Deadline) to terminate the licenses under Section 2.1 (License
Grants). 

  
 46 

 3.6 Activities of Others. Licensee may satisfy its obligations under Sections 3.1
(Diligence) through 3.5 (Failure to Meet Development Milestone: Opportunity to Cure) by the actions of itself, its Affiliates, its Sublicensees, or by the actions of any combination of the foregoing, subject to the terms and conditions
set forth in Section 2.3 (Affiliates) and Section 2.4 (Sublicenses); provided, however, that the activities of a Sublicensee to whom Licensee grants a Cross License that is not part of a
collaboration or other license agreement that is materially broader in scope than such Cross License (and that includes a development plan under which such Sublicensee has diligence obligations to Licensee) shall not be deemed to so satisfy
Licensee’s obligation under Sections 3.1 (Diligence) through 3.5 (Failure to Meet Development Milestone: Opportunity to Cure). 
 4.
Consideration for Grant of License. 
 4.1 Equity. 

4.1.1 Initial Issuance. In accordance with the terms of the Subscription Agreement, Licensee shall, on the Effective Date and concurrent
with the execution of this Agreement, as partial consideration for the licenses granted hereunder, issue to Broad or designees identified to Licensee in writing prior to the Effective Date (the “Broad Designees”), an aggregate of
560,000 shares of Licensee’s common stock, representing eight and four-tenths percent (8.4%) of Licensee’s outstanding capital stock on a Fully-Diluted Basis as of the date of such issuance and after giving effect to such issuance
(the “Shares”). Broad hereby agrees that, as a condition to and effective as of the issuance of the Shares, Broad and, if applicable, the Broad Designees, will execute a joinder to that certain Right of First Refusal and Co-Sale Agreement by and among the Licensee and the stockholders set forth therein and that certain Voting Agreement by and among the Licensee and the stockholders set forth therein, each dated on or about the date
hereof, as a common stockholder of Licensee. 
 4.1.2 Anti-Dilution Issuances. If, at any time prior to the achievement of the
Financing Threshold, Licensee issues Additional Securities that would cause the Shares to represent less than [**] of Licensee’s outstanding capital stock on a Fully-Diluted Basis (excluding Exempted Issuances), Licensee shall immediately issue
to Broad and the Broad Designee on a pro rata basis, for no additional consideration, such additional number of shares of common stock of Licensee (the “Anti-Dilution Shares”) such that the Shares plus the Anti-Dilution Shares
(including any Anti-Dilution Shares previously issued to Broad pursuant to this Section 4.1.2 (Anti-Dilution Issuances), and any Shares or Anti-Dilution Shares transferred by Broad to a third party or held by an Affiliate
of Broad) would then represent in the aggregate [**] of Licensee’s outstanding capital stock on a Fully Diluted Basis (excluding Exempted Issuances), as calculated after giving effect to the anti-dilutive issuance up to the Financing Threshold,
but not any issuances in consideration for investment amounts in excess of the Financing Threshold; provided however, that to the extent such Additional Securities are issued pursuant to an equity incentive plan, Licensee shall issue the
Anti-Dilution Shares upon the earlier of (a) the end of Licensee’s fiscal year in which the issuances took place, (b) the closing of the next preferred stock financing, and (c) immediately prior to a Beam Change of Control or a
Change of Control, in each case, calculated as of the date contemplated by (a), (b) or (c), as applicable. Licensee shall provide Broad with evidence of the issuance of such Anti-Dilution Shares promptly after their issuance. Such issuances shall
continue only up to, and until such time as Licensee has achieved, the Financing Threshold. Thereafter, no additional shares shall be due to Broad pursuant to this Section 4.1.2 (Anti-Dilution Issuances). The Anti-Dilution
Shares will be subject to the same restrictions as the Shares in accordance with the terms of the Subscription Agreement. 
  

  
 47 

 4.1.3 Preemptive Rights. Broad and the Broad Designees shall have, pursuant to the
Subscription Agreement, the right to purchase from Licensee in offerings of equity securities by Licensee (excluding (a) Exempted Issuances, (b) shares of common stock issued or issuable, and options, warrants or other rights to purchase
Common Stock issued or issuable to Licensee’s employees, consultants, officers, directors, or advisors as part of an incentive compensation arrangement or to Licensee’s former employees, consultants, officers, directors, or advisors as
part of a settlement of any dispute regarding incentive compensation arrangements, (c) shares of Common Stock issued or issuable to banks, equipment lessors, real property lessors, financial institutions or other Persons engaged in the business
of making loans pursuant to a debt financing, commercial leasing or real property leasing transaction, and (d) shares of Common Stock issued or issuable in connection with any settlement of any action, suit, proceeding or litigation) after the
Financing Threshold has been achieved that portion of such equity securities as equals the proportion that the common stock then held by Broad or a Broad Designee, as applicable (including all shares of common stock then issuable upon conversion or
exercise, as applicable, of preferred stock and any other equity securities then held by Broad) bears to the total common stock of Licensee then outstanding on a Fully-Diluted Basis. The foregoing right shall be subject to the terms, conditions and
exceptions as are contained in the Subscription Agreement, which terms, conditions and exceptions shall be no less favorable to Broad and the Broad Designees than the terms, conditions and exceptions offered to the holders of preferred stock holding
similar rights, unless otherwise provided in this Section 4.1.3 (Preemptive Rights), and to the extent the terms of this Section 4.1.3 (Preemptive Rights) and the Subscription Agreement conflict,
the terms of the Subscription Agreement shall control. The Subscription Agreement shall provide that during the period prior to any Change of Control of Licensee or any Initial Public Offering, Broad and the Broad Designees may not sell or otherwise
transfer the shares acquired by them upon exercise of the foregoing right without the consent of Licensee to any third party other than a holder of the preferred stock of Licensee. The Subscription Agreement shall provide that during the period
prior to any Change of Control of Licensee or any Initial Public Offering, Broad and the Broad Designees may sell or otherwise transfer the shares acquired by them upon exercise of the foregoing right without the consent of Licensee to any third
party other than a holder of the preferred stock of Licensee; provided, in each such case, that Broad or the applicable Broad Designee notifies Licensee in writing, and the transferee agrees and consents to be bound in writing by the transaction
agreements pursuant to which such securities were originally acquired. The Subscription Agreement shall provide that Broad and the Broad Designees may not assign the foregoing right without the consent of Licensee to any third party other than a
holder of the preferred stock of Licensee. The Subscription Agreement shall provide that Broad and the Broad Designees may assign the foregoing right without the consent of Licensee to any third party other than a holder of the preferred stock of
Licensee; provided, that, in each such case, Broad or the applicable Broad Designee notifies Licensee in writing in connection with the transfer of such rights. With regard to assignment of the foregoing right to a holder of the preferred stock of
Licensee, the Subscription Agreement shall provide that Broad or the applicable Broad Designee may assign the foregoing right in whole or in part and in any one or more instances. 

  
 48 

 4.1.4 Representations and Warranties. Licensee represents and warrants to Broad that,
upon issuance of the Shares, and upon issuance of any Anti-Dilution Shares: 
 4.1.4.1 the capitalization table as provided
by Licensee (the “Cap Table”) upon issuance of the Shares or the Anti-Dilution Shares, as the case may be, sets forth all of the capital stock of Licensee on a Fully-Diluted Basis as of the date of issuance of the Shares or the
Anti-Dilution Shares, on a pro forma basis as of immediately subsequent to the issuance of the Shares or the Anti-Dilution Shares, as applicable; 

4.1.4.2 other than as set forth in the Cap Table, as of the date of issuance of the Shares or Anti-Dilution Shares, as
applicable, there are no outstanding shares of capital stock, convertible securities, outstanding warrants, options or other rights to subscribe for, purchase or acquire from Licensee any capital stock of Licensee and there are no contracts or
binding commitments providing for the issuance of, or the granting of rights to acquire, any capital stock of Licensee or under which Licensee is, or may become, obligated to issue any of its securities; and 

4.1.4.3 the Shares or the Anti-Dilution Shares, as the case may be, when issued pursuant to the terms hereof, shall, upon such
issuance, be duly authorized, validly issued, fully paid and nonassessable. 
 4.1.5 Information. Upon request, but no more frequently
than [**] per Calendar Quarter, Licensee will deliver to Broad a statement of the outstanding capital stock of Licensee on a Fully Diluted Basis in sufficient detail as to permit Broad to calculate its percentage equity ownership in Licensee. Prior
to the Initial Public Offering or a Change of Control, at the request of Broad or a Broad Designee, but in no event more than [**] per Calendar Year, representatives of Licensee with knowledge of the Licensee’s general business shall meet with
representatives of Broad to discuss matters pertaining to Licensee and its business; provided that Licensee shall have no obligation to deliver such information to the extent delivery could adversely affect the attorney-client privilege between
Licensee and its counsel or because Licensee owes a duty of confidentiality with respect to such information to a Third Party. 
 4.2
Annual License Maintenance Fees. Licensee shall pay Broad annual license maintenance fees (“Maintenance Fees”) as follows: 
  

			
	 Calendar Year(s)
	  	Maintenance Fee (U.S. Dollars)
	2018	  	[**]
	2019	  	[**]
	 2020 and each subsequent Calendar Year during the Term
	  	[**]

  
 49 

 Each such Maintenance Fee shall be due and payable on [**] of the Calendar Year to which such fee applies;
provided that with respect to the Maintenance Fee due for Calendar Year 2018, the Maintenance Fee shall be due and payable within [**] days of the Effective Date. 

4.3 Milestone Payments. 

4.3.1 Product Milestone Payments. With respect to each of Base Editor Products and DNA Cleaving Products, Licensee shall pay Broad the
following milestone payments for each Royalty-Bearing Product to reach each milestone, regardless of whether such milestone is achieved by Licensee or any Affiliate or Sublicensee of Licensee, subject to Section 4.3.4
(Milestone Payments); provided that once, with respect to any milestone event, the total milestone payments set forth in Column C for such milestone event have become payable by Licensee for each of Base Editor Products and DNA Cleaving
Products, no further milestone payments will be payable by Licensee for the achievement of such milestone event. By way of illustration, no further milestones would become payable for a milestone event for Base Editor Products after three Base
Editor Products that are Licensed Products and four Base Editor Enabled Products that are Enabled Products achieved such milestone event. For clarity, if the Royalty-Bearing Product to reach a milestone is a Licensed Product, Column A of the table
below sets forth the milestone payment due and if the Royalty-Bearing Product to reach a milestone is an Enabled Product, Column B of the table below sets forth the milestone payment due. 

 

							
	 	  	Column A	 	Column B	 	Column C
	 Milestone Event
	  	Milestone Payment for
Licensed Products
(U.S. Dollars)	 	Milestone Payment for
Enabled Products
(U.S. Dollars)	 	Total Milestone
Payments in Aggregate
for Milestone Event
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]

 Upon the consummation (i.e., closing) of a Change of Control of Licensee at any time during the Term, the dollar amounts set
forth in the table above under “Milestone Payments (U.S. Dollars)” shall be deleted and the milestone payments set forth in the table below shall be substituted for the corresponding milestone payments for occurrences of a milestone event
after the consummation of Change of Control; provided that, for milestone events achieved prior to the applicable Change of Control, the milestone payments payable for such milestone event shall be deemed to have been paid in the
corresponding amounts set forth in the substituted table. For 

  
 50 

 
example, if the milestone event for [**] was achieved for a Licensed Product prior to the Change of Control, the $[**] milestone payment payable shall be deemed, for the purposes of calculating
the total milestone payments made in the aggregate for such milestone event under the substituted table, as a $[**] milestone payment. It is understood that the increased milestone amounts shall only apply on a going-forward basis from the time of a
Change of Control; no increase to the amounts of the milestone payments due for milestone events achieved prior to the Change of Control shall be due. 
  

							
	 	  	Column A	 	Column B	 	Column C
	 Milestone Event
	  	Milestone Payment for
Licensed Products
(U.S. Dollars)	 	Milestone Payment for
Enabled Products
(U.S. Dollars)	 	Total Milestone
Payments in Aggregate
for Milestone Event
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]

 4.3.2 Financing Milestone Payments. 

4.3.2.1 Series A Financing. Subject to the terms of this Section 4.3.2.1 (Series A Financing),
Licensee shall pay to Broad, in accordance with Section 4.3.3 (Milestone Payments), upon achievement by Licensee (together with its Affiliates for purposes of this Section 4.3.2.1 (Series A
Financing), including the calculation of sales by Licensee of shares of Series A Preferred Stock) of each of the financing milestone events set forth below the applicable milestone payment set forth opposite such milestone event set forth below:

  

			
	 Milestone Event
	  	Milestone Payment (U.S. Dollars)
	 1. Closing of sale by Licensee, in a single transaction or series of transactions since inception,
of shares of Series A Preferred Stock yielding aggregate gross proceeds to Licensee of [**]
	  	[**]
	 2. Closing of sale by Licensee, in a single transaction or series of transactions since inception,
of shares of Series A Preferred Stock yielding aggregate gross proceeds to Licensee of [**]
	  	[**]
	 3. Closing of sale by Licensee in a single transaction or series of transactions since inception,
of shares of Series A Preferred Stock yielding aggregate gross proceeds to Licensee of [**]
	  	[**]

  
 51 

 Each milestone payment set forth in table above in this
Section 4.3.2.1 (Series A Financing) shall be payable only once. 
 If a Beam Change of Control occurs prior to the
achievement of any milestone event(s) in the table above in this Section 4.3.2.1 (Series A Financing), then all then unpaid milestone payments will be due from Licensee to Broad within [**] days of the consummation of the
Beam Change of Control transaction. 
 If Licensee sells any equity security other than Series A Preferred Stock (excluding common stock sold
to employees or consultants as part of an incentive compensation arrangement) as part of a financing transaction of Licensee prior to the sale of $[**] in Series A Preferred, the aggregate gross proceeds from such financing transaction shall be
applied towards the achievement of a milestone event set forth in the table above in this Section 4.3.2.1 (Series A Financing) as if the cash proceeds were for the purchase of Series A Preferred Stock, and if any milestone
event is deemed achieved as a result, then the corresponding milestone payment set forth in the table above in this Section 4.3.2.1 (Series A Financing) shall be paid to Broad in accordance with
Section 4.3.3 (Milestone Payments). 
 If prior to the payment by Licensee of an aggregate of $[**] to Broad
pursuant to this Section 4.3.2.1 (Series A Financing), a milestone payment becomes due under this Agreement for achievement by Licensee or any Affiliate or Sublicensee of Licensee of the milestone event described in the
table above in Section 4.3.1 (Product Milestone Payments) as [**] becomes due under this Agreement, any milestone payment set forth in the table above in this Section 4.3.2.1 (Series A Financing)
remaining unpaid shall be paid on the date such milestone payment or [**], as the case may be, is due. 
 In no event shall Licensee be
required to pay more than $[**] to Broad pursuant to this Section 4.3.2.1 (Series A Financing). 

4.3.2.2 Series B Financing prior to Beam Change of Control. Prior to a Beam Change of Control, upon each closing of the
sale by Licensee (together with its Affiliates for purposes of this Section 4.3.2.2 (Series B Financing prior to Beam Change of Control), including the calculation of sales by Licensee of shares of Series B Preferred Stock)
of shares of Series B Preferred Stock, Licensee shall pay Broad a milestone payment in an amount equal to $[**] multiplied by the product of the Valuation Factor multiplied by the Proceeds Factor, until such time as the aggregate payments under this
Section 4.3.2.2 (Series B Financing prior to Beam Change of Control) total $[**]. 

  
 52 

 If prior to the payment by Licensee of an aggregate of $[**] to Broad
pursuant to this Section 4.3.2.2 (Series B Financing prior to Beam Change of Control), a milestone payment becomes due under this Agreement for achievement by Licensee or any Affiliate or Sublicensee of Licensee of the
milestone event described in the table above in Section 4.3.1 (Product Milestone Payments) as [**] becomes due under this Agreement, the unpaid balance of such $[**] shall be paid to Broad on the date such milestone payment
or [**], as the case may be, is due. 
 4.3.2.3 Series B Financing Following Beam Change of Control. Following a Beam
Change of Control that occurs prior to the closing of the sale by Licensee in a single transaction or series of transactions, of shares of Series B Preferred Stock yielding aggregate gross proceeds to Licensee of at least [**] dollars ($[**])],
then, upon each closing of the sale by Beam (together with its Affiliates for purposes of this Section 4.3.2.3 (Series B Financing Following Beam Change of Control), including the calculation of sales by Beam of shares of
Beam Series B Preferred Stock) of shares of Beam Series B Preferred Stock, Licensee shall pay Broad a milestone payment in an amount equal to $[**] multiplied by the product of the Beam Valuation Factor multiplied by the Beam Proceeds Factor, until
such time as the aggregate payments under Section 4.3.2.2 (Series B Financing prior to Beam Change of Control) and this Section 4.3.2.3 (Series B Financing Following Beam Change of Control) total
$[**]. 
 If prior to the payment by Licensee of an aggregate of $[**] to Broad pursuant to
Section 4.3.2.2 (Series B Financing prior to Beam Change of Control) and this Section 4.3.2.3 (Series B Financing Following Beam Change of Control), a milestone payment becomes due under this
Agreement for achievement by Licensee or any Affiliate or Sublicensee of Licensee of the milestone event described in the table above in Section 4.3.1 (Product Milestone Payments) as “FSFD in Phase 3 Clinical
Study” or a [**] becomes due under this Agreement, the unpaid balance of such $[**] shall be paid to Broad on the date such milestone payment or [**], as the case may be, is due. 

4.3.2.4 In no event shall Licensee be required to pay more than $[**] in the aggregate to Broad pursuant to
Section 4.3.2.2 (Series B Financing prior to Beam Change of Control) and Section 4.3.2.3 (Series B Financing Following Beam Change of Control). 

4.3.3 Licensee shall notify Broad in writing within [**] days following the achievement of each milestone described in
Section 4.3.1 (Product Milestone Payments) or 4.3.2 (Financing Milestone Payments), and shall make the appropriate milestone payment within [**] days after the achievement of such milestone. 

  
 53 

 4.3.4 The milestone payments set forth in Section 4.3.1 (Product
Milestone Payments) shall not be payable: 
 (a) with respect to a subsequent achievement of the same milestone event by a Royalty-Bearing
Product that is a replacement for another Royalty-Bearing Product, the development of which has been discontinued after achievement of such same milestone event; 

(b) with respect to a subsequent achievement of the same milestone event by any back-up Royalty-Bearing
Product that is a Related Product to a first Royalty-Bearing Product that has already achieved such same milestone event; and 
 (c) with
respect to a subsequent achievement of the same milestone event by a Royalty-Bearing Product that differs from a first Royalty-Bearing Product that has achieved such same milestone event only by virtue of such subsequent Royalty-Bearing
Product’s being a different dosage strength or formulation of or using a different delivery system than such first Royalty-Bearing Product. 

4.3.5 The milestones set forth in Section 4.3.1 (Product Milestone Payments) are intended to be successive. If a
Royalty-Bearing Product is not required to undergo the event associated with a particular milestone for a given Royalty-Bearing Product (“Skipped Milestone”), such Skipped Milestone will be deemed to have been achieved upon the
achievement by such Royalty-Bearing Product of the next successive milestone (“Achieved Milestone”). Payment for any Skipped Milestone that is owed in accordance with the provisions of Section 4.3.1
(Product Milestone Payments) shall be due within [**] days after the Licensee learned of the achievement of the Achieved Milestone. For clarity, Regulatory Approval in a jurisdiction shall not trigger payment of another Regulatory Approval milestone
not yet achieved (for example, First Regulatory Approval in the EU shall not trigger a payment obligation for First Regulatory Approval in the United States as a Skipped Milestone and vice versa, and First Regulatory Approval in Japan shall
not trigger a payment obligation for First Regulatory Approval in the United States or Europe, nor vice versa), 
 4.4 Royalty on
Net Sales. 
 4.4.1 Rate for Licensed Products. Licensee shall pay Broad an amount equal to [**] percent ([**]%) of Net Sales of
Licensed Products, calculated in accordance with and subject to the remainder of this Section 4.4 (Royalty on Net Sales). 

4.4.2 Rate for Enabled Products. Licensee shall pay Broad an amount equal to [**] percent ([**]%) of Net Sales of Enabled Products,
calculated in accordance with and subject to the remainder of this Section 4.4 (Royalty on Net Sales). 
 4.4.3
Royalty Term. On a country-by-country and Royalty-Bearing Product by Royalty-Bearing Product basis, royalties shall be paid on the sum of Net Sales of such
Royalty-Bearing Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Patent Rights Covering the applicable Royalty-Bearing Product (or if the last Covering Valid Claim with respect to such
Royalty-Bearing Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid Claim; provided, however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such
issuance to the expiration date of such Valid Claim); (b) the period of regulatory 

  
 54 

 
exclusivity associated with such Royalty-Bearing Product in such country; or (c) [**] years after the First Commercial Sale of such Royalty-Bearing Product in such country (the “Royalty
Term”). During time periods when the Royalty Term is only in effect in a given country for a given Licensed Product due to clause (c) of the foregoing sentence, then the royalty rate provided for such Licensed Product in such country
shall be reduced by [**] percent ([**]%) from that set forth in Section 4.4.1 (Rate for Licensed Products) above for such portions of the Royalty Term for such Licensed Product in such country. 

4.4.4 Third Party Royalty Set-Off. On a Licensed Product-by-Licensed Product basis, if Licensee is legally required by a future court order, settlement agreement, contract, or other legally binding written commitment to make payments to a Third Party for a
license under or the use of patent rights held by such Third Party that (i) Cover such Licensed Product in a country in the Territory and (ii) are necessary for the commercialization of such Licensed Product in a country in the Territory,
then Licensee may offset [**] percent ([**]%) of any running royalty payments on net sales actually paid by Licensee to such Third Party under such third-party license with respect to such patent application(s) or patent(s) with respect to sales of
Licensed Products against the running royalty payments that are due to Broad with respect to Net Sales of such Licensed Products in such country; provided that in no event shall (a) the running royalty payments to Broad with respect to such
Licensed Products be reduced by more than [**] percent ([**]%) of the amount otherwise due under Section 4.4.1 (Rate for Licensed Products), as may be reduced by Section 4.4.3 (Royalty Term), and
(b) with respect to royalties paid to the Third Party solely on the basis of claims of pending patent applications of the third party (and no issued patent claim of the third party covers the applicable Licensed Product), such amounts shall
only be offsettable in accordance with the foregoing in this Section 4.4.4 (Third Party Royalty Set-Off) if the Covering pending claim of the third party’s pending application
would meet the definition of Valid Claim set forth in this Agreement were such pending claim within the Patent Rights as of the Effective Date and (c) the royalty offset provided in this Section 4.4.4 (Third Party
Royalty Set-Off) may be applied to any Combination Product for which an adjustment to Net Sales has been made in accordance with Section 4.4.7 (Combination Products), but to avoid
doubt only as relates to royalties on patent applications and patents that would apply in the absence of the Other Active Components (third party patent royalties due because of the presence of the Other Active Components shall not be offsettable
against adjusted Net Sales of a Combination Product). 
 4.4.5 Loss of Market Exclusivity. If a Loss of Market Exclusivity exists in a
country with respect to a Royalty-Bearing Product, then the royalty rate for such Royalty-Bearing Product in such country shall be reduced by [**] percent ([**]%) of the applicable rate determined pursuant to Section 4.4.1
(Rate for Licensed Products) as may be reduced in Section 4.4.3 (Royalty Term), in the case of a Licensed Product, and Section 4.4.2 (Rate for Enabled Products), in the case of an Enabled Product.
In the event that Licensee reasonably believes in good faith that a Loss of Market Exclusivity will exist in a Calendar year with respect to a Royalty-Bearing Product in a country, then Licensee shall provide Broad with written notice describing
Licensee’s reasonable basis for believing that Loss of Market Exclusivity may exist and Licensee may reduce by [**] percent ([**]%) the applicable royalty rate for such Royalty-Bearing Product in such country for each Calendar Quarter in such
Calendar Year. Within [**] days following the end of any Calendar Year in which Licensee has taken the deduction under this Section 4.4.5 (Loss of Market Exclusivity) in a country, Licensee shall determine whether a

  
 55 

 
Loss of Market Exclusivity actually occurred in such country in such prior Calendar Year, and if it is subsequently determined that a Loss of Market Exclusivity did not exist, then Licensee shall
reimburse Broad for any erroneous reductions to royalties owed to Broad in such Calendar Year taken under this Section 4.4.5 (Loss of Market Exclusivity) within [**] days of the end of the applicable Calendar Year. 

4.4.6 Royalty Reduction Cap. Notwithstanding anything to the contrary herein, on a country-by-country and Royalty-Bearing Product-by-Royalty-Bearing Product basis, in no event shall the effective royalty rate
applied to Net Sales of such Royalty-Bearing Product in such country be reduced as a result of the application of the terms of (a) Section 4.4.4 (Third Party Royalty Set-Off)and
Section 4.4.5 (Loss of Market Exclusivity) to less than [**] percent ([**]%) of the applicable rate determined pursuant to Section 4.4.1 (Rate for Licensed Products), as may be reduced by
Section 4.4.3 (Royalty Term), in the case of a Licensed Product and (b) Section 4.4.5 (Loss of Market Exclusivity) to less than [**] percent ([**]%) of the applicable rate determined pursuant
to Section 4.4.2 (Rate for Enabled Products), in the case of an Enabled Product. 
 4.4.7 Combination
Products. If a Royalty-Bearing Product is sold as part of a combination product with other active pharmaceutical ingredient(s) (or active biologic(s)) that are not Royalty-Bearing Products and perform a function distinct from the Royalty-Bearing
Product component of the combination (“Other Active Component(s)”) (no matter the form, including as a fixed dose combination or co-packaged product offering) for a single invoice price (a
“Combination Product”), then Net Sales of the Combination Product shall be adjusted prior to calculation of the royalty to Broad hereunder, by multiplying total Net Sales of the Combination Product by the fraction, A/A+B,
where A is the [**] and B is the [**], in each case during the applicable royalty reporting period or, if sales of both the Royalty-Bearing Product and the Other Active Component(s) did not occur in such period, then in the most recent royalty
reporting period in which sales of both occurred. In the event that such average sale price cannot be determined for both the Royalty-Bearing Product and Other Active Component(s) included in such Combination Product, the Parties shall determine any
adjustment to Net Sales of the Royalty-Bearing Product by virtue of its being sold as part of a Combination Product with Other Active Components in such country by mutual agreement based on the relative contribution of value of the Royalty-Bearing
Product and the Other Active Component(s) in the Combination Product. If the Parties do not reach written agreement as to such allocation within [**] days, then the matter shall be decided by arbitration in accordance with Exhibit 4.4.7. To
avoid doubt, the royalty offset provided in Section 4.4.4 (Third Party Royalty Set-Off) does not allow for the offset of royalties on third party patent applications and patents that
are necessary only for the Other Active Component(s), and would not apply to the Royalty-Bearing Product component as a single agent. 
 4.5
Patent Challenge. 
 4.5.1 If Licensee, its Affiliate or a Sublicensee takes any action that constitutes a Patent Challenge (a
“Challenging Party”), then (a) Licensee shall provide Broad with at least [**] days’ notice prior to a Challenging Party taking any such action, provided that with respect to a Sublicensee, such notice shall be provided
upon Licensee becoming aware of such action, (b) Licensee shall pay all reasonable costs, fees and expenses associated with such 

  
 56 

 
Patent Challenge that are incurred by Institutions and their trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel, and staff, including reasonable
attorneys’ fees and all reasonable costs associated with administrative, judicial or other proceedings, within [**] days after receiving an invoice from Broad for the same, (c) subject to Section 4.5.3 (Patent
Challenge), the fees, milestones, royalties and other amounts payable to Broad under Sections 4.2 (Annual License Maintenance Fees), 4.3 (Milestone Payments), and 4.4 (Royalty on Net Sales) will be [**] with respect to any
payments that become due and Net Sales of Royalty-Bearing Products that are sold during the pendency of such Patent Challenge, and all such payments shall be made directly to Broad and not into escrow, (d) subject to
Section 4.5.3 (Patent Challenge), the exclusive licenses granted in this Agreement may, as of the date of initiation of such challenge or opposition, upon notice by Broad to Licensee, be converted by Broad at its option
into a non-exclusive license for the remainder of the Term, and in such event the Institutions shall have the right to grant licenses under the Patent Rights to any Person, subject to the then-existing non-exclusive licenses provided herein, and (e) at any time after the Patent Challenge is brought, Broad may, at its option, terminate this Agreement according to Section 10.2.3
(Termination for Patent Challenge); provided that if any of subsections (a) through (e) are held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any of the other said subsections. If the outcome of
such Patent Challenge is a determination against the Challenging Party, the fees, milestones, royalties and other amounts payable to Broad under Sections 4.2 (Annual License Maintenance Fees), 4.3 (Milestone Payments), and 4.4
(Royalty on Net Sales) shall remain at such [**] rate and Licensee shall reimburse Broad [**] the amount of all reasonable expenses incurred by Broad (including reasonable attorneys’ fees) in connection with such Patent Challenge. If the
outcome of such Patent Challenge is a determination in favor of the Challenging Party, Licensee will have no right, nor will any Affiliate or Sublicensee have any right, to recoup any royalties or other amounts paid before or during the pendency of
such Patent Challenge. Notwithstanding any provision of this Agreement to the contrary, Licensee shall not have the right to assume or participate in the defense, settlement or other disposition of such Patent Challenge through its status as
licensee under this Agreement, but shall pay associated costs, fees and expenses as provided in this Section 4.5.1 (Patent Challenge). The Parties agree that any Patent Challenge by Licensee, or any of its Affiliates or
Sublicensees, may be detrimental to the Institutions, and that the foregoing provisions shall constitute reasonable liquidated damages to reasonably compensate the Institutions for any loss they may incur as a result of Licensee, or any of its
Affiliates’ or Sublicensees’, taking such action. 
 4.5.2 Licensee shall include in each agreement for a Sublicense a clause
equivalent with respect to the Sublicensee to the provisions found in the foregoing Section 4.5.1 (Patent Challenge) (adjusted for party names, section references, and the like) and shall make the Institutions explicit
third party beneficiaries thereof. 
 4.5.3 Notwithstanding Section 4.5.1 (Patent Challenge), if the
Challenging Party that takes an action that constitutes a Patent Challenge is a Sublicensee rather than Licensee or an Affiliate, then, the adjustment contemplated under Section 4.5.1 (Patent Challenge) to the fees,
milestones, royalties and other amounts payable to Broad under Sections 4.2 (Annual License Maintenance Fees), 4.3 (Milestone Payments), and 4.4 (Royalty on Net Sales) shall apply only to the calculation of royalties on
Net Sales by such challenging Sublicensee and the adjustment to the milestone payments under Section 4.3 (Milestone 

  
 57 

 
Payments) with respect to Royalty-Bearing Products achieved by Sublicensees shall apply only to the milestone payments with respect to Royalty-Bearing Products achieved by such challenging
Sublicensee. Licensee will make Broad an explicit intended third-party beneficiary of the obligation in the Sublicense agreement for the Sublicensee to pay Broad [**] the amount of all expenses incurred by Broad (including reasonable attorneys’
fees) in connection with such Patent Challenge, and will reasonably assert its rights under the Sublicense for such [**] payments to be made, and reasonably cooperate with Broad if Broad takes enforcement actions of its own as to such right to [**]
payment. Notwithstanding Section 4.5.1 (Patent Challenge), if the Challenging Party that takes an action that constitutes a Patent Challenge is solely a Sublicensee and not Licensee or its Affiliates, Broad shall not have
the right to convert Licensee’s exclusive licenses to non-exclusive licenses as contemplated by clause (d) of Section 4.5.1 (Patent Challenge) if Licensee terminates the
Sublicense of such Sublicensee within [**] days of receiving notice of such challenge; provided that, neither Licensee nor its Affiliates assist or participate in the Patent Challenge either prior to or after such termination. 

To avoid doubt, the fees, milestones, royalties and other amounts owed by Licensee and its Affiliates and Sublicensees who are not Challenging Parties shall
not be [**] under Section 4.5.1 (Patent Challenge) as a result of Patent Challenge actions by an unrelated Sublicensee Challenging Party. 

4.6 Non-Royalty Sublicense Income. Licensee will pay Broad a percentage in accordance with the
following table of all Non-Royalty Sublicense Income, without deduction (other than as provided in the definition of Non-Royalty Sublicense Income in
Section 1.111 (“Non-Royalty Sublicense Income”)); provided, however, that Licensee may deduct from Non-Royalty Sublicense Income
received by Licensee as a result of the achievement by a Sublicensee of a milestone event set forth in Section 4.3.1 (Product Milestone Payments) the amount of the corresponding milestone payment due Broad under
Section 4.3.1 (Product Milestone Payments) in connection with the achievement of such milestone event. For the avoidance of doubt, in the event any Sublicensee transfers rights granted or transferred by Broad under this
Agreement along with rights owned by the Licensee or granted to the Licensee by a Third Party, Licensee shall pay to Broad the following percentages of all Non-Royalty Sublicense Income received by Licensee or
its Affiliates under such Sublicense without deduction from or apportionment of any part of such consideration. Licensee agrees that all rights controlled by Licensee and reasonably expected to be relevant at the given time to make, use, sell, offer
to sell or import particular Royalty-Bearing Products shall be included in or deemed to be included in the same Sublicense under which the rights granted or otherwise transferred to Licensee hereunder are granted with respect to such Royalty-Bearing
Product for the purpose of calculating Non-Royalty Sublicense Income. 
  

			
	 Category of Sublicense
	  	Percentage of Non-
Royalty Sublicense
Income
	 (a) With respect to a Sublicense executed [**]
	  	[**]%
	 (b) With respect to a Sublicense executed [**]
	  	[**]%
	 (c) With respect to a Sublicense executed [**]
	  	[**]%

  
 58 

 Subject to Section 1.111
(“Non-Royalty Sublicense Income”), in the case of Non-Royalty Sublicense Income received in kind in the form of a freely transferable security (except for such
restrictions on transfer imposed by Applicable Law), Licensee shall nonetheless distribute the applicable Non-Royalty Sublicense Income to Broad in the form of cash. 

4.7 Complex Consideration. Licensee acknowledges and agrees that the Parties have chosen to apply set royalty rates and milestone
payments to the rights granted under this Agreement for Licensee’s convenience in calculating and paying royalties and milestones. In doing so, Licensee acknowledges and agrees that certain royalty rates and milestones payments chosen
incorporate discounts reflecting that certain products and services may not be Covered by the Valid Claims of the Patent Rights but may be based upon, derived from or use the Patent Rights or other licensed intellectual property rights, so that
Licensee, unless explicitly provided otherwise in this Agreement, shall not be entitled to a reduction in the royalty rate or milestone payment, even if it does not at all times need or use a license to specific Patent Rights, until the end of the
Royalty Term for such product or service. 
 4.8 Success Payments. Licensee shall make such payments (each, a “[**]” and
collectively, the “[**]”) as are determined in accordance with Exhibit 4.8 hereto. 
 4.9 Assumption of Obligations.
Any acquirer, lessee, exclusive licensee or other transferee of all or substantially all of the Licensee’s assets, or any successor entity to the Licensee (each, an “Acquirer”), shall be obligated to assume and guarantee the
Licensee’s obligations pursuant to Article 4 and Exhibit 4.8 hereto, as such obligations are set forth herein and therein and subject to the terms and conditions (including contingent events) set forth herein and therein. For the
avoidance of doubt, following a Beam Change of Control, Beam shall be deemed an Acquirer under this Agreement. 
 5. Reports; Payments; Records. 

5.1 Reports and Payments. 

5.1.1 Reports. Within [**] days after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which Net
Sales are generated or Non-Royalty Sublicense Income is received, Licensee shall deliver to Broad a report containing the following information (in each instance, with a Royalty-Bearing Product-by-Royalty-Bearing Product and country-by-country breakdown): 

5.1.1.1 the number of units of Royalty-Bearing Products sold, leased or otherwise transferred by Invoicing Entities for the
applicable Calendar Quarter; 
 5.1.1.2 the gross amount billed or invoiced for Royalty-Bearing Products sold, leased or
otherwise transferred by Invoicing Entities during the applicable Calendar Quarter; 

  
 59 

 5.1.1.3 a calculation of Net Sales for the applicable Calendar Quarter,
including an itemized listing of allowable deductions; 
 5.1.1.4 a detailed accounting of all
Non-Royalty Sublicense Income received during the applicable Calendar Quarter, including an itemized listing of allowable exclusions, as well as a reasonably detailed description of any profit share
arrangement, as applicable; 
 5.1.1.5 the total amount payable to Broad in U.S. Dollars on Net Sales and Non-Royalty Sublicense Income for the applicable Calendar Quarter, together with the exchange rates used for conversion; and 

5.1.1.6 a good faith list of [**] for all Patent Rights that have Valid Claims covering the Licensed Products; 

provided that, Licensee shall use reasonable efforts to include in each Sublicense a provision requiring the Sublicensee to provide the
information required under this Section 5.1.1 (Reports) and provided further that, to the extent that the information set forth on such report is provided by a Sublicensee, Licensee shall, notwithstanding anything to the
contrary in this Section 5.1 (Reports and Payments), provide such report within [**] days after the conclusion of each such Calendar Quarter and in any event shall promptly provide such report from Sublicensee to Broad
following Licensee’s receipt of such. Each such report shall be certified on behalf of Licensee as true, correct and complete in all material respects. If no amounts are due to Broad for a particular Calendar Quarter, the report shall so state.
Broad may reasonably request further information regarding the calculation of payments under any report and Licensee will consider such reasonable requests in good faith. 

5.1.2 Payment. Within [**] days after the end of each Calendar Quarter, Licensee shall pay Broad all amounts due with respect to Net
Sales and Non-Royalty Sublicense Income for the applicable Calendar Quarter; provided, however, that for royalties to Broad on Net Sales by Sublicensees, Licensee shall have until the earlier of (a) [**]
business days after receiving the quarterly royalty payment from the Sublicensee and (b) [**] days after the end of the applicable Calendar Quarter to turn around payment to Broad on the underlying Net Sales. 

5.2 Payment Currency. All payments due under this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S. Dollars
will be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the applicable Calendar Quarter. Such payments will be without deduction of exchange, collection or other charges.
Notwithstanding the foregoing, a reasonable and customary currency conversion methodology as is set forth in a Sublicense agreement shall be the method used for currency conversion of amounts due in relation to such Sublicense agreement, provided
that such conversion methodology governs payments received by Licensee under such Sublicense agreement. 

  
 60 

 5.3 Records. Licensee shall maintain, and shall cause its Affiliates and Sublicensees
to maintain, complete and accurate records of Royalty-Bearing Products that are made, used, sold, leased or transferred under this Agreement, any amounts payable to Broad in relation to such Royalty-Bearing Products, and all Non-Royalty Sublicense Income received by Licensee and its Affiliates, which records shall contain sufficient information to permit Broad to confirm the accuracy of any reports or notifications delivered to Broad
under Section 5.1 (Reports and Payments). Licensee and its Affiliates shall, and shall use reasonable efforts to require its Sublicensees to, as applicable, retain such records relating to a given Calendar Quarter for at
least [**] years after the conclusion of that Calendar Quarter; provided that Licensee shall require that its Sublicensees retain such records relating to a given Calendar Quarter for no fewer than [**] years after the conclusion of that
Calendar Quarter (the “Record Retention Period”). 
 5.3.1 Audit of Licensee and Affiliates. During the Record
Retention Period, Broad will have the right, at its expense, to cause an independent, certified public accountant (or, in the event of a non-financial audit, other appropriate auditor) chosen by Broad to
inspect such records during normal business hours for the purposes of verifying the accuracy of any reports and payments delivered under this Agreement and Licensee’s compliance with the terms hereof. Such accountant or other auditor, as
applicable, shall be under reasonable written obligations of confidentiality to the audited party and shall not disclose to Broad any information other than information relating to the accuracy of reports and payments delivered under this Agreement.
In addition, the auditor shall disclose its draft conclusions to Licensee and Broad, and the basis for such conclusions to Licensee, prior to making its final report to Broad, and shall be instructed to read the Licensee’s comments in response
thereto (if any). The accounting records as to any accounting period shall not be audited more than [**] per accounting period, nor more than [**] years after the end of such accounting period. The Parties shall reconcile any underpayment or
overpayment within [**] days after the accountant delivers the results of the audit. If any audit performed under this Section 5.3 (Records) reveals an underpayment in excess of [**] percent ([**]%) in any Calendar Year,
Licensee shall reimburse Broad for all amounts incurred in connection with such audit. Broad may exercise its rights under this Section 5.3 (Records) only [**] every year per audited entity and only with reasonable prior
notice to the audited entity. 
 5.3.2 Audit of Sublicensees. Notwithstanding the foregoing, provided that the Licensee obtains an
[**] audit right for itself with respect to a Sublicensee’s records, as well as the right to share the results of such audit with Broad, the Licensee shall not be required to obtain from such Sublicensee a direct audit right for Broad. During
the Record Retention Period, Broad shall have the right, at its expense, to require Licensee to make available to an independent, certified public accountant (or, in the event of a non-financial audit, other
appropriate auditor) chosen by Broad, during normal business hours, such information as Licensee has in its possession with respect to reports and payments from Sublicensees for the purposes of verifying the accuracy of any reports and payments
delivered under this Agreement and Licensee’s compliance with the terms hereof. If such information as Licensee has in its possession is not sufficient for such purposes, Broad shall have the right, at its expense, in any Calendar Year in which
Licensee would not otherwise exercise its right to audit a given Sublicensee, to cause Licensee to exercise such audit right. If Licensee does not have the right to conduct an audit of such Sublicensee for the relevant Calendar Year, Licensee and
Broad shall meet and use reasonable efforts to agree on an appropriate course of action. The Parties shall reconcile any underpayment or overpayment within [**] days the applicable accountant delivers the results of the audit. If any audit performed
under this Section 5.3.2 (Audit of Sublicensees) reveals an underpayment (either by the Sublicensee alone or when taken together with all other contemporaneous audits conducted by or at the request of Broad) to Broad in
excess of [**] percent ([**]%) in any Calendar Year, Licensee shall reimburse Broad for all amounts incurred in connection with such audit. 

  
 61 

 5.4 Late Payments. Any payments by Licensee that are not paid on or before the date
such payments are due under this Agreement will bear interest at the lower of (a) [**] percent ([**]%) per month (to be pro-rated for any partial month) and (b) the maximum rate allowed by law. Interest
will accrue beginning on the first day following the due date for payment and will be compounded [**]. Payment of such interest by Licensee shall not limit, in any way, Broad’s right to exercise any other remedies Broad may have as a
consequence of any payment due but unpaid hereunder. 
 5.5 Payment Method. Each payment due to Broad under this Agreement shall be
paid by check or wire transfer of funds to Broad’s account in accordance with written instructions provided by Broad. If made by wire transfer, such payments shall be marked so as to refer to this Agreement. 

5.6 Withholding and Similar Taxes. All amounts to be paid to Broad pursuant to this Agreement shall be without deduction of exchange,
collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of Net Sales; provided that Licensee shall be entitled to make
payment to an account of Broad held in the United States. 
 6. Patent Filing, Prosecution and Maintenance. 

6.1 Control. Subject to Section 7.7 (Declaratory Judgment), Broad shall be responsible for the preparation,
filing, prosecution, protection, defense, issuance and maintenance of all Patent Rights, including oppositions, inter partes reviews, interferences, post-grant reviews and similar proceedings before any patent office (or appeals therefrom)
(collectively, the “Prosecution”). Broad shall: (a) choose patent counsel; (b) instruct such patent counsel to furnish the Licensee with copies of all correspondence relating to the DNA Cleaving Patent Rights or the Base
Editor Patent Rights received from and sent to the United States Patent and Trademark Office (USPTO) and any other patent office, as well as copies of all proposed responses to such correspondence received from any patent office in time for Licensee
to review and comment on such response; (c) supply Licensee with a copy of the application as filed, together with notice of its filing date and serial number; (d) supply Licensee with a draft copy of proposed preliminary amendments to be
filed subsequent to the filing of a non-provisional application within the DNA Cleaving Patent Rights or the Base Editor Patent Rights on the express condition that Licensee will not propose any claim
amendment or new claim that it believes, or has reason to believe, would result in the addition of any new inventor(s) to the application in question; and (e) keep Licensee advised of the status of actual patent filings related to the DNA
Cleaving Patent Rights and the Base Editor Patent Rights. Broad shall give Licensee the opportunity to provide comments on and make requests of Broad concerning the Prosecution of the DNA Cleaving Patent Rights and the Base Editor Patent Rights and
shall consider such comments and requests in good faith; [**]. [**], Broad shall allow Licensee to propose claims to pose in draft applications prior to filing and will consider the proposed claims in good faith. 

  
 62 

 6.1.2 Broad shall provide notice to Licensee in the event Prosecution of the Patent Rights
involves an interference or derivation proceeding. Upon declaration of any such interference or initiation of any such derivation proceeding, Licensee’s rights under Section 6.1 (Control), including the right to
receive correspondence to or from a patent office and the right to review draft responses, shall be suspended with respect to the Patent Rights involved in the interference or derivation proceeding. Notwithstanding the foregoing, any such
interference or derivation proceeding is considered Prosecution of the Patent Rights and Licensee remains responsible for [**] in connection with such Prosecution, including costs and expenses associated with settlement or attempts to settle the
interference. Notwithstanding the foregoing, if Licensee does not have an interest, such as by ownership, license or opinion, in opposing patents or applications involved in the interference or derivation proceeding, Broad shall enter into a common
interest agreement to facilitate the sharing of the materials set forth in Section 6.1 (Control) with the Licensee. 

6.1.3 Notwithstanding the foregoing, if Licensee, its Affiliates or Sublicensees is or becomes a Challenging Party, then Licensee’s rights
to participate in Prosecution under Section 6.1 (Control), including the right to receive correspondence to or from a patent office and the right to review draft responses, shall be suspended during the pendency of the
relevant Patent Challenge with respect both to the Patent Rights that are the subject of the Patent Challenge and to any related Patent Rights. 

6.1.4 No later than [**] days prior to the deadline for entering into the national/regional phase with respect to any PCT application included
in the Patent Rights, Licensee shall provide Broad with a list of countries in which Licensee would like Broad to file the patent application (each, a “List of Countries”). Broad shall consider each List of Countries in good faith
and, except as provided below in this Section 6.1.4 (Control), shall file national/regional phase applications in all countries on each List of Countries. Notwithstanding anything to the contrary contained in this
Agreement, and without intending to limit any of Broad’s rights hereunder, Broad expressly reserves the right (i) to decline to initiate Prosecution of any of the Patent Rights in a Developing Country(ies) (excluding Brazil, China and
India) included on a List of Countries or (ii) to initiate, and in its discretion, continue Prosecution of any of the Patent Rights in a Developing Country(ies) (excluding Brazil, China and India) whether or not included on a List of Countries
at Broad’s expense, provided that Broad provides Licensee with [**] days’ advance notice of its intention to take the action described in the foregoing clause (i) or (ii), provides Licensee an opportunity for Licensee to meet with
Broad to discuss, and reasonably considers Licensee’s comments regarding such intention. Broad shall thereafter notify Licensee of the taking of any action described in the foregoing clause (i) or (ii) at least [**] days before the taking
of such action. If Broad takes the action described in clause (ii) of the immediately preceding sentence, then Broad expressly reserves the right, upon notice to Licensee, either (A) to remove the applicable Patent Right in such Developing
Country(ies) from the scope of the licenses granted pursuant to Section 2.1.1 (License Grants) and Section 2.1.2 (License Grants), effective upon such notice, or (B) treat the applicable
Patent Right as an Abandoned Patent Right, in which case under this clause (B) all licenses granted to the Licensee under such Patent Right in such Developing Country(ies) shall terminate upon such notice; whereupon Broad shall be free, without
further notice or obligation to Licensee, to grant non-exclusive or exclusive rights in and to such Patent Right to Third Parties for all purposes within such Developing Country(ies). Further, Broad may, in
its sole discretion, file additional 

  
 63 

 
national/regional phase applications (the “Additional National Stage Filings”) in countries not included on a List of Countries provided by Licensee, and all expenses, including
translation fees associated with Prosecution of such Additional National Stage Filings shall be expenses associated with Prosecution under this Agreement, in accordance with Section 6.3 (Expenses). If Licensee does not wish
to reimburse Broad for all expenses associated with Prosecution of such Additional National Stage Filings, such Additional National Stage Filings shall be deemed Abandoned Patent Rights and treated in accordance with
Section 6.4.1 (Abandonment by Licensee). 
 6.2 Common Interest. All
non-public information disclosed by Broad or its outside patent counsel to Licensee regarding Prosecution of the Patent Rights, including [**], shall be deemed Broad Confidential Information (either for itself
or on behalf of another Institution, as applicable). In addition, the Parties acknowledge and agree that, with regard to such Prosecution of the Patent Rights, the interests of the Parties as licensor and licensee are aligned and are legal in
nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patent Rights or their Confidential Information, including privilege under the common
interest doctrine and similar or related doctrines. 
 6.3 Expenses. [**]. In addition, subject to
Section 6.4 (Abandonment) below, Licensee shall reimburse Broad for [**] documented, out-of-pocket expenses, including attorneys’ fees,
translation costs and official fees, incurred by Broad in the Prosecution of the Patent Rights pursuant to this Article 6, incurred after the Effective Date within [**] days after the date of each invoice from Broad for such expenses. In the
event that after the Effective Date, Broad enters into an exclusive license with a third party with respect to (a) any of the Base Editor Patent Rights (other than Product-Specific Base Editor Patent Rights) or DNA Cleaving Patent Rights
outside the Field or (b) any of the Product-Specific Base Editor Patent Rights or Gene Targeting Patent Rights outside the Field or for products other than Base Editor Products, then Broad shall use reasonable efforts to secure a provision
under such license that provides for payment of an appropriate portion of past and future expenses related to such Patent Rights by such licensee at the time such expenses are incurred, taking into consideration the scope of such license. In the
event that Broad is able to collect such amounts, Broad shall credit Licensee for the applicable share previously paid by Licensee for past expenses and Licensee shall thereafter be obligated to only pay its applicable share of such expenses. 

6.4 Abandonment. 
 6.4.1
Abandonment by Licensee. If Licensee decides that it does not wish to pay for the Prosecution of any Patent Rights in a particular country, then Licensee shall provide Broad with prompt written notice of such election and upon such written
notice, the Patent Rights that were the subject of the notice, solely in the countries identified in the notice for such Patent Rights, shall be “Abandoned Patent Rights.” Upon receipt of such notice by Broad, Licensee shall be
released from its obligation to reimburse Broad for the expenses incurred thereafter as to such Abandoned Patent Rights; provided, however, that expenses authorized prior to the receipt by Broad of such notice that cannot be cancelled as of the date
of the notice shall be deemed incurred prior to the notice. Any license granted by Broad to Licensee hereunder with respect to any Abandoned Patent Rights will terminate, and Licensee will have 

  
 64 

 
no rights whatsoever to exploit such Abandoned Patent Rights. Broad will then be free, without further notice or obligation to Licensee, to grant rights in and to such Abandoned Patent Rights to
third parties without limitation. In addition, if Abandoned Patent Rights represent substantially all the material patentable claims within a Sub-Category of Base Editor Patent Rights or a Sub-Category of the Gene Targeting Patent Rights, Broad shall have the right to grant to third party licensees of such Abandoned Patent Rights within such Sub-Category, a non-exclusive license under the Patent Rights solely to make, have made, offer for sale, sell, have sold and import products, including Base Editor Products, that are claimed or covered by Patent Rights within such Sub-Category in any field solely in the countries applicable to such Abandoned Patent Rights, which non-exclusive license shall not extend to components of such products that
are a different category of Base Editor than the category of Base Editor that is the subject matter of such Abandoned Patent Rights (for non-limiting example, [**]). For clarity, Abandoned Patent Rights are
defined on a country-by-country basis, not a worldwide basis, and Licensee shall retain its rights in all other countries to the Patent Rights that are counterparts in
other countries to the Abandoned Patent Rights (and the non-exclusive licenses referred to in this paragraph shall not extend to such other countries). 

6.4.2 Abandonment by Broad. Broad agrees to maintain any application or patent within the Patent Rights for as long as (a) Licensee
continues to meet its obligation to reimburse expenses associated with such application or patent in accordance with Section 6.3 (Expenses) and (b) there is a good faith basis for doing so. In the event that Broad is
permitted under this Section 6.4.2 (Abandonment by Broad) to cease Prosecution of an application or patent within the Patent Rights and elects to do so, it shall notify Licensee at least [**] prior to ceasing Prosecution
for such Patent Right and shall discuss such proposed action with Licensee in good faith. For the avoidance of doubt, this Section 6.4.2 (Abandonment by Broad) shall not apply and shall not limit Broad’s right to cease
Prosecution of a given application within the Patent Rights in lieu of a divisional, continuation or continuation-in-part application that is also within the Patent
Rights. 
 6.5 Marking. Licensee shall, and shall cause its Affiliates and Sublicensees to, mark all Royalty-Bearing Products sold or
otherwise disposed of in such a manner as to conform with the patent laws and practice of the country to which such products are shipped or in which such products are sold for purposes of ensuring maximum enforceability of Patent Rights in such
country. 
 6.6 CREATE Act. No Party shall have the right to use this Agreement as a joint research agreement to make an election
under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3), as amended by the America Invents Act and set forth in 35 U.S.C. 102(b)(2)(C) and 102(c), without the prior written consent of each other Party having
an ownership interest in a patent or patent application involved in such election, such consent to be granted or withheld in the sole discretion of each such other Party. 

7. Enforcement of Patent Rights. 
 7.1
Notice. In the event either Party becomes aware of any possible or actual infringement of any Patent Rights with respect to Licensed Products, that Party shall promptly notify the other Party and provide it with details regarding such
Infringement. 

  
 65 

 7.2 Suit by Licensee. So long as Licensee remains the exclusive licensee of the DNA
Cleaving Patent Rights or the Base Editor Patent Rights (other than the Product-Specific Base Editor Patent Rights) with respect to a Licensed Product in the Field, or the exclusive licensee of the Gene Targeting Patent Rights or the
Product-Specific Base Editor Patent Rights with respect to a Licensed Product that is a Base Editor Product in the Field, Licensee shall have the first right, but not the obligation, to institute infringement suits under the Patent Rights with
respect to such Licensed Product in the Field where Licensee reasonably determines that a Third Party is marketing or has specific plans and is preparing to market an infringing product in any country that competes with such Licensed Product in the
Field (“Infringement”); provided that prior to initiating action against the Third Party with respect to such Infringement, Licensee has provided evidence to Broad and other Institutions, as applicable, that there is a good faith
basis for doing so. Notwithstanding anything to the contrary contained herein with respect to any Infringement, if Licensee owns one or more patents that cover the allegedly infringing product (“Other IP”), Licensee shall not
initiate action under the Patent Rights unless it (i) also asserts [**] of such Other IP or (ii) obtains written consent from Broad. Licensee shall use the same degree of diligence in prosecuting such Infringement as it uses or would use
in prosecuting infringement of its own patent rights. Notwithstanding anything to the contrary contained herein with respect to any Infringement, Licensee’s right to enforce the Gene Targeting Patent Rights and the Product-Specific Base Editor
Patent Rights shall be limited solely to those claims of the Gene Targeting Patent Rights and the Product-Specific Patent Rights that are expressly limited in scope to Base Editing unless Licensee obtains written consent from Broad. 

7.2.1 Before Licensee commences an action with respect to any Infringement, Licensee shall give Broad no less than [**] days’ advance
written notice, and Licensee shall consult with Broad and the other Institutions, as applicable, and, to the extent feasible, any other exclusive licensee of the applicable Patent Rights who have a right to enforce such Patent Rights
outside of the Field, upon such exclusive licensee’s request, subject, in the case of any such other exclusive licensee to an obligation of confidentiality that apply to such other licensee that is no less strict than that set forth herein,
with respect to its proposed course of action to address the Infringement and Licensee shall consider in good faith the views and concerns (if any) of Broad, the other Institutions, and, as applicable, other exclusive licensees of such Patent Rights
outside of the Field, and potential effects on the public interest in making its decision whether to take such action, especially with regard to the locally affordable availability of Licensed Products or equivalents thereof, e.g., generic products,
in Developing Countries. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Licensee agrees that, consistent with Section 6.1 (Control), Broad shall hold final decision-making authority,
to be exercised in good faith, on a case-by-case basis, as to whether Licensee shall be permitted to enforce the Patent Rights in any Developing Country. 

7.2.2 Should Licensee elect (and, where consent of Broad is required, be permitted) to take action against an actual or potential infringer,
Licensee shall select counsel reasonably acceptable to Broad, shall keep Broad and other Institutions, as applicable, reasonably informed of the progress of the action and shall give Broad and other Institutions, as applicable, a reasonable
opportunity in advance to consult with Licensee and offer its views about major decisions affecting the action. Licensee shall give careful consideration to those views, but shall have the right to control the action; provided, however, that if
Licensee fails to defend in good faith the validity or enforceability of the Patent Rights in the action, or if 

  
 66 

 
Licensee’s exclusive license to a Valid Claim in the suit terminates pursuant to Section 10.2 (Termination), or if infringement in the Field terminates, Broad may
elect to take control of the action pursuant to Section 7.3 (Suit by Broad). The expenses of Licensee with respect to any suit or suits that Licensee elects to bring in accordance with this
Section 7.2 (Suit by Licensee) shall be paid for entirely by Licensee. If required under Applicable Law to establish standing for the initiation or maintenance of such infringement action by Licensee, (a) Broad and
other Institutions, as applicable, shall, upon request of Licensee or as required by a court or procedural rules, or may voluntarily, join or be joined as a party to such action, provided that neither Broad nor another Institution, as applicable,
shall be the first named party in such action, (b) Licensee shall hold Broad (and other Institutions, if applicable) free, clear and harmless from and against any and all costs and expenses, including attorneys’ fees, incurred in
conjunction with the prosecution, adjudication, defense, management or settlement of, or joinder to, such suits and any related appeals, remands or other related proceedings (“Litigation Expenses”), (c) Licensee shall reimburse any
and all Litigation Expenses incurred by Broad (and other Institutions, if applicable) within [**] days after receiving an invoice (including a copy of detailed time and expense entries from attorneys) from Broad (and other Institutions, if
applicable) for same and (d) Licensee shall hold Broad (and other Institutions, if applicable) free, clear and harmless from and against any and all Litigation Expenses incurred by Broad (or other Institutions, if applicable). Licensee shall
not compromise or settle such litigation without the prior written consent of Broad (subject to concurrence of other Institutions, as applicable), which shall not be unreasonably withheld or delayed. In the event Licensee exercises its right to sue
pursuant to this Section 7.2 (Suit by Licensee), then out of any sums recovered in such suit or in settlement thereof, such recoveries shall first be used to reimburse Licensee for its Litigation Expenses incurred in the
prosecution of any such suit. If, after such reimbursement, any funds remain from said recovery, then Broad shall receive an amount of such remaining funds equal to the applicable percentage in Section 4.6 (Non-Royalty Sublicense Income) had the infringer been a Sublicensee instead (and such recovery was Non-Royalty Sublicense Income paid under a Sublicense executed on the
effective date of such settlement or the date of entry of judgment by the court awarding such recovered sums, whichever is applicable), and the remainder of such funds shall be retained by Licensee. 

7.3 Suit by Broad. If Licensee does not take action in the prosecution, prevention, or termination of any Infringement pursuant to
Section 7.2 (Suit by Licensee) above, and has not commenced negotiations with the suspected infringer for the discontinuance of said Infringement, within [**] days after receipt of notice of the existence of an actual
Infringement, then Broad may elect to do so. Broad shall give due consideration to Licensee’s reasons for not initiating a lawsuit or otherwise making or prosecuting a claim. Subject to Section 7.2 (Suit by Licensee),
any and all expenses, including reasonable attorneys’ fees, incurred by Broad with respect to the prosecution, adjudication or settlement of such suit in accordance with this Section 7.3 (Suit by Broad), including any
related appeals, shall be paid for entirely by Broad. In the event Broad exercises its right to sue pursuant to this Section 7.3 (Suit by Broad), out of any sums recovered in such suit or in settlement thereof, such
expenses incurred by Broad shall be first reimbursed and then Licensee shall receive [**] percent ([**]%) of the remaining funds, with the remainder of such funds to be retained by Broad. 

  
 67 

 7.4 Own Counsel. The party initiating the suit shall have the sole and exclusive
right to elect counsel for any suit initiated by it pursuant to Section 7.2 (Suit by Licensee) or Section 7.3 (Suit by Broad); provided that such counsel is reasonably acceptable to the other Party. Each Party
shall have the right to participate in and be represented by counsel of its own selection and at its own expense in any suit instituted under this Article 7 by the other Party for Infringement. 

7.5 Cooperation. Each Party agrees to cooperate fully in any action under this Article 7 that is controlled by the other Party,
including executing legal papers and cooperating in the prosecution as may be reasonably requested by the controlling Party; provided that the controlling Party reimburses the cooperating Party promptly for any costs and expenses incurred by the
cooperating Party in connection with providing such assistance within [**] days after receiving an invoice from the cooperating Party for same. 

7.6 Patent Validity Challenge. Each Party shall promptly notify the other Party in the event it receives notice of any legal or
administrative action by any Third Party against a Patent Right, including any opposition, nullity action, revocation, inter partes review, post-grant review, compulsory license proceeding or declaratory judgment action. Any such actions are
Prosecution of the Patent Rights and shall be addressed as provided in Section 6.1 (Control) and Section 6.3 (Expenses). 

7.7 Declaratory Judgment. If a declaratory judgment action is brought naming Licensee or any of its Affiliates or Sublicensees as a
defendant and alleging invalidity or unenforceability of any claims within the Patent Rights, Licensee shall promptly notify Broad in writing. Similarly, if Broad is named as a defendant in a declaratory judgment action related to the Patent Rights,
Broad shall promptly notify Licensee in writing. In either case, Broad may elect, upon written notice to Licensee (such written notice to be given within [**] days after Broad receives notice of the commencement of such action, in the case of
actions of which Licensee notifies Broad) to conduct or to take over the sole defense of the invalidity or unenforceability aspect of the action at Licensee’s expense in accordance with Section 6.3 (Expenses). In such
event, Broad shall keep Licensee fully informed in advance of the strategy in responding to such declaratory judgment action, the Parties shall enter into a common interest/joint defense agreement as appropriate (which shall not be in conflict with
this Agreement), and Broad shall reasonably consult with and consider the comments of Licensee and its counsel. If Broad does not promptly elect to conduct the defense or take over the defense of the applicable suit (or portion thereof), then it
shall so notify the Licensee and, upon Licensee’s request, the Parties shall discuss in good faith Broad’s reasons for not conducting such defense and the possibility of Broad permitting Licensee to conduct the defense at Licensee’s
expense, and if Licensee does so conduct such defense, Broad shall reasonably cooperate with Licensee in relation thereto. The rights granted to Broad under this Section 7.7 (Declaratory Judgment) shall be in addition to
any rights granted under Section 6.1 (Control) and Section 6.3 (Expenses). In the event that after the Effective Date, Broad enters into an exclusive license with a Third Party with respect to any
of the Patent Rights outside the Field, then Broad shall use reasonable efforts to secure a provision under such license that provides for payment of an appropriate portion of past and future expenses related to such Patent Rights under this
Section 7.7 (Declaratory Judgment) by such licensee at the time such expenses are incurred, taking into consideration the scope of such license. In the event that Broad is able to collect such amounts, Broad shall credit
Licensee for the applicable share previously paid by Licensee for past expenses under this Section 7.7 (Declaratory Judgment) and Licensee shall thereafter be obligated to only pay its applicable share of such expenses
under this Section 7.7 (Declaratory Judgment). 

  
 68 

 7.8 Actions Against Infringement Outside the Field. Prior to taking action to enforce
any Patent Rights against infringement outside the Field, Broad shall, and shall cause its exclusive licensees of the applicable Patent Rights who have a right to enforce such Patent Rights outside of the Field, to the extent feasible and consistent
with any obligations of confidentiality that apply to Broad or such exclusive licensee, give Licensee no less than [**] days’ advance written notice. Promptly after such notice, if requested by Licensee, Broad shall, and shall cause its
exclusive licensee of the applicable Patent Right to, meet and confer with Licensee, subject to any obligations of confidentiality that apply to Broad or such licensee, and consider in good faith Licensee’s views and concerns (if any) related
to the potential enforcement action. 
 7.9 Licensee Actions in Support of Affiliates and Sublicensees. Unless, based on the advice of
counsel to Broad, it is reasonably likely to adversely affect attorney-client privilege, it is understood that the Licensee may, upon [**] days prior written notice to Broad, exercise its rights under this Article 7 in support of its
Affiliates and Sublicensees, and may seek the comments and financial support of Affiliates and Sublicensees on patent prosecution and enforcement, and may make comments and seek to enforce Patent Rights in accordance with this Article 7 to
protect the interests of its Affiliates and Sublicensees, in addition to the Licensee’s own interests. 
 7.10 RESERVED 

8. Warranties and Covenant: Limitation of Liability. 

8.1 Compliance with Law. Licensee represents and warrants that it will comply, and will ensure that its Affiliates and Sublicensees
comply, with all Applicable Law, including all local, state, federal and international laws and regulations relating to the development, manufacture, use, sale and importation of Royalty-Bearing Products. Without limiting the foregoing, Licensee
represents and warrants, on behalf of itself and its Affiliates and Sublicensees, that it shall comply with all Applicable Laws and regulations controlling the export of certain commodities and technical data, including without limitation all Export
Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries. Licensee
hereby gives written assurance that it will comply with, and will cause its Affiliates to comply with (and will contractually obligate its Affiliates and Sublicensees to comply with), all applicable United States export control laws and regulations,
that as between the Parties it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or Sublicensees, and that it will indemnify, defend, and hold Indemnitees harmless (in accordance with
Section 9.1 (Indemnity)) for the consequences of any such violation. 

  
 69 

 8.2 Option Agreement. Attached as Exhibit 8.2 is the Option Agreement dated as
of the date hereof between Beam and Licensee (the “Option Agreement”). During the Term of this Agreement, Licensee agrees that it shall not amend the Option Agreement or enter into any other agreement that would result in a Beam
Change of Control (an “Alternative Agreement”) that would (a) diminish or otherwise adversely affect Broad’s right or ability to receive at least the amount of compensation upon a Beam Change of Control contemplated in the
Option Agreement as of the Effective Date, (b) modify Beam’s obligation to assume or guarantee Licensee’s obligations to Broad and the Broad Designees under this Agreement following a Beam Change of Control contemplated in this
Agreement, or (c) modify Broad’s right or ability to enforce Beam’s obligation to satisfy Licensee’s obligations under this Agreement following a Beam Change of Control, in each case without Broad’s prior written consent.

 8.3 Services Agreement. Attached as Exhibit 8.3 hereto is a Services Agreement dated as of the Effective Date hereof between
Beam and Licensee (the “Services Agreement”). During the Term of this Agreement until a Beam Change of Control, Licensee agrees that it shall not (a) amend the Services Agreement in any manner that would limit Licensee’s
ability to perform its obligations under this Agreement or (b) enter into any other agreement, in each case ((a) or (b)), that would materially alter the allocation of intellectual property rights under the Services Agreement, without
Broad’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. 
 8.4 Representations and
Warranties. 
 8.4.1 By Broad. Broad represents and warrants that (A) Broad has the authority and right to enter into and
perform its obligations under this Agreement and grant the licenses granted to Licensee herein on behalf of itself and the other Institutions, (B) as of the Effective Date, to the best of the knowledge of Broad’s Office of Strategic
Alliances and Partnering, the execution, delivery and performance of this Agreement by Broad does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound, and
(C) as of the Effective Date, to the best of the knowledge of Broad’s Office of Strategic Alliances and Partnering, no consent of any Third Party, including without limitation any governmental authority, is required for Broad to execute,
deliver and perform under this Agreement, including without limitation to grant the licenses granted to Licensee herein, except for such consents as may have been obtained prior to the Effective Date. 

8.4.2 By Licensee. Licensee represents and warrants that (A) Licensee has the authority and right to enter into and perform its
obligations under this Agreement, (B) as of the Effective Date, to the best of Licensee’s knowledge, the execution, delivery and performance of this Agreement by Licensee does not conflict with, or constitute a breach of, any order,
judgment, agreement or instrument to which it is a party or, to its knowledge, is otherwise bound, and (C) as of the Effective Date, to the best of Licensee’s knowledge, no consent of any Third Party, including without limitation any
governmental authority, is required for Licensee to execute, deliver and perform under this Agreement, except for such consents as may have been obtained prior to the Effective Date. 

8.5 No Warranty. 
 8.5.1
Broad makes no representations or warranties other than those set forth above. 

  
 70 

 8.5.2 Nothing contained herein shall be deemed to be a warranty by Broad or by any other
Institution that it can or will be able to obtain patents on patent applications included in the Patent Rights, or that any of the Patent Rights will afford adequate or commercially worthwhile protection. 

8.5.3 NEITHER BROAD NOR ANY INSTITUTION MAKES ANY WARRANTIES WHATSOEVER AS TO THE COMMERCIAL OR SCIENTIFIC VALUE OF THE PATENT RIGHTS OR THE
TRANSFERRED MATERIALS. NEITHER BROAD NOR ANY INSTITUTION MAKES ANY REPRESENTATION THAT THE PRACTICE OF THE PATENT RIGHTS OR USE OF THE TRANSFERRED MATERIALS OR THE DEVELOPMENT, MANUFACTURE, USE, SALE OR IMPORTATION OF ANY ROYALTY-BEARING PRODUCT, OR
ANY ELEMENT THEREOF, WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS. 
 8.5.4 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER LICENSEE NOR BROAD NOR ANY INSTITUTION MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH OF LICENSEE, BROAD AND THE INSTITUTIONS EACH HEREBY DISCLAIM
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
 8.6
Limitation of Liability. 
 8.6.1 EXCEPT WITH RESPECT TO MATTERS FOR WHICH LICENSEE IS OBLIGATED TO INDEMNIFY INDEMNITEES UNDER
ARTICLE 9, AND LIABILITY RESULTING FROM A BREACH BY LICENSEE OF THE LICENSE GRANT RESTRICTIONS UNDER SECTION 2.1.2 (LICENSE GRANTS), NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT
UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR (A) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR (B) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES.

 8.6.2 Institutions’ aggregate liability for all damages of any kind arising out of or relating to this Agreement or its subject
matter under any contract, negligence, strict liability or other legal or equitable theory shall not exceed the amounts paid to Broad under this Agreement. 

9. Indemnification and Insurance. 
 9.1
Indemnity. 
 9.1.1 Licensee shall (and shall cause its Affiliates and Sublicensees to) indemnify, defend and hold harmless each
Institution and each of their current and former directors, governing board members, trustees, officers, faculty, affiliated investigators, medical and professional staff, employees, students, and agents and their respective successors, heirs and
assigns (collectively, the “Indemnitees”) from and against any claim, suit, investigation, action, 

  
 71 

 
demand, judgment, liability, cost, expense, damage, deficiency, loss or obligation of any kind or nature (including reasonable attorneys’ fees and other costs and expenses of litigation or
defense), based upon, arising out of, or otherwise relating to this Agreement or any Sublicense or subcontract, including any cause of action relating to product liability concerning any product, process, or service made, used, sold or
performed pursuant to any right or license granted under this Agreement (collectively, “Claims”) except to the extent any such Claim results from or arises out of the gross negligence or willful misconduct of an Indemnitee or
material breach of this Agreement by Broad. No Affiliate of Licensee (other than an Affiliate controlling Licensee) shall have an obligation to indemnify Broad for any Claim based upon, arising out of, or otherwise relating to the exercise of rights
under this Agreement by a different Affiliate of Licensee or by any other Person unless such Affiliate or other Person is exercising rights granted by such first Affiliate or acting on such first Affiliate’s behalf or upon its instruction or
advice. No Sublicensee shall have an obligation to indemnify Broad for any Claim based upon, arising out of, or otherwise relating to the exercise of rights under this Agreement by a different Sublicensee, Licensee, any Affiliate of Licensee or by
any other Person unless such different Sublicensee, Licensee or Affiliate or other Person is exercising rights granted by such first Sublicensee or acting on such first Sublicensee’s behalf or upon its instruction or advice. 

9.1.2 Procedures. For purposes of this Section 9.1.1 (Procedures), Licensee and each of its Affiliates and
Sublicensees are referred to as “Indemnitor”. The Indemnitees agree to provide Licensee with prompt written notice of any Claim for which indemnification is sought under this Agreement; provided, however, that an Indemnitee’s
delay in providing or failure to provide such notice shall not relieve Indemnitor of its indemnification obligations under this Agreement, except to the extent Indemnitor can demonstrate actual prejudice due to the delay or lack of notice.
Indemnitor agrees, at its own expense, to provide attorneys reasonably acceptable to Broad and the applicable indemnified Institution to defend against any such Claim. The Indemnitees shall cooperate with Indemnitor, at Indemnitor’s expense, in
such defense and shall permit Indemnitor to conduct and control such defense and the disposition of such Claim (including without limitation all decisions relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall
have the right to retain its own counsel, at the expense of Indemnitor, if representation of such Indemnitee by the counsel retained by Indemnitor would be inappropriate because of actual or potential differences in the interests of such Indemnitee
and any other party represented by such counsel. Each Institution agrees to use diligent efforts to select counsel, and to cause any other Indemnitees affiliated with their respective institutions to select counsel, that minimizes the number of
counsel retained by all Indemnitees if representation of an Indemnitee by the counsel retained by Indemnitor would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party represented by
such counsel. Indemnitor agrees to keep counsel(s) for Indemnitees informed of the progress in the defense and disposition of such claim and to consult with Broad and the indemnified Institution (as applicable) with regard to any proposed
settlement. Licensee shall not settle any Claim that has an adverse effect on the rights of any Indemnitee hereunder that is not immaterial or that admits any liability by or imposes any obligation on any Indemnitee without the prior written consent
of such Indemnitee, which consent shall not be unreasonably withheld, conditioned or delayed. An Indemnitee may not settle any Claim without the prior written consent of Licensee, which consent shall not be unreasonably withheld, conditioned or
delayed. 

  
 72 

 9.1.3 Notwithstanding anything express or implied, Licensee shall not be required to
indemnify, defend, or hold harmless any Indemnitee with respect to any dispute amongst any Indemnitee(s) and/or subsets of any of the foregoing, as to the division amongst themselves of the consideration paid by Licensee under this Agreement. 

9.2 Insurance. 
 9.2.1
Beginning at the time any Royalty-Bearing Product is being commercially distributed or sold (other than for the purpose of obtaining Regulatory Approvals) by Licensee, or by an Affiliate, Sublicensee or agent of Licensee, Licensee shall, at its sole
cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[**] per incident and $[**] annual aggregate and naming the Indemnitees as additional insureds. During Clinical Studies of any such
Royalty-Bearing Product Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such equal or lesser amount as Broad or any other Institution shall require, naming the Indemnitees as additional
insureds. Such commercial general liability insurance shall provide: (a) product liability coverage and (b) broad form contractual liability coverage for Licensee’s indemnification obligations under this Agreement. 

9.2.2 If Licensee elects to self-insure all or part of the limits described above in Section 9.2.1 (Insurance)
(including deductibles or retentions that are in excess of $[**] annual aggregate) such self-insurance program must be acceptable to Broad and the other Institutions and Federal Insurance Company ((Broad’s insurer) in their sole discretion. The
minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with respect to its indemnification obligations under this Agreement. 

9.2.3 Licensee shall provide each Institution with written evidence of such insurance upon request of such Institution. Licensee shall provide
each Institution with written notice at least [**] days prior to the cancellation, non-renewal or material change in such insurance. If Licensee does not obtain replacement insurance providing comparable
coverage within such [**] day period, Broad shall have the right to terminate this Agreement effective at the end of such [**] day period without notice or any additional waiting periods. 

9.2.4 Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during:
(a) the period that any Royalty-Bearing Product is being commercially distributed or sold by Licensee, or an Affiliate, Sublicensee or agent of Licensee; and (b) a reasonable period after the period referred to in (a) above which in
no event shall be less than [**] years. 
 10. Term and Termination. 

10.1 Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article
10, shall continue in full force and effect until the expiration of the later of: (a) the last to expire Valid Claim or (b) the end of the last Royalty Term of a Product in the Field in a country in the Territory (the
“Term”). 

  
 73 

 10.2 Termination. 

10.2.1 Termination Without Cause. Licensee may terminate this Agreement upon [**] days prior written notice to Broad, with or without
cause. 
 10.2.2 Termination for Default. 

10.2.2.1 Subject to Section 3.1.2.2 (Sub-Categories of Patent
Rights) and 3.5.6 (Unmet Deadline), in the event that either party commits a material breach of its obligations under this Agreement and fails to cure that breach within [**] days after receiving written notice thereof which written notice
explicitly states that it is a notice of material breach under this Section 10.2.2.1 (Termination for Default), the other party may terminate this Agreement immediately upon written notice to the party in breach. 

10.2.2.2 If Licensee defaults in its obligations under Section 9.2 (Insurance) to procure and
maintain insurance or, if Licensee has in any event failed to comply with the notice requirements contained therein, then Broad may terminate this Agreement immediately without notice or additional waiting period. 

10.2.2.3 Broad shall be entitled to, in accordance with the provisions of Section 3.1.2.2 (Sub-Categories of Patent Rights), terminate licenses granted to Licensee under Section 2.1 (License Grants) with respect to a Failed Sub-Category of
Patent Rights. 
 10.2.2.4 Broad shall be entitled to, in accordance with the provisions of
Section 3.5.6 (Unmet Deadline), (a) terminate this Agreement in its entirety under Section 3.5.6.1 (Unmet Deadline), (b) under Section 3.5.6.2 (Unmet Deadline), terminate
licenses granted to Licensee under Section 2.1 (License Grants) with respect to a Licensed Product, (c) under Section 3.5.6.3 (Unmet Deadline), terminate licenses granted to Licensee under
Section 2.1 (License Grants) with respect to Royalty-Bearing Products that are not either a Retained Product or a Related Product to a Retained Product, (d) under Section 3.5.6.3 (Unmet
Deadline), terminate licenses granted under a Sub-Category of Patent Rights to Licensee under Section 2.1 (License Grants) except with respect to Royalty-Bearing Products that are
either a Retained Product or a Related Product to a Retained Product. 
 10.2.3 Termination for Patent Challenge. If Licensee or any
of its Affiliates or Sublicensees directly or indirectly brings, assumes or participates in, or knowingly, willfully or recklessly assists in bringing a Patent Challenge (except as required under a court order or subpoena), then the following shall
apply: (a) if Licensee or any of its Affiliates is the party so bringing, assuming, participating in or assisting in such Patent Challenge, then Broad shall be entitled to immediately terminate this Agreement upon written notice to Licensee,
and (b) if a Sublicensee is the party so bringing, assuming, participating in or assisting in such Patent Challenge, then (i) Broad shall be entitled to immediately terminate the rights hereunder as and to the extent sublicensed to a
Sublicensee upon written notice to Licensee and (ii) Broad shall grant Licensee a period not to exceed [**] days from the date of notice by Broad to Licensee for Licensee to inform Sublicensee of its intention to terminate this Agreement due to
such Sublicensee bringing, assuming, participating in or assisting in a Patent Challenge, during which period Licensee may terminate any and all agreements with such Sublicensee that contain a 

  
 74 

 
Sublicense. If, pursuant to the foregoing clause (ii), Licensee terminates such sublicense agreement(s) during such [**] day period, then Broad shall not be entitled to terminate this Agreement,
in whole or in part, by virtue of such Sublicensee bringing, assuming, participating in or assisting in such Patent Challenge. However, if Licensee does not terminate such agreement(s) during such [**] day period, then Broad shall be entitled to
immediately terminate this Agreement in whole or in part upon written notice to Licensee thereof. 
 10.2.4 Bankruptcy. Broad may
terminate this Agreement upon written notice to Licensee if Licensee becomes subject to a Bankruptcy Event or if Licensee becomes the subject of dissolution proceedings or otherwise discontinues all business operations to which this Agreement
relates. 
 10.2.5 Termination without Prejudice. Broad’s right of termination in this Section 10.2
(Termination) shall be in addition and without prejudice to, and shall not constitute a waiver of, any right of Broad for recovery of any monies then due to it hereunder or any other right or remedy Broad may have at law, in equity or under this
Agreement. 
 10.3 Effect of Termination. 

10.3.1 Termination of Rights. Upon expiration or termination of this Agreement, in whole or in part, by either Party pursuant to any of
the provisions of Section 10.2 (Termination) or this Agreement: (a) the applicable rights and licenses granted to Licensee under Article 2 shall terminate, all rights in and to and under the applicable Patent
Rights will revert to Broad and neither Licensee nor its Affiliates may make any further use or exploitation of the applicable Patent Rights; and (b) any existing agreements that contain a Sublicense of rights terminated under this Agreement
shall automatically terminate to the extent of such terminated rights [**] days following the effective date of termination of this Agreement; provided, that if a Sublicensee is (i) an Affiliate of Licensee, (ii) in material default of any
material provision of the applicable Sublicense such that Licensee would have the right to terminate the Sublicense or (iii) the basis for the termination of the Agreement due to such Sublicensee’s actions or inactions ((i), (ii) and
(iii) together, “Ineligible Sublicensees”), then the applicable Sublicense to which such Sublicensee is a party shall terminate effective immediately upon termination of this Agreement. Upon termination of this Agreement, in
whole or in part, under any of the provisions in Section 10.2 (Termination), each Sublicensee subject to potential automatic termination under this Section 10.3.1 (Termination of Rights) that is
not an Ineligible Sublicensee shall have the right to enter into a direct license from Broad (a “Direct License”) on substantially the same non-economic terms and conditions set forth in the
Sublicense and on economic terms providing for the payment by such Sublicensee to Broad of the consideration that otherwise would have been payable to Broad if the applicable Sublicense and this Agreement were still simultaneously in effect. Broad
agrees to negotiate in good faith the final form of such Direct License on such financial terms and conditions; such final form of Direct License agreement shall not (i) impose any representations, warranties, obligations or liabilities on
Broad or any other Institution that are not included in this Agreement, (ii) have any obligations that are greater than or inconsistent with the obligations of Broad under this Agreement or the nature of Broad as an academic and non-profit entity, and (iii) have any fewer rights than Broad has under this Agreement, as applicable to the Direct License. If any Sublicensee, other than Ineligible Sublicensees, desires to enter into such a
Direct License with Broad, it shall wholly be the responsibility of 

  
 75 

 
Sublicensee to notify Broad of such desire no later than [**] days after the effective date of termination of this Agreement. If Broad and the applicable Sublicensee, for any reason, do not enter
into a Direct License within [**] days after the effective date of termination of this Agreement, the applicable Sublicense subject to potential automatic termination under this Section 10.3.1 (Termination of Rights), and
all rights granted thereunder, shall automatically terminate. 
 10.3.2 Accruing Obligations. Termination or expiration of this
Agreement shall not relieve the Parties of obligations accruing prior to such termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration. After the date of termination or expiration
of this Agreement in its entirety (except in the case of termination by Broad pursuant to Section 10.2 (Termination)), Licensee, its Affiliates and Sublicensees may sell (a) Licensed Products then in stock and
(b) Enabled Products; provided that Licensee shall pay the applicable royalties and payments to Broad in accordance with Article 4, provide reports and audit rights to Broad pursuant to Article 5 and maintain insurance in
accordance with the requirements of Section 9.2 (Insurance). The Parties agree that the obligations in Section 4.1 (Equity), Section 4.8 (Success Payments), and
Section 6.3 (Expenses) (with respect to patent expenses incurred by Broad prior to the Effective Date) will accrue immediately upon execution of this Agreement by both Parties, regardless of the events, invoice and payment
timing details set forth therein. 
 10.3.3 Documentation, Right of Reference and License. Upon termination of the Agreement in its
entirety, subject to the terms of any Direct Licenses and Sublicenses: 
 10.3.3.1 At Broad’s request, the parties will
discus in good faith (and subject to Licensee’s other contractual commitments with Third Parties) during the [**] day period after such termination, whether and on what terms Licensee will grant Broad a sublicensable license to any patents,
patent applications, data and other information controlled by Licensee or its Affiliates that improve or are otherwise related to the Patent Rights or that Cover a Licensed Product that Broad is interested in pursuing either itself or through a
licensee; provided that the terms of any such license shall be consistent with Licensee’s obligations under its then existing contracts and Applicable Law and its officers’ and directors’ fiduciary obligations. 

10.3.3.2 At Broad’s request, Licensee shall deliver to Broad, and Broad and its licensees shall be free to use,
(a) all records required by all Regulatory Authorities to be maintained with respect to the applicable Licensed Products, all regulatory filings, approvals, reports, records, correspondence and other regulatory materials (including any related
to reimbursement or pricing approvals), and all documents, data and other information related to Clinical Studies and other studies of the applicable Licensed Products and (b) any documentation and technical information that are necessary or
useful for the manufacture of the applicable Licensed Products, in each case (a) and (b), if and to the extent that the provision of, access to and delivery of such documentation shall not conflict with Licensee’s obligations under its
then existing contracts and Applicable Law. Licensee shall retain the right to use, and grant to Affiliates and Third Parties the right to use, any records, filings, documentation or other information given to Broad under this
Section 10.3.3.2 (Documentation, Right of Reference and License). 

  
 76 

 10.3.3.3 Licensee shall permit Broad and its licensees to utilize,
reference, cross reference, incorporate in applications and filings, and otherwise have the benefit of all Regulatory Approvals of, or Clinical Studies or other studies conducted on, and all filings made with regulatory agencies with respect to, the
applicable Licensed Products. 
 10.4 Survival. The Parties’ respective rights, obligations and duties under Articles 5,
9, 10 and 11, and Sections 4.1 (Equity) and 4.2 (Annual License Maintenance Fees) (to the extent of payment obligations accruing prior to the effective date of expiration or termination), 4.3 (Milestone
Payments) (to the extent of payment obligations accruing prior to the effective date of expiration or termination), 4.4 (Royalty on Net Sales) (to the extent of Net Sales prior to the effective date of expiration or termination), 4.5
(Patent Challenge) (to the extent applicable at the effective date of expiration or termination), 4.7 (Complex Consideration) (for so long as Licensee, its Affiliate or a Sublicensee is researching, developing or commercializing an Enabled
Product(s)), Section 6.3 (Expenses) (for expenses incurred prior to the effective date of expiration or termination), Section 8.4 (Representations and Warranties) and 8.5 (No Warranty),
8.6 (Limitation of Liability) shall survive any expiration or termination of this Agreement. In addition, Licensee’s obligations under Section 4.4 (Royalty on Net Sales), and 4.6 (Non-Royalty Sublicense Income) with respect to Sublicenses granted prior to the effective date of expiration or termination of the Agreement shall survive such expiration or termination. Further, any rights,
obligations and duties which by their nature extend beyond the expiration or termination of this Agreement shall survive any expiration or termination of this Agreement. 

11. Miscellaneous. 
 11.1
Confidentiality. 
 11.1.1 Definitions. 

11.1.1.1 “Broad Confidential Information” means (a) any information related to Prosecution of Patent
Rights provided to Licensee by or on behalf of Broad; (b) any information or material in tangible form that is marked as “confidential” or proprietary by or on behalf of Broad at the time it is sent to Licensee; (c) information
that is furnished orally by or on behalf of Broad if Broad identifies such information as “confidential” or proprietary in writing by a memorandum delivered to Licensee within [**] days after the date of disclosure; and (d) the terms
of this Agreement (but not its existence or its general subject matter), which shall constitute the Confidential Information of both Parties. The Parties agree the terms of this Agreement may be shared with the Institutions. 

11.1.1.2 “Licensee Confidential Information” means (a) any Development Plan, any Current Development
Demonstration, and any plan provided to Broad under Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or Commercialization), or 2.5.9 (Third Party Development or Commercialization),
(b) [**]; (c) any information or evidence provided to Broad in accordance with Sections 2.5.7 (Intended Development or Commercialization), 2.5.8 (Proposing Party Development or Commercialization), or

  
 77 

 
2.5.9 (Third Party Development or Commercialization) that is not included within the preceding clause (a); (d) any reports prepared by Licensee and provided to Broad pursuant to this
Agreement (including any under Section 3.3 (Regulatory Filings) and Section 5.1.1) (Reports); (e) any copies of Sublicenses, or information extracted therefrom, provided by Licensee to Broad under
Section 2.4.3 (Delivery of Sublicense Agreement); (f) any information or material in tangible form that is provided to Broad’s Office of Strategic Alliances in connection with this Agreement and is marked as
“confidential” or proprietary by Licensee at the time it is sent to Broad; (g) information that is furnished orally by Licensee if Licensee identifies such information as “confidential” or proprietary in writing by a
memorandum delivered to Broad’s Office of Strategic Alliances and Partnering within [**] days after the date of disclosure; or (h) the terms of this Agreement (but not its existence or its general subject matter), which shall constitute
the Confidential Information of both Parties. Notwithstanding anything to the contrary in this Agreement, Broad may, in response to a Bona Fide Proposal, inform a Proposing Party that the [**] that is the subject of such Bona Fide Proposal is
currently under research or development in a manner consistent with the Inclusive Innovation Model, without providing additional detail as to the specific manner pursuant to which such [**] is unavailable. 

11.1.1.3 “Confidential Information” means the Broad Confidential Information and the Licensee Confidential
Information, as applicable. 
 11.1.2 Obligations of Confidentiality. For the Term of this Agreement and a period of [**] years
thereafter, (a) Licensee shall maintain in confidence and shall not disclose to any third party any Broad Confidential Information without the prior written consent of Broad, and (b) Broad shall maintain in confidence and shall not
disclose to any third party any Licensee Confidential Information without the prior written consent of Licensee, provided that Broad may disclose to the Institutions (1) this Agreement including any Exhibits, and (2) such Confidential
Information of Licensee as the Institutions reasonably request, provided that any disclosure under the foregoing clause (1) shall be made in confidence to the applicable Institution, and that any disclosure under the foregoing clause
(2) shall be under terms of a written confidentiality agreement prohibiting the use and further disclosure by the applicable Institution(s) of such Confidential Information on terms as least as restrictive as those contained herein. Each Party
shall take all reasonable steps to protect the Confidential Information of the other Party with the same degree of care used to protect its own confidential or proprietary information. Neither Party shall use the Confidential Information of the
other Party for any purpose other than those contemplated by this Agreement. The foregoing obligations under this Section 11.1.2 (Obligations of Confidentiality) shall not apply to: 

(i) information that is known to the receiving Party or independently developed by the receiving Party prior to the time of disclosure without
use of or reference to the other Party’s Confidential Information, in each case, to the extent evidenced by contemporaneous written records; 

(ii) information that is independently developed by the receiving Party at or after the time of disclosure without use of or reference to the
other Party’s Confidential Information, to the extent evidenced by contemporaneous written records; 

  
 78 

 (iii) information disclosed to the receiving Party by a third party that has a right to make
such disclosure; 
 (iv) information that is or becomes generally known or available to the public, other than as a result of a breach of
this Agreement by the receiving Party; or 
 (v) information that is required to be disclosed by order of the FDA or similar authority or a
court of competent jurisdiction or other government authority or agency; provided that the Parties shall use commercially reasonable efforts to obtain confidential treatment of such information by the agency, authority, or court. 

11.1.3 Permitted Disclosures. Notwithstanding Section 11.1.2 (Obligations of Confidentiality), either Party
may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following instances: 

11.1.3.1 prosecuting or defending litigation in accordance with Article 7 of this Agreement; provided that the party
making a disclosure under this Section 11.1.3.1 (Permitted Disclosures) shall seek confidential treatment, a protective order, or seek to file under seal if reasonably requested by the other party; 

11.1.3.2 making filings with the Securities and Exchange Commission or foreign equivalent, any stock exchange or market, or any
Regulatory Authorities, which shall include publicly disclosing or filing this Agreement as a “material agreement” in accordance with Applicable Law or applicable stock exchange regulations; provided, however, that in the case of
Licensee as the disclosing party, Licensee shall provide Broad with an opportunity to review, redact and comment on any such filing and shall incorporate Broad’s reasonable comments and redactions to the extent consistent with Applicable Law;
provided, further, that the terms of the Inclusive Innovation Model included in this Agreement shall be disclosed in full and such terms shall not be subject to any redactions in any such filing; 

11.1.3.3 complying with Applicable Law or submitting information to governmental authorities, including without limitation any
Regulatory Authority, and including without limitation any order of a court or agency of competent jurisdiction, including without limitation any Regulatory Authority; provided that if either Party is required by Applicable Law to make any
public disclosure of Confidential Information of the other Party, to the extent the Party so required may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure
confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); 

11.1.3.4 in the case of Licensee as the receiving Party, to its Affiliates and its and their prospective and actual acquirers,
licensees, sublicensees, distributors, investors, lenders and underwriters, each of which prior to disclosure must be bound by written or legally enforceable professional ethical obligations of confidentiality and
non-use of substantially equivalent or greater scope and duration than those set forth in this Section 11.1 (Confidentiality), and (a) its and their employees, consultants,
agents, and 

  
 79 

 
advisors, on a need to know basis, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use of substantially
equivalent or greater scope and duration than those set forth in this Section 11.1 (Confidentiality), and (b) its and their accountants and lawyers, on a need to know basis, each of whom prior to disclosure must be
bound by written or legally enforceable professional ethical obligations of confidentiality and non-use of substantially equivalent or greater scope and duration than those set forth in this
Section 11.1 (Confidentiality); provided that the scope of Confidential Information that may be disclosed to any Person under this Section 11.1 (Confidentiality) is limited to the terms of this
Agreement and any notices given hereunder and not any other Broad Confidential Information unless otherwise agreed to in writing by Broad; and 

11.1.3.5 in the case of Broad as the receiving Party, to Broad’s prospective and actual licensees (including Sublicensees
in the event of termination of this Agreement) acquirers of payment or equity rights, lenders and underwriters, each of which prior to disclosure must be bound by written or legally enforceable professional ethical obligations of confidentiality and
non-use of substantially equivalent or greater scope and duration than those set forth in this Section 11.1 (Confidentiality) and (a) its and their employees, consultants,
agents, and advisors, on a need to know basis, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use of substantially equivalent or greater scope and duration
than those set forth in this Section 11.1 (Confidentiality), and (b) its and their accountants and lawyers, on a need to know basis, each of whom prior to disclosure must be bound by written or legally enforceable
professional ethical obligations of confidentiality and non-use of substantially equivalent or greater scope and duration than those set forth in this Section 11.1 (Confidentiality);
provided that the disclosure to prospective or actual licensees (and the related Persons noted in the foregoing clauses (a) and (b)) is limited this Agreement and such Confidential Information of Licensee as is reasonably necessary for such
prospective or actual licensee to conduct technical or legal due diligence or exercise its rights under the license granted or proposed to be granted under the Patent Rights to such actual or prospective licensee by Broad. 

11.2 Additional Permitted Disclosure. In addition to the rights set forth elsewhere in this Section 11.2
(Additional Permitted Disclosure), each Institution and Licensee shall have the right to disclose (i) to Third Parties without an obligation of confidentiality all or part of a redacted copy of this Agreement, or the substance thereof, in the
form filed by Licensee to comply with its obligations under the Securities Act or the Exchange Act and (ii) to Third Parties, without an obligation of confidentiality, the existence of this Agreement, the general subject matter of this
Agreement, Broad’s right to receive consideration under this Agreement, and all or a portion or summary of the terms of the [**] Proposed Product provisions. 

11.3 Preference for United States Industry. During the period of exclusivity of this license in the United States, Licensee shall comply
with 37 C.F.R. § 401.14 (i) or any successor rule or regulation. 

  
 80 

 11.4 No Security Interest. Licensee shall not enter into any agreement under which
Licensee grants to or otherwise creates in any third party a security interest in this Agreement or any of the rights granted to Licensee herein. Any grant or creation of a security interest purported or attempted to be made in violation of the
terms of this Section 11.4 (No Security Interest) shall be null and void and of no legal effect. 
 11.5 Use of
Names. Except as provided below, Licensee shall not, and shall ensure that its Affiliates and Sublicensees shall not, use or register the name “The Broad Institute, Inc.,” “Broad,” “President and Fellows of
Harvard College,” the “Massachusetts Institute of Technology,” “Lincoln Laboratory,” or “Wyss Institute for Biologically Inspired Engineering at Harvard University,” or any variation, adaptation, or abbreviation
thereof (alone or as part of another name), or of any of their trustees, directors, officers, faculty, students, staff, employees, agents, or affiliated investigators or any trademark owned by any Institution, or any logos, seals, insignia or other
words, names, symbols or devices that identify Broad or Institutions or any Institution’s school, unit, or division (“Institution Names”) for any purpose except with the prior written approval of, and in accordance with
restrictions required by the applicable Institution. Without limiting the foregoing, Licensee shall, and shall ensure that its Affiliates and Sublicensees shall, cease all use of Institution Names on the termination or expiration of this Agreement
except as otherwise approved by the applicable Institution. This restriction shall not apply to any information required by Law to be disclosed to any governmental entity. 

11.6 Entire Agreement. This Agreement is the sole agreement with respect to the subject matter hereof and except as expressly set forth
herein, supersedes all other agreements and understandings between the Parties with respect to the same. 
 11.7 Notices. Unless
otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by e-mail, expedited delivery or certified mail, return
receipt requested, to the following addresses, unless the Parties are subsequently notified of any change of address in accordance with this Section 11.7 (Notices): 

 

			
	If to Licensee (other than invoices) prior to October 1, 2018:	  	 Blink Therapeutics Inc.
 325 Vassar St.

Suite 2A
 Cambridge, MA 02139

Email: [**]
 Attn.: CEO

 
 With required email copies to each of:

[**] and
 Marc.Rubenstein@ropesgray.com

		
	If to Licensee (other than invoices) as of and following October 1, 2018:	  	 Blink Therapeutics Inc.
 26 Landsdowne
Street
 Cambridge, MA 02139
 Email: [**]

Attn.: CEO
 With required email copies to each of:

[**] and

[**]

  
 81 

			
	If to Licensee (invoices only):	  	Same as above until updated by Licensee by written notice as per this Section 11.7 (Notices).
		
	If to Broad:	  	 The Broad Institute. Inc.
 415 Main Street

Cambridge, MA 02142
 Email: [**]

Attn.: [**]

 Any notice shall be deemed to have been received as follows: (a) by personal delivery or expedited
delivery, upon receipt; (b) by e-mail, upon transmission and electronic confirmation of delivery; (c) by certified mail, as evidenced by the return receipt. If notice is sent by e-mail, a confirming copy of the same shall be sent by mail to the same address. 
 11.8 Dispute
Resolution. If any dispute between the Parties arises out of or relates to this Agreement (a “Dispute”), either Party by written notice to the other Party may have such issue referred for resolution to the Chief Executive
Officer of Licensee, and the Chief Business Officer of Broad (collectively, the “Executive Officers”). The Executive Officers shall meet promptly to discuss the matter submitted and to determine a resolution. If the Executive
Officers are unable to resolve the Dispute within [**] days after it is referred to them, then the Parties may pursue all other rights and remedies available to them under this Agreement, including the right to terminate this Agreement, and the
matter may be brought by a Party as a Suit in a court of competent jurisdiction in accordance with Section 11.9 (Governing Law and Jurisdiction). 

11.9 Governing Law and Jurisdiction. This Agreement will be governed by, and construed in accordance with, the substantive laws of the
Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have
been granted. Any action, suit or other proceeding arising under or relating to this Agreement (a “Suit”) shall be brought in a court of competent jurisdiction in the Commonwealth of Massachusetts, and the Parties hereby consent to
the sole jurisdiction of the state and federal courts sitting in the Commonwealth of Massachusetts. Each party agrees not to raise any objection at any time to the laying or maintaining of the venue of any Suit in any of the specified courts,
irrevocably waives any claim that Suit has been brought in any inconvenient forum and further irrevocably waives the right to object, with respect to any Suit, that such court does not have any jurisdiction over such party. 

11.10 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal
representatives, successors and permitted assigns. 
 11.11 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form a part of this Agreement. 

  
 82 

 11.12 Counterparts. The Parties may execute this Agreement in two or more
counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. Transmission by facsimile or electronic mail of an executed counterpart of this Agreement shall be deemed to constitute
due and sufficient delivery of such counterpart. If by electronic mail, the executed Agreement must be delivered in a .pdf format. 
 11.13
Amendment; Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay
or failure of either party at any time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce the same. No waiver by either party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this
Agreement. 
 11.14 No Agency or Partnership. Nothing contained in this Agreement shall give either party the right to bind the other,
or be deemed to constitute either party as agent for or partner of the other or any third party. 
 11.15 Assignment and Successors.
This Agreement may not be assigned by either Party without the consent of the other Party, which consent shall not be unreasonably withheld, provided that, Licensee may assign this Agreement and the rights, obligations and interests of Licensee
hereunder without Broad’s prior consent (a) to Beam in connection with a Beam Change of Control, (b) to an Affiliate of Licensee after a Beam Change of Control or (c) any purchaser of all or substantially all of its assets or all
of its equity, or to any successor corporation resulting from any merger or consolidation of Licensee with or into such corporation; provided, in all cases, that (i) the assignee agrees in writing to be bound by the terms of this
Agreement, (ii) the assignee is in compliance with Section 9.2 (Insurance) at the time of transfer, and (iii) a copy of such writing is provided to the Broad within [**] business days after such assignment;
provided also that in the case of clause (b), Licensee remains responsible and liable for the performance of this Agreement by such Affiliate; and provided further that in the case of clause (c), if such assignee does not itself have assets
in excess of [**] U.S. Dollars ($[**]) and active drug development or commercialization operations beyond those contemplated under this Agreement, then the ultimate controlling (as defined in Section 1.7
(“Affiliate”)) Person agrees to guarantee the performance of this Agreement by such assignee. For clarity, such assignee’s investors shall not be deemed the ultimate controlling Person in the immediately foregoing sentence.
Notwithstanding anything to the contrary in this Agreement, Broad may, without the consent of Licensee, assign this Agreement and the rights, obligations and interests of Broad to (x) an Affiliate of Broad or (y) any purchaser of all or
substantially all of its assets or all of its equity, or to any successor corporation resulting from any merger or consolidation of Broad with or into such corporation, provided that (1) in each case of clause (x) and (y), such assignee is
also an assignee of the Patent Rights, such assignee agrees in writing to be bound by the terms of this Agreement and a copy of such writing is provided to Licensee within [**] business days after such assignment and (2) Broad may assign its
right to receive payments and distributions under this Agreement without restriction. This Agreement shall be binding upon a party’s permitted successors and assigns. Any assignment purported or attempted to be made in violation of the terms of
this Section 11.15 (Assignment and Successors) shall be null and void and of no legal effect. 

  
 83 

 11.16 Force Majeure. Except for monetary obligations hereunder, neither party will be
responsible for delays resulting from causes beyond the reasonable control of such party, including fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such
causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. 
 11.17
Interpretation. Each Party hereto acknowledges and agrees that: (a) it or its counsel reviewed and negotiated the terms and provisions of this Agreement and has contributed to its revision; (b) the rule of construction to the effect
that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; (c) the terms and provisions of this Agreement shall be construed fairly as to both Parties hereto and not in favor of
or against either Party, regardless of which Party was generally responsible for the preparation of this Agreement; (d) the use of “include,” “includes,” or “including” herein shall not be limiting; (e) the
word “hereof”, “herein”, “hereby” and derivative or similar work refers to this Agreement (including any Exhibits); (f) the words “will” and “shall” shall have the same obligatory meaning; and
(g) the use of “or” shall not be exclusive. 
 11.18 Severability. If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, or interferes with the enforceability of any Patent Right, it is the intention of the Parties that the remainder of this Agreement shall not be affected.

 11.19 Publicity. Notwithstanding the terms of Section 11.5 (Use of Names) above, the Parties hereby agree
to issue a mutually-acceptable press release (which press release shall also be acceptable to the Institutions, to the extent of any reference to such Institution in such press release) announcing the execution of this Agreement, within [**] days
following the Effective Date; provided, however, that Beam may extend such [**] day period one time for an additional [**] days upon advance written notice to Broad if Licensee has a good faith belief that premature disclosure of the
existence of this Agreement would be detrimental to the business or affairs of Beam or Licensee in light of then ongoing negotiations with a third party(ies) regarding a license(s) or strategic transaction(s), and the Parties may extend such period
by additional [**]-day increments by mutual written consent. Licensee shall provide Broad with a written summary of the basis for such belief with any such notice. Each Party agrees that it will not issue a
press release or other public statement relating to this Agreement or the relationship of the Parties without obtaining the prior written approval of the other Party. Permission shall not be required to repeat information that has already been
publicly released or to disclose information that a Party is permitted to disclose under Section 11.1 (Confidentiality). Notwithstanding any other provision of this Agreement, the Parties agree that the Institutions may
make the Inclusive Innovation Model highly visible as a new and transformative open innovation model, including by disclosing such model publicly or to Third Parties. 

[Remainder of Page Intentionally Left Blank] 

  
 84 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives as of the date first written above. 
  

									
	The Broad Institute, Inc.	 		  	Blink Therapeutics Inc.
					
	By:	 	 /s/ Issi Rozen
	 		  	By:	  	 /s/ John Evans

	Name: Issi Rozen	 		  	Name: John Evans
	Title: Chief Business Officer	 		  	Title: CEO

 Exhibit 1.42 

Competitors 
  

	 	1)	 [**] 

  

	 	2)	 [**] 

  

	 	3)	 [**] 

  

	 	4)	 [**] 

  

	 	5)	 [**] 

  

	 	6)	 [**] 

  

	 	7)	 [**] 

  

	 	8)	 [**] 

  
 86 

 Exhibit 1.66 

[**] 

  
 87 

 Exhibit 1.117 

Patent Rights 

  
 88 

 Exhibit 3.1.1 

[**] 

  
 89 

 Exhibit 3.2.1 

Development Plan 

  
 90 

 Exhibit 3.2.1-1 

[**] 

  
 91 

 Exhibit 4.1 

Form of Subscription Agreement 

SUBSCRIPTION AGREEMENT 

This Subscription Agreement (the “Agreement”) is made and entered into as of [_________], 2018, by and between Blink
Therapeutics Inc., a Delaware corporation (the “Company”) and the Broad Institute Inc., a Massachusetts non-profit corporation (the “Purchaser”). 

WHEREAS, on the terms and subject to the conditions set forth herein, the Purchaser desires to subscribe for and purchase, and the
Company proposes to sell to the Purchaser, [______] shares (the “Shares”) of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”), as partial payment for the licenses and other rights
granted to the Company by the Purchaser, pursuant to Section [_] of that certain License Agreement, by and between the Company and the Purchaser, dated as of [__________], 2018 (the “License Agreement”). 

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and obligations hereinafter set forth and of other good
and valuable consideration, the adequacy and receipt of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 

1. Purchase And Sale Of Shares. 

1.1. Purchase and Sale of Shares. Subject to the terms and conditions set forth herein, upon the execution hereof, the Company shall
sell to the Purchaser, and the Purchaser shall purchase from the Company, the Shares as consideration for the licenses and other rights granted to the Company by the Purchaser pursuant to the License Agreement. 

1.2. Delivery of Certificates Representing Purchased Shares. The Company shall deliver to the Purchaser a certificate in the name of the
Purchaser representing the Shares purchased by the Purchaser. 
 1.3. Delivery of Joinder Agreements. The Purchaser shall deliver to
the Company a joinder signature page to that certain Voting Agreement, by and among the Company and the parties set forth therein, dated on or about the date hereof, in substantially the form attached hereto as Exhibit
A-1, and that certain Right of First Refusal and Co-Sale Agreement, by and among the Company and the parties set forth therein, dated on or about the date hereof, in
substantially the form attached hereto as Exhibit A-2. 
 2. Representations and Warranties of the
Purchaser. The Purchaser hereby represents and warrants as of the date hereof to the Company as follows: 
 2.1. Investment
Representation. Such Purchaser is an “accredited investor” under Regulation D of the Securities Act. Such Purchaser is aware that the Shares have not been registered under the Securities Act, or qualified under any state securities
laws. The Shares are being acquired for investment purposes only and not for sale or with a view to distribution of all or any part thereof in violation of the securities laws. 

  
 92 

 2.2. Access to Information. Such Purchaser has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of its purchase of the Shares and regarding the business, financial affairs and other aspects of the Company, and it has further had the opportunity to obtain any information
(to the extent the Company possesses or can acquire such information without unreasonable effort or expense) which it deems necessary to evaluate its investment or to verify the accuracy of information otherwise provided to it. 

2.3. Restricted Securities. Such Purchaser understands that the Shares will be characterized as “restricted securities” under
the Securities Act and that under such laws and applicable regulations, the Shares may be resold without registration under the Securities Act only in certain limited circumstances, and that otherwise the Shares must be held indefinitely. Such
Purchaser further represents that it is familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and the conditions which must be met in order for Rule 144 to be available for resale of “restricted securities,”
and understands the resale limitations imposed by the Securities Act. 
 2.4. Authority. Such Purchaser has authority to execute and
deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and validly executed and delivered by such Purchaser and (assuming the due authorization, execution and delivery by the Company) constitutes the legal,
valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms. 
 2.5. Organization.
Such Purchaser is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation. 
 3. Representations and
Warranties of the Company. The Company represents and warrants as of the date hereof to the Purchaser as follows: 
 3.1.
Authorization. The Company has all requisite corporate power and authority to execute and deliver this Agreement, sell the Shares and otherwise perform its obligations hereunder. The execution, delivery and performance of this Agreement and
the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action. This Agreement has been duly and validly executed and delivered by the Company and (assuming the due
authorization, execution and delivery by the Purchaser) this Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against it in accordance with its terms. 

3.2. Organization. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of
Delaware. 
 3.3. Capitalization. The authorized capital stock of the Company immediately prior to consummation of the transactions
contemplated by this Agreement consists solely of [_______] shares of Common Stock, of which [________] shares are issued and outstanding, and [__________] shares of Preferred Stock of which [__________] shares are issued and outstanding. The
Company has not adopted an equity incentive plan for issuance to officers, 

  
 93 

 
directors, employees and consultants of the Company. Other than as described above, immediately prior to consummation of the transactions contemplated by this Agreement, there are no outstanding
shares of capital stock, convertible securities, outstanding warrants, options or other rights to subscribe for, purchase or acquire from Licensee any capital stock of Licensee and there are no contracts or binding commitments providing for the
issuance of, or the granting of rights to acquire, any capital stock of Licensee or under which Licensee is, or may become, obligated to issue any of its securities. 

3.4. Valid Issuance. All currently issued and outstanding shares of Company capital stock are duly authorized, validly issued, fully
paid, non-assessable and free of all preemptive rights. The Shares, when issued to the Purchaser under this Agreement, will be duly authorized, validly issued, fully paid,
non-assessable and free of all preemptive rights. All currently issued and outstanding shares of Company capital stock and all shares when issued to the Purchaser under this Agreement were or will be, issued
in accordance with all Applicable Law. 
 4. Preemptive Rights. 

4.1. Subject to the terms and conditions of this Section 4 (Preemptive Rights) and applicable securities laws, if the
Company proposes to offer or sell any New Securities after the Financing Threshold (as defined in the License Agreement) has been achieved, the Purchaser shall have the right to purchase from the Company that portion of such New Securities as equals
the proportion that the Common Stock then held by the Purchaser (including all shares of Common Stock then issuable upon conversion or exercise, as applicable, of Preferred Stock and any other equity securities then held by the Purchaser) bears to
the total Common Stock of Licensee then outstanding on a Fully-Diluted Basis (as defined in the License Agreement). Following notice by the Company to the Purchaser, stating (i) its bona fide intention to offer such New Securities,
(ii) the number of such New Securities to be offered in aggregate and the corresponding number the Purchaser has the right to purchase, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities, the
Purchaser may elect to purchase or otherwise acquire, at the price and on the terms specified in the notice, up to that portion of such New Securities eligible for purchase by the Purchaser by notification to the Company within twenty (20) days
after the offer notice is given. The Company must give notice to the Purchaser at least twenty-five (25) days in advance of the issuance of New Securities. 

4.2. “New Securities” shall mean, collectively, equity securities of the Company, whether or not currently authorized, but shall not
include (a) Exempted Issuances (as defined in the License Agreement), (b) shares of common stock issued or issuable, and options, warrants or other rights to purchase Common Stock issued or issuable to Licensee’s employees, consultants,
officers, directors, or advisors as part of an incentive compensation arrangement or to Licensee’s former employees, consultants, officers, directors, or advisors as part of a settlement of any dispute regarding incentive compensation
arrangements, (c) shares of Common Stock issued or issuable to banks, equipment lessors, real property lessors, financial institutions or other Persons engaged in the business of making loans pursuant to a debt financing, commercial leasing or
real property leasing transaction, or (d) shares of Common Stock issued or issuable in connection with any settlement of any action, suit, proceeding or litigation. 

  
 94 

 4.3. The Purchaser may not assign the rights set forth pursuant to this
Section 4 (Preemptive Rights) without the consent of the Company to any third party other than a holder of the Preferred Stock of the Company; provided, however, that the Purchaser may assign the foregoing right without the
consent of the Company to (x) any third party other than a holder of the preferred stock of Licensee provided that in each such case, the Purchaser notifies the Company in writing in connection with the transfer of such rights or to [___] or
[____]. 
 4.4. The preemptive rights in this Section 4 (Preemptive Rights) shall not be applicable to
(i) Exempted Securities (as defined in the Company’s Certificate of Incorporation, as it may be amended or restated from time to time); or (ii) shares of Common Stock issued in a public offering. 

4.5. The covenants set forth in this Section 4 (Preemptive Rights) shall terminate and be of no further force or
effect upon the earliest to occur of (i) immediately before the consummation of the Company’s first underwritten public offering of securities, or (ii) when the Company (or its ultimate parent company) first becomes subject to the
periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon a Deemed Liquidation Event (as defined in the Company’s Certificate of Incorporation, as it may be amended or restated from time to time), or
(iv) upon the termination of the License Agreement. 
 5. Miscellaneous. 

5.1. Governing Law. This Agreement and all matters arising hereunder shall be governed by and construed under the laws of the State of
Delaware, without regard to its conflicts of law rules or provisions. 
 5.2. Severability. If any provision of this Agreement or the
application of such provision to any Person or circumstance shall be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable under the Applicable Laws of any jurisdiction, (i) the remainder of this Agreement or the
application of such provisions to other Persons or circumstances or in other jurisdictions shall not be affected thereby, (ii) such invalid, illegal, or unenforceable provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such law, and (iii) such invalid, illegal, or unenforceable provision shall not affect the validity or enforceability of any other provision of this Agreement. 

5.3. Counterparts. This Agreement may be executed in one or more counterparts, each of which when so executed and delivered shall be
deemed an original, and all of which when taken together shall constitute one and the same instrument. The execution of this Agreement may be by actual or facsimile signature. 

5.4. Entire Agreement; Survival. This Agreement constitutes the entire agreement of the parties hereto in respect of the subject matter
hereof and thereof, and supersedes any and all prior agreements or understandings between the parties hereto in respect of such subject matter. Either party’s failure to enforce any provision or provisions of this Agreement shall not in any way
be construed as a waiver of any such provision or provisions, nor prevent that party thereafter from enforcing each and every other provision of this Agreement. The rights granted both parties herein are cumulative and shall not constitute a waiver
of either party’s right to assert all other legal remedies available to it under the circumstances. The representations and warranties of the parties contained in this Agreement shall survive the execution and delivery of this Agreement and the
consummation of the transactions contemplated by this Agreement. 
 [Reminder of Page Intentionally left Blank] 

  
 95 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, all
as of the date first written above. 
  

			
	BLINK THERAPEUTICS INC.
		
	By:	 	 
		 	Name:
		 	Title:
	
	THE BROAD INSTITUTE, INC.
		
	By:	 	 
		 	Name:
		 	Title:

  
 96 

 Exhibit 4.4.7 

Arbitration 
  

	1.	 If Broad and Licensee do not agree within [**] days upon (a) the allocation based on the relative
contribution of value of the Royalty-Bearing Product and the Other Active Component(s) in a combination product as provided in Section 4.4.7 (Combination Products), or (b) whether or not Licensee has been engaged in
active negotiations under Section 2.5.5.2 (Proposed Product Development Period), then either party may refer such disagreement (a “Dispute”) for resolution by arbitration in accordance with the terms of this Exhibit
4.4.7. 

  

	2.	 If a party desires to pursue resolution of the Dispute, then the Dispute shall be submitted by either party for
resolution in arbitration pursuant to the then current CPR Non-Administered Arbitration Rides (“CPR Rules”) (www.cpradr.org), except where they conflict with the
provisions of this Exhibit 4.4.7, in which case these provisions control. The arbitration will be held in Boston, Massachusetts. All aspects of the arbitration shall be treated as confidential. 

 

	3.	 The arbitrators will be chosen from the CPR Panel of Distinguished Neutrals, unless a candidate not on such
panel is approved by both Parties in writing. Each arbitrator shall be an attorney (active or retired) admitted to practice in a state of the United States with at least [**] ([**]) years’ experience with a law firm or corporate law department
of over [**] ([**]) lawyers, with a preference for substantial experience in negotiating or litigating complex transactions in the biopharmaceutical industry. 

 

	4.	 The arbitration tribunal shall consist of a single arbitrator (having the qualifications referred to in
Paragraph 3 above) if the Parties in their discretions agree, chosen in accordance with the CPR Rules. If the Parties are unable to so agree, then the arbitration tribunal shall consist of three (3) arbitrators (each having the qualifications
referred to in Paragraph 3 above), of whom each party shall designate one in accordance with the “screened” appointment procedure provided in CPR Rule 5.4. The chair will be chosen in accordance with CPR Rule 6.4. Candidates for the
arbitrator position(s) may be interviewed by representatives of the Parties in advance of their selection, provided that both Parties are represented. 

  

	5.	 The Parties agree to select the arbitrator(s) within [**] days after initiation of the arbitration. The hearing
will be concluded within [**] days after selection of the arbitrator(s), and the determination (as provided in Paragraph 8 below) will be rendered within [**] days after the conclusion of the hearing, or of any post-hearing briefing, which briefing
will be completed by both sides within [**] days after the conclusion of the hearing. In the event the Parties cannot agree upon a schedule, then the arbitrator(s) shall set the schedule following the time limits set forth above as closely as
practical. 

  

	6.	 The hearing will be concluded in [**] hearing days or less. Multiple hearing days will be scheduled
consecutively to the greatest extent possible. A transcript of the hearing shall be made and shall be made available to the arbitrator(s) and each party. 

  
 97 

	7.	 The arbitrator(s) shall be guided, but not bound, by the then current CPR Protocol on Disclosure of
Documents and Presentation of Witnesses in Commercial Arbitration (www.cpradr.org) (“Protocol”). The Parties will attempt to agree on modes of document disclosure, electronic discovery, witness presentation, etc. within
the parameters of the Protocol. If the Parties cannot agree on discovery and presentation issues, the arbitrator(s) shall decide on presentation modes and provide for discovery guided by the Protocol, understanding that the Parties contemplate
reasonable discovery. 

  

	8.	 If the Dispute is a dispute under Section 1(a) of this Exhibit 4.4.7, the arbitrator(s) shall determine
the fraction, C/C+D, by which total Net Sales of a combination product that is the subject of the Dispute shall be multiplied (as contemplated under Section 4.4.7 (Combination Products)) in a country during the applicable
royalty reporting period prior to calculation of the royalty to Broad, where C is [**] and D is [**]. 

  

	9.	 If the Dispute is a dispute under Section 1(b) of this Exhibit 3.3.7, the arbitrator(s) shall determine
whether, and for how long, Licensee has been engaged in active negotiations with the Proposing Party under Section 2.5.5.2 (Proposed Product Development Period). 

 

	10.	 The arbitrator(s) shall decide the merits of any Dispute in accordance with the laws of the Commonwealth of
Massachusetts, without application of any principle of conflict of laws that would result in reference to a different law. The arbitrator(s) may not apply principles such as “amiable compositeur” or “natural justice and
equity.” 

  

	11.	 The arbitrator(s) are expressly empowered to decide dispositive motions in advance of any hearing and shall
endeavor to decide such motions as would a United States District Court Judge located in the District of Massachusetts. A determination shall be entered if a dispositive motion is granted that fully resolves the Dispute. 

 

	12.	 The arbitrator(s) shall render a written opinion stating the reasons upon which the determination is based. The
Parties irrevocably consent to the jurisdiction of any and all state and federal courts sitting in the Commonwealth of Massachusetts for the enforcement of the provisions of this Exhibit 4.4.7. Any other court with jurisdiction may act in the
same fashion. 

  

	13.	 Rule 14 of the CPR Rules does not apply to this Agreement. The Parties shall share equally the cost of the
arbitration by the arbitrator(s), and each party shall bear its own costs and attorneys’ fees associated with the arbitration. 

  
 98 

 Exhibit 4.8 

Success Payments 
 1.
Definitions. Capitalized terms used in this Exhibit that are not otherwise defined in the Agreement to which this Exhibit is attached shall have the following meanings: 

1.1. “Affiliate” means, with respect to a Person, organization or entity, any Person, organization or entity controlling,
controlled by or under common control with, such Person, organization or entity. For purposes of this definition only, “control” of another Person, organization or entity will mean the possession, directly or indirectly, of the power to
direct or cause the direction of the activities, management or policies of such Person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, control will be presumed to
exist when a Person, organization or entity (a) owns or directly controls fifty percent (50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity or (b) possesses, directly or indirectly,
the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the other organization or entity. The parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of
the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage will be substituted in the preceding sentence. 

1.2. “Fair Market Value” [**]. 

1.3. “Multiple of Initial Equity” [**]. 

1.4. “Series A Preferred Stock” means shall mean Licensee’s Series A Preferred Stock, par value $0.0001 per
share, and any securities received upon conversion thereof or in exchange therefor. [**]. 
 1.5. “Success Payment Amount”
means the positive difference, if any between (A) the amount ([**]) set forth in the table in Section 2 (Success Payments) of this Exhibit 4.7 set forth opposite the greatest Trigger Value that the Multiple of
Initial Equity as of the [**] meets or exceeds, less (B) all payments that had previously been paid or become payable to Broad in accordance with Section 2 (Success Payments) on a prior [**]. 

1.6. “Success Payment Date” means (i) with respect to any Success Payment arising as a result of an [**], each such [**]
(plus a grace period of up to [**] days at Licensee’s option if Licensee is evaluating in good faith whether to undertake a capital market transaction during the grace period such as a follow-on offering,
provided that no grace period shall be available to Licensee as a result of a secondary offering with no primary offering component and Licensee shall not request such grace period more than [**] times during the [**]), (ii) with
respect to any Success Payment arising as a result of a [**], the earlier of (a) the date on which any proceeds from the Licensee Sale are paid or distributed to any stockholder of Licensee and (b) the date that is [**] days after the
[**], and (iii) with respect to any other Success Payment, the date that is the [**] pursuant to which such Success Payment obligation arises. 

  
 99 

 1.7. [**] 

1.8. “Success Payment Value” means, with respect to each share of [**] and as of any [**], the aggregate of (i) all
dividends and other distributions (including the fair market value of non-cash distributions) made to the holders of [**] with respect to each such share on or before the [**] and (ii) the [**] of each
such share of [**] (excluding any dividends and other distributions included under the foregoing clause (i)) as of such [**]. 
 1.9.
[**] 
 2. Success Payments. 

2.1. [**]. If the Multiple of Initial Equity as determined with respect to such [**] is equal to or exceeds any of the values of the Multiple
of Initial Equity set forth in the table below (the “Trigger Values”), Licensee shall notify Broad, or its designee, within [**] calendar days of such [**] and pay to Broad or its designee an aggregate payment equal to the Success
Payment Amount. Such Success Payment Amount shall payable within [**] days of the Success Payment Date with respect to such Success Payment Amount, in cash or, in the Licensee’s sole discretion and subject to
Section 2.2 (Registration Rights) of this Exhibit 4.7, in publicly tradable shares of the Licensee’s common stock (“Success Shares”), or any combination thereof. For clarity, no more than One
Hundred Five Million Dollars ($105,000,000) shall be owed by Licensee in the aggregate under this Section 2 (Success Payments). 
  

			
	[**]	  	Success Payment (U.S. Dollars)
	[**]	  	Five Million Dollars ($5,000,000)
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	One Hundred Five Million Dollars ($105,000,000)

 Notwithstanding any termination of the [**], Licensee’s obligation to pay the Success Payment Amount already earned and
accrued with respect to a transaction (taking account of all payments received under such transaction, including post-closing payments) at the time of the termination of the [**], shall survive such termination of the [**] until such payment has
actually been made in full. Furthermore, notwithstanding any termination of the [**] or any other provision to the contrary herein, any post-closing payments will be aggregated with all prior payments made at the closing of the applicable
transaction for purposes of determining the Success Payment Value and any Success Payment Amount due, with the Success Payment Value and the Success Payment Amount being recalculated as post-closing payments are received, and giving such
post-closing payment the same weight in the calculation of the Success Payment Amount as payments that had already been received pursuant to the transaction as of its [**]. 

  
 100 

 For purposes of this Section 2 (Success Payments) of this Exhibit 4.7 (and
the other provisions of this Section 2 (Success Payments) to the extent necessary for the application or interpretation of the terms of this Section 2 (Success Payments)), the term
“Licensee” shall include the term “Acquirer”; provided that, notwithstanding anything in this Exhibit 4.7 to the contrary, in the event of a consummation of a Beam Change of Control transaction,
(a) the term “Series A Preferred Stock” shall be replaced by the term “Beam Series A Preferred Stock”, (b) the term “Series B Preferred Stock” shall be replaced by the term “Beam Series B Preferred Stock”
and (c) the term “Series A Investors” shall be replaced by “Beam Series A Investors”. 
 2.2. Registration
Rights. 
 2.2.1. Prior to the issuance of any Success Shares, Licensee shall file a registration statement on Form S-1 or Form S-3 filed by Licensee with the Securities and Exchange Commission under the Securities Act (a “Resale Registration Statement”) to permit the
resale by Broad or its designee of all of such Success Shares. Such Resale Registration Statement shall have been declared effective by the Securities and Exchange Commission on or before the date of issuance of any Success Shares. All expenses
related to the registration, qualification or compliance with registration of the Success Shares shall be borne by Licensee.  

2.2.2. Any Resale Registration Statement shall include a “final” prospectus, including the information required by Item 507 of
Regulation S-K of the Securities Act, as provided by the holders of the Success Shares covered by such Resale Registration Statement. Notwithstanding the foregoing, before filing the Resale Registration
Statement, Licensee shall furnish to Broad a copy of the Resale Registration Statement and afford Broad a reasonable opportunity to review and comment on the Resale Registration Statement. Broad shall furnish to Licensee such information regarding
itself and its designees as Licensee may reasonably request and as shall be reasonably required in connection with any Resale Registration Statement referred to in this Agreement. Broad agrees to, as promptly (and in any event prior to any sales
made pursuant to a prospectus), furnish to Licensee all information required to be disclosed in order to make the information previously furnished to Licensee by Broad not misleading. 

2.2.3. If the Resale Registration Statement has not been declared effective on or before the date the shares are issued and the per share price
of the Success Shares declines between such date of issuance and the date such Resale Registration Statement is declared effective, then Licensee shall pay to Broad promptly following such effectiveness date, an amount equal to the product of the
number of Success Shares issued to Broad multiplied by the difference between the per share closing price of the Success Shares on date of issuance minus the closing per share price of the Success Shares on the effectiveness date. Licensee and
Broad agree that the payment described in this Section 2.2.3 shall be the sole and exclusive remedy with respect to any breach of the second sentence of Section 2.2.1. 

  
 101 

 3. Fair Market Value. The Fair Market Value with respect to each share of [**] as of any [**]
shall be determined as follows: 
 3.1. With respect to any Success Payment arising as a result of the [**], the “Fair Market
Value” will be the volume weighted average of the closing trading prices of a share of the common stock of Licensee over the consecutive [**] period ending on the applicable [**] as calculated using the VWAP function on a Bloomberg
Terminal. 
 3.2. With respect to any [**] in which the sole consideration received for each share of Series A Preferred Stock is cash, the
“Fair Market Value” will be the cash received for each share of Series A Preferred Stock. 
 3.3. With respect to any [**]
in which the sole consideration received for each share of Series A Preferred Stock is common stock traded on a national securities exchange, the “Fair Market Value” with the price per share of each such share of common stock
multiplied by the number of shares of such stock for each share of Series A Preferred Stock. 
 3.4. With respect to any [**] in which the
consideration received for each share of Series A Preferred Stock is other than solely cash, or securities traded on a national exchange, then the “Fair Market Value” shall be the cash, marketable securities, or other property
received for each share of the Licensee’s Series A Preferred Stock in such transaction, determined as set forth below and in accordance with the Fair Market Value Methodology (as defined in Section 4.5 (Notice of and
Objection to Fair Market Value) of this Exhibit 4.7). 
 4. Notice of and Objection to Fair Market Value. 

4.1. Within [**] calendar days of the [**], Licensee shall deliver to Broad a proposed Fair Market Value by written notice (the
“Licensee Notice”), which notice shall include a description of the method used to calculate, and the details of the calculation of, such Fair Market Value. If Broad does not object to such written notice by delivering written
notice to Licensee of Broad’s objection within [**] calendar days (an “Objection Notice”), the Fair Market Value shall be the Fair Market Value proposed in such Licensee Notice. Within [**] calendar days of the delivery of such
Objection Notice (the end of such [**] calendar day period being the “Trigger Date”), each of Broad and Licensee shall consult with each other and attempt in good faith to agree upon a Fair Market Value with the Fair Market Value
being the price so agreed in writing if agreement is reached within such time period. 
 4.2. If Broad and Licensee fail to mutually agree on
a Fair Market Value by the Trigger Date, then a Person(s) selected in accordance with the provisions of Section 4.4 (Notice of and Objection to Fair Market Value) of this Exhibit 4.7, to act as an expert and not as
an arbitrator (the “Valuation Expert”), at the expense of each of Broad and Licensee in equal proportions, for the purpose of making the determination referred to here, with such Valuation Expert instructed to determine its
independent estimate of the Fair Market Value (the “Valuation Expert’s Estimate”) in accordance with the Fair Market Value Methodology within [**] calendar days after being appointed (it being understood that neither Party
shall provide the Valuation Expert with its respective Fair Market Value Notices nor disclose to such Valuation Expert the contents thereof and that the Parties shall make available to such Valuation Expert access on a confidential basis to such
books, accounts, records and forecasts as reasonably requested and believed to be necessary to determine the Fair Market Value). 

  
 102 

 4.3. The Fair Market Value shall then conclusively be deemed to equal the Valuation
Expert’s Estimate, and such value shall be final and binding on the Parties hereto (it being understood that for the avoidance of doubt no Party shall be able to contest the Valuation Expert’s Estimate based on any claim of non-adherence to the Fair Market Value Methodology). 
 4.4. If Licensee and Broad fail to mutually agree
on a Valuation Expert within [**] calendar days of the Trigger Date, each of Licensee and Broad shall, within [**] calendar days thereafter, appoint two independent public accountants (that shall each not be an Affiliate or service provider of any
of Licensee or its Affiliates or Broad at the time of arbitration), who shall try to mutually agree on a third party Valuation Expert. If such independent public accountants fail to mutually agree on such Valuation Expert within [**] calendar days
from appointment, each of such independent public accountants shall appoint two additional independent public accountants within [**] calendar days, and the Valuation Expert will be selected from among the four (4) independent public
accountants by drawing lots. The Success Payment Date will be extended by up to [**] calendar days if necessary to complete the process of designation of the Valuation Expert. 

4.5. All Fair Market Value determinations set forth in any Fair Market Value Notice pursuant to this Exhibit 4.7 and all valuations
estimated or determined by the Valuation Expert must adhere to the following requirements (the “Fair Market Value Methodology”): 

4.5.1. subject to the below, be in accordance with industry standard valuation methodologies including but not limited to revenues,
price-earnings ratio, free cash flow, EBITDA multiples or other appropriate metrics; 
 4.5.2. be, subject to
Section 4.5.3 (Notice of and Objection to Fair Market Value) of this Exhibit 4.7, based on the actual historical results of the operations of Licensee as reflected on its audited and unaudited financial statements
and reasonable forecasts of up to [**] years assuming ordinary course of operations of Licensee consistent with past practice unless Licensee’s results of operations show a loss for any portion of such period; and 

4.5.3. for the avoidance of doubt, specifically, take into full account the working capital balances of Licensee and assume that any financial
indebtedness or negative working capital balances of Licensee are paid off or offset in full with available cash (with the consequences or repayment or failure to offset with available cash transferred reflected as a degradation to the Fair Market
Value). 

  
 103 

 Exhibit 8.2 

Option Agreement 

  
 104 

 Exhibit 8.3 

Services Agreement 

  
 105EX-10.6

 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT 

by and between 
 EDITAS
MEDICINE, INC. 
 and 

BEAM THERAPEUTICS INC. 

May 9, 2018 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”), effective as of May 9, 2018 (the “Effective Date”), is made
by and between Editas Medicine, Inc., a Delaware corporation (“Editas”), and Beam Therapeutics Inc., a Delaware corporation (“Beam”) (each, a “Party” and collectively, the
“Parties”). 
 WHEREAS, Editas is a biotechnology company focused on the application of its industry-leading genome editing
technology to the discovery and development of gene editing therapies for the treatment of a broad range of diseases and conditions; 

WHEREAS, Beam is a biotechnology company focused on developing precision genetic medicines through base editing; 

WHEREAS, Beam wishes to obtain license rights from Editas with respect to certain Editas-controlled Patents and an option to obtain license
rights from Editas with respect to other Editas-controlled Patents, each as more particularly set forth herein. 
 NOW, THEREFORE, in
consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1 
 DEFINITIONS
AND INTERPRETATION 
 1.1 Definitions. Unless the context otherwise requires, the terms in this Agreement, when used with initial
capital letters, shall have the meanings set forth below unless otherwise expressly specified in this Agreement: 
 “2014 MGH
Agreement” means the Exclusive Patent License Agreement [**] by and between The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”) and Editas, dated as of August 29, 2014, as amended by the
First Amendment, dated as of June 29, 2015 and the Second Amendment, dated as of November 17, 2016, as may be further amended by such parties from time to time. 

“2016 MGH Agreement” means the Exclusive Patent License Agreement [**] by and between MGH and Editas, dated as of
August 2, 2016, as may be amended by such parties from time to time. 
 “[**] License” shall have the meaning set
forth in Section 2.5.3. 
 “[**] Patents” shall have the meaning set forth in
Section 2.5.3. 
 “Additional Licensor” shall have the meaning set forth in
Section 2.5.3. 
 “Affiliate” means, with respect to a Party, any person, corporation, firm,
joint venture or other entity which, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. As used in this definition, “control” means the possession of the
majority of the ownership, or the power to direct or cause the direction of the management and policies, of an entity, whether through the ownership of the outstanding voting securities thereof, by contract or otherwise. 

  
 - 1 - 

 [**] 

[**] 
 [**] 

“Alliance Coordinator” shall have the meaning set forth in Section 3.1. 

“Allocation Schedule” means Exhibit A. 

“Annual Maintenance Fees” means, with respect to an Institutional In-License, any
annual license, maintenance, minimum royalty or similar fees payable by Editas to the applicable Institution under the terms of such Institutional In-License for the maintenance of Editas’s rights
thereunder. 
 “Annual Patent Costs” shall have the meaning set forth in Section 4.6.2. 

“Arbitration Request” shall have the meaning set forth in Section 10.3. 

“Bankruptcy Laws” shall have the meaning set forth in Section 2.8. 

“Base Editing Therapy” means a therapeutic product that utilizes a Base Editor to achieve conversion of the applicable
nucleobase. 
 “Base Editing” means [**]. 

“Base Editing Window” means a region within [**] nucleotides of a specific polynucleotide sequence bound by the nucleic acid
binding protein. 
 “Base Editor” means [**]. 

“Beam Common Stock” means shares of common stock, $0.01 par value per share, issued by Beam. 

“Beam Indemnitee” shall have the meaning set forth in Section 8.2. 

“Beam Patents” means Patents owned or controlled by Beam. 

“Beam Preferred Stock” means shares of the same class and series of capital stock issued by Beam to bona fide investors in
its most recent convertible preferred stock financing in which Beam raised at least $[**] through the sale and issuance of such stock. 

“Beam Series A Shares” shall have the meaning set forth in Section 4.2. 

“Breaching Party” shall have the meaning set forth in Section 9.3. 

  
 - 2 - 

 “Broad” means the Broad Institute, Inc. 

“Cas9-I Agreement” means the Amended and Restated
Cas9-I License Agreement entered into by and among Harvard, Broad and Editas, dated as of December 16, 2016, as amended on March 3, 2017, as may be further amended by such parties from time to time.

 “Cas9-II Agreement” means the Cas9-II
License Agreement by and between Broad and Editas, dated as of December 16, 2016, as may be amended by such parties from time to time. 

“Claims” shall have the meaning set forth in Section 8.1.1. 

“Commercialization” and “Commercialize” means all activities undertaken relating to the marketing, promotion
(including advertising, detailing, sponsored product or continuing medical education), any other offering for sale, distribution, and sale of a product. 

“Commercially Reasonable Efforts” means (a) with respect to the efforts to be expended by a Party with respect to an
agreed objective, except as otherwise provided in clause (b), such reasonable, diligent and good faith efforts as such Party would normally use to accomplish a similar objective under similar circumstances taking into account the reasonable
allocation of such Party’s resources under the circumstances, and [**]. 
 “Competitive Product” means, with respect
to a Licensed Product, a Third Party Base Editing Therapy that is directed to the same target or indication to which such Licensed Product is directed. 

“Confidential Information” shall have the meaning set forth in Section 6.1. 

“Control” means with respect to any product, Patent or other tangible or intangible intellectual property right, the
possession (whether by ownership or license, other than licenses granted pursuant to this Agreement) by a Party or its Affiliate of the ability to grant to the other Party access to, ownership of, or a license or sublicense under, such product,
Patent, or other intellectual property without violating the terms of any agreement or other arrangement with any Third Party. 

“Cover,” “Covering,” “Covered,” or “Covers” means, as to any subject
matter and a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, offering for sale or importation of such subject matter would infringe such Patent or, as to a pending Patent, the
making, using, selling, offering for sale, importation or other practice of such subject matter would infringe such Patent if such Patent were to issue without modification, in each case, without regard to the validity or enforceability of such
Patent. 
 “CPA” shall have the meaning set forth in Section 4.6.2. 

“Cpf1 Agreement” means the Cpf1 License Agreement by and between Broad and Editas, dated as of December 16, 2016, as may
be amended by such parties from time to time. 

  
 - 3 - 

 “Develop” or “Development” means, with respect to a
product, all activities relating to non-clinical and preclinical testing and trials, clinical testing and trials, including clinical trials, toxicology testing, modification, optimization and animal efficacy
testing of pharmaceutical compounds, statistical analysis, publication and presentation of study results and reporting, preparation and submission to Regulatory Authorities with respect to such product. 

“Disclosing Party” shall have the meaning set forth in Section 6.1. 

“Dollars” or “$” means the legal currency of the United States. 

“Editas Indemnitee” shall have the meaning set forth in Section 8.1.1. 

“Editas-Owned Patents” means the Family of Patents set forth on Exhibit C under the heading [**]. 

“EMA” means the European Medicines Agency, and any successor entity thereto. 

“Executive Officers” means the respective chief executive officers of Editas and Beam. 

“Exercise Date” shall have the meaning set forth in Section 4.3. 

“Existing Confidentiality Agreement” shall have the meaning set forth in Section 6.6. 

“Family” means a group of (a) Licensed Patents or (b) Optioned Patents for which an Option applies (or formerly
applied). Families are categorized based on subject matter and inventorship as set forth in Exhibits B and C. 

“FDA” means the U.S. Food and Drug Administration, and any successor entity thereto. 

“Field” means the use (including the manufacture, Development and Commercialization) of Base Editing Therapies for the
treatment of any field of human diseases or conditions other than (a) the [**], (b) the [**] and (c) [**]. 

“GAAP” means generally accepted accounting principles. 

“Governmental Authority” means any United States federal, state or local or any foreign government, or political subdivision
thereof, or any multinational organization or authority or any authority, agency, division, board or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or
tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 “Harvard”
means the President and Fellows of Harvard College. 
 “HHMI” means the Howard Hughes Medical Institute. 

“HHMI Names” shall have the meaning set forth in Section 6.5. 

“IND” means an investigational new drug application submitted to the FDA pursuant to Part 312 of Title 21 of the U.S. Code of
Federal Regulations, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the U.S. for the investigation of any product in any other country or group of countries (such
as a clinical trial application in the European Union). 

  
 - 4 - 

 “Indemnified Party” shall have the meaning set forth in
Section 8.3. 
 “Indemnifying Party” shall have the meaning set forth in
Section 8.3. 
 “Infringement Action” shall have the meaning set forth in
Section 5.2.2. 
 “Initial Fee” shall have the meaning set forth in
Section 4.1. 
 “Initial Public Offering” means the initial public offering and sale of Beam
Common Stock for cash pursuant to an effective registration statement under the Securities Act. 
 “Institution” initially
means each of Harvard, Broad and MGH and shall be expanded to include any Additional Licensor as required by Section 2.5.3. 

“Institution Indemnitees” shall have the meaning set forth in Section 8.1.3. 

“Institution Names” shall have the meaning set forth in Section 6.5. 

“Institutional In-Licenses” means the 2014 MGH Agreement, the 2016 MGH Agreement, the
Cas9-I Agreement, the Cas9-II Agreement, the Cpfl Agreement, and any Additional Cas9 Licenses deemed to be an Institutional
In-License pursuant to Section 2.5.3. 
 “Institutional
Milestone” means any commercial, regulatory, development, sales or other milestone event triggering an Institutional Milestone Payment under an Institutional In-License. 

“Institutional Milestone Payment” means, with respect to a Licensed Product Covered by an Institutional Patent, a payment
payable by Editas to an Institution with respect to achievement of an Institutional Milestone by such Licensed Product under the terms of an Institutional In-License after the application of any offsets,
reductions, deductions or adjustments to such milestone payment allowable pursuant to the terms of such Institutional In-License. 

“Institutional Patents” means, at any given time, all Licensed Patents, if any, other than the Editas-Owned Patents. 

“Institutional Royalty Rate” means, with respect to a Licensed Product Covered by an Institutional Patent, the royalty rate
payable by Editas to an Institution with respect to net sales of such Licensed Product under the terms of an Institutional In-License, calculated pursuant to the terms thereof (including, as applicable, any
offsets, reductions, deductions or adjustment to such royalty rate allowable pursuant to the terms of such Institutional In-License). 

“Institutional Sublicense Income Payment” means, on an Institutional In-License-by-Institutional In-License basis, “Sublicense Income” as defined in such Institutional In-License that is payable by Editas to an Institution under such Institutional In-License. 

“Iowa” means the University of Iowa Research Foundation. 

  
 - 5 - 

 [**] 

[**] 
 [**] 

“Law” means the applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of
any Governmental Authorities (including any Regulatory Authorities) that may be in effect from time to time in any country or jurisdiction of the Territory. 

“Licensed Patents” means (a) (i) the Patents set forth on Exhibit B, as may be amended or supplemented in writing
by the Parties from time to time in accordance with this Agreement, (ii) any substitutions, divisionals, continuations, continuations-in-part (only to the extent of
claims that are entitled to the priority date of and directed specifically to the subject matter claimed in the applications listed on Exhibit B), substitutes, counterparts and foreign equivalents thereof filed in any country, and any patents
issuing thereon (but in the case of Patents issuing on continuation-in-part applications, only to the claims thereof that are entitled to the priority date of and
directed specifically to the subject matter claimed in the applications listed on Exhibit B) and any reissues, reexaminations or extensions thereof, in each case, that are Controlled by Editas or its Affiliates during the Term and
(b) any Optioned Patents for which Beam properly exercises its Option pursuant to Section 2.5.1. 

“Licensed Product” means any (a) Base Editing Therapy the making, using, selling, offering for sale, exporting or
importing of which is Covered by a Valid Claim of a Licensed Patent or (b) any Base Editing Therapy that is a (i) Product (as defined in the 2014 MGH Agreement or 2016 MGH Agreement, as applicable) or (ii) an Enabled Product, Enabled
Service or Licensed Service (each as defined in the Cas9-I Agreement, Cas9-II Agreement or Cpf1 Agreement, as applicable) during the applicable period of time that
royalties are due under the applicable Institutional In-License on the sale of such Base Editing Therapy under this Agreement. 

“Losses” shall have the meaning set forth in Section 8.1.1. 

“Major Markets” means each of the United States, Japan, United Kingdom, Germany, France, Italy and Spain. 

“MGH” shall have the meaning set forth in the definition of “2016 MGH Agreement.” 

“MGH Indemnitees” shall have the meaning set forth in Section 8.1.2. 

“MIT” means the Massachusetts Institute of Technology. 

“Net Sales” means the gross amount billed or invoiced by or on behalf of Beam, its Affiliates, sublicensees and any
Affiliates of such sublicensees (in each case, the “Invoicing Entity”) or if not billed or invoiced the gross amount received by the Invoicing Entity, on sales, leases, uses or other transfers of Licensed Products, less the
following to the extent applicable with respect to such sales, leases or other transfers and not previously deducted from the gross invoice price: 

(a) customary trade, quantity or cash discounts to the extent actually allowed and taken; 

  
 - 6 - 

 (b) amounts actually repaid or credited by reason of rejection, return or recall of any
previously sold, leased or otherwise transferred Licensed Products; 
 (c) rebates granted or given; 

(d) allowances for non-collectible receivables; 

(e) customer freight charges that are paid by or on behalf of the Invoicing Entity; and 

(f) to the extent separately stated on purchase orders, invoices or other documents of sale, any sales, value added or similar taxes, custom
duties or other similar governmental charges levied directly on the production, sale, transportation, delivery or use of a Licensed Product that are paid by or on behalf of the Invoicing Entity, but not including any tax levied with respect to
income; 
 provided that: 

(i) in no event shall the aggregate amount of all deductions made pursuant to clauses (d) and (e) above in any calendar quarter exceed
[**] percent ([**]) of Net Sales in such calendar quarter;  
 (ii) Net Sales shall not include (1) sales or other
transfers of any Licensed Product used for clinical trials or other research, or (2) donations for charity or compassionate use for which an Invoicing Entity does not receive consideration; 

(iii) in any transfers of Licensed Products between an Invoicing Entity and an Affiliate or sublicensee of such Invoicing Entity not for the
purpose of resale by such Affiliate or sublicensee, Net Sales shall be equal to the fair market value of the Licensed Products so transferred, assuming an arm’s length transaction made in the ordinary course of business; 

(iv) in the event that (1) an Invoicing Entity receives non-cash consideration for any Licensed
Products, (2) an Invoicing Entity sells Licensed Products in a transaction not at arm’s length with a non-Affiliate of an Invoicing Entity, or (3) any Licensed Product is sold by an Invoicing
Entity at a discounted price that is substantially lower than the customary prices charged by such Invoicing Entity, Net Sales shall be calculated based on the fair market value of such consideration or transaction, assuming an arm’s length
transaction made in the ordinary course of business, provided that, if a Licensed Product is sold under circumstances in which the discounted price is the result of market forces and not a quid pro quo for value other than the monetary
consideration charged in such sale of Licensed Product, such discounted price shall be deemed to be a customary price; 
 (v) with respect to
any provision hereof requiring a calculation of fair market value, assuming an arm’s length transaction made in the ordinary course of business, Invoicing Entity may use the average price of the relevant Licensed Product sold for cash during
the relevant period in the relevant country; and 

  
 - 7 - 

 (vi) sales of Licensed Products by an Invoicing Entity to its Affiliate or a sublicensee for
resale by such Affiliate or sublicensee shall not be deemed Net Sales. Instead, Net Sales shall be determined based on the gross amount billed or invoiced by such Affiliate or sublicensee upon resale of such Licensed Products any third party that is
not an Affiliate or sublicensee of the Invoicing Entity. 
 “Non-Breaching Party”
shall have the meaning set forth in Section 9.3. 
 “Non-Exclusive
Targets” means [**]. 
 [**] 

“Option” shall have the meaning set forth in Section 2.5.1. 

“Option Exercise Payment” shall have the meaning set forth in Section 4.3. 

“Option Period” means, on a Family of Optioned
Patents-by-Family of Optioned Patents basis, the Effective Date through the earliest of: (a) filing the first Biologics License Application or foreign equivalent
for a Licensed Product Covered by an Optioned Patent within such Family, (b) the tenth anniversary of the Effective Date and (c) the termination of Editas’s license to such Family of Optioned Patents as contemplated by
Section 2.3 of this Agreement. 
 “Optioned Patents” means (a) the Patents set forth on
Exhibit C, as may be amended or supplemented in writing by the Parties from time to time in accordance with this Agreement, (b) any substitutions, divisionals, continuations, continuations-in-part (only to the extent of claims that are entitled to the priority date of and directed specifically to the subject matter claimed in the applications listed on Exhibit C),
substitutes, counterparts and foreign equivalents thereof filed in any country, and any patents issuing thereon (but in the case of Patents issuing on
continuations-in-part applications, only to the claims thereof that are entitled to the priority date of and directed specifically to the subject matter claimed in the
applications listed on Exhibit C) and any reissues, reexaminations or extensions thereof, in each case, that are Controlled by Editas or its Affiliates during the Term. For the avoidance of doubt, “Optioned Patents” do not include
Additional Cas9 Patents. 
 “Other IP” shall have the meaning set forth in Section 5.2.5. 

“Pass-Through Amount” shall have the meaning set forth in Section 4.11. 

“Patent” means (a) all patents and patent applications in any country or supranational jurisdiction in the Territory,
(b) any substitutions, divisionals, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications, (c) foreign counterparts of any of the foregoing, (d) all applications claiming
priority to any of the foregoing, (e) any patents issuing on any patent application identified in clauses (a) through (e), (f) any application to which any of the foregoing claim priority and (g) any application that claims common
priority with any of the foregoing. 

  
 - 8 - 

 “Patent-Based Exclusivity” means, with respect to a Licensed Product in a
country in the Territory, that at least one Valid Claim of the Licensed Patents Covers such Licensed Product in such country. 

“Patent Challenge” means any direct or indirect dispute or challenge, or any knowing, willful or reckless assistance in the
dispute or challenge, of the validity, patentability, scope, priority, construction, non-infringement, inventorship, ownership or enforceability of any Subject Patent or any claim thereof, or opposition or
assistance in the opposition of the grant of any letters patent within the Subject Patents, in any legal or administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in
any jurisdiction, or in arbitration including by reexamination, inter partes review, opposition, interference, post-grant review, nullity proceeding, preissuance submission, third party submission, derivation proceeding or declaratory judgment
action; provided, however, that the term Patent Challenge shall not include (a) Beam or any of its Affiliates or sublicensees being an essential party in any patent interference proceeding before the United States Patent and
Trademark Office, which interference Beam or its applicable Affiliate or sublicensee acts in good faith to try to settle or (b) Beam or any of its Affiliates or sublicensees, due to its status as an exclusive licensee of patent rights other
than the Subject Patents, being named by the licensor of such patent rights as a real party in interest in such an interference, so long as Beam or its applicable Affiliate or sublicensee either abstains from participation in, or acts in good faith
to settle, the interference. For clarity, a Patent Challenge shall not include arguments made by Beam that (x) distinguish the inventions claimed in Beam Patents from those claimed in the Subject Patents but (y) do not disparage the
Subject Patents or raise any issue of Subject Patents’ compliance with or sufficiency under applicable patent laws, regulations or administrative rules, in each case (i) in the ordinary course of ex parte prosecution of the Beam Patents or
(ii) in inter partes proceedings before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction (excluding interferences or derivation proceedings), or in arbitration, wherein the Beam Patents have
been challenged. 
 “Patent Costs” means the reasonable fees and expenses paid to outside legal counsel, and filing,
maintenance and other out-of-pocket expenses paid to Third Parties, incurred in connection with the Prosecution and Maintenance of the Subject Patents, whether incurred
prior to or after the Effective Date, including fees and expenses reimbursed by Editas to the Institutions pursuant to the Institutional In-Licenses, as determined in accordance with GAAP. 

“Per Share Price” means (a) with respect to Beam Preferred Stock, the greater of (i) $[**] and (ii) the price per
share of Beam Preferred Stock then most recently paid by the cash purchasers thereof and (b) with respect to Beam Common Stock, the volume weighted average closing price of shares of Beam Common Stock for the
10-day period ending on the end of the last trading day of Beam Common Stock prior to the date of issuance. 

“Person” means any individual, incorporated or unincorporated organization or association, Governmental Authority, or other
entity. 

  
 - 9 - 

 “Prosecution and Maintenance” means, with respect to a Patent, the
preparing, filing, prosecuting and maintenance of such Patent, as well as re-examinations and reissues, with respect to such Patent, together with the conduct of interferences, the defense of oppositions and
other similar post-grant proceedings with respect to the particular Patent; and “Prosecute and Maintain” shall have the correlative meaning. 

“Receiving Party” shall have the meaning set forth in Section 6.1. 

“Regulatory Approval” means the approval, license or authorization of the applicable Regulatory Authority for the marketing
and sale of a product for a particular indication in a country in the Territory. 
 “Regulatory Authority” means the FDA in
the U.S. or any health regulatory authority in another country in the Territory that is a counterpart to the FDA and holds responsibility for granting Regulatory Approval in such country, including the EMA and any successor(s) thereto. 

“Regulatory Materials” means regulatory applications, submissions, notifications, registrations, marketing authorizations or
other written materials, correspondence, submissions made to or with a Regulatory Authority that are necessary or reasonably desirable in order to Develop, manufacture or Commercialize the Licensed Products in the Field in a particular country. 

“Rockefeller” means The Rockefeller University. 

“Royalty Term” means, as to a Licensed Product and a country, the period commencing on the date of the first sale by Beam,
its Affiliates, licensees, or sublicensees of the relevant Licensed Product in the relevant country and shall expire on a country-by-country basis and Licensed Product-by-Licensed Product basis on the later of the following: 

(a) with respect to a Licensed Product not Covered by an Editas-Owned Patent, the expiration of the last-to-expire royalty term under any Institutional In-Licenses that is applicable to such Licensed Product in such country; and 

(b) with respect to a Licensed Product Covered by an Editas-Owned Patent, the later of (i) the expiration of Patent-Based Exclusivity with
respect to such Licensed Product in such country and (ii) the expiration of the last-to-expire royalty term under any Institutional
In-Licenses that is applicable to such Licensed Product in such country. 
 “Securities
Act” shall mean the Securities Act of 1933, as in effect from time to time. 
 “Stock Purchase Agreement” means
that certain Amended and Restated Series A Preferred Stock Purchase Agreement, by and among Beam and the purchasers named therein, dated as of February 9, 2018. 

“Subject Patents” means the Licensed Patents and the Optioned Patents. 

“Territory” means worldwide. 

  
 - 10 - 

 “Third Party” means any Person other than Editas, Beam or any Affiliate of
either Party. 
 “Transaction Agreements” shall have the meaning set forth in Section 4.2. 

“UTokyo” means the University of Tokyo. 

“Valid Claim” means (a) a claim of an issued patent in the U.S. or in a jurisdiction outside the U.S., that has not
expired, lapsed, been cancelled or abandoned, or been dedicated to the public, disclaimed, or held unenforceable, invalid, or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has
been or can be taken, including through opposition, reexamination, reissue or disclaimer, or (b) a claim of a pending patent application that is filed and being prosecuted in good faith and that has not been finally abandoned or finally
rejected and which has been pending for no more than [**] years from the date of filing of the earliest patent application to which such pending patent application claims priority. 

“Wageningen” means Wageningen University. 

1.2 Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in
construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Sections or Exhibits shall refer to the particular Sections or Exhibits of or to this Agreement and references to this Agreement
include all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement: 
 1.2.1 any definition of or
reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein or therein), 
 1.2.2 any reference to any Law refers to such Law as from time to time enacted, repealed or
amended, 
 1.2.3 the words “include” or “including” shall be construed as incorporating, also, “but not limited
to” or “without limitation;” 
 1.2.4 the word “day,” “quarter” or “year” (and derivatives
thereof, e.g., “quarterly”) shall mean a calendar day, calendar quarter or calendar year unless otherwise specified (and “annual” or “annually” refer to a calendar year); 

1.2.5 the word “notice” shall mean notice in writing (whether or not specifically stated) and shall include notices, consents,
approvals and other written communications contemplated under this Agreement; 
 1.2.6 the word “hereof,” “herein,”
“hereby” and derivative or similar word refers to this Agreement (including any Exhibits); 
 1.2.7 the word “or” shall
have its inclusive meaning identified with the phrase “and/or;” 

  
 - 11 - 

 1.2.8 the words “will” and “shall” shall have the same obligatory
meaning; 
 1.2.9 provisions that require that a Party or the Parties hereunder “agree,” “consent” or “approve”
or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; 

1.2.10 the word “sublicensee”, when used to refer to Beam’s sublicensees, shall include any Third Party that Editas enters into
a direct license with pursuant to Section 2.4; 
 1.2.11 words of any gender include the other gender; and 

1.2.12 words using the singular or plural number also include the plural or singular number, respectively. 

ARTICLE 2 
 LICENSE AND
OPTIONS 
 2.1 License Grants to Beam. 

2.1.1 Exclusive License. Subject to the terms and conditions of this Agreement, commencing on the Effective Date, Editas hereby grants
to Beam an exclusive (even as to Editas and its Affiliates) right and license in the Field in the Territory, with the right to grant sublicenses subject to Section 2.4, under Editas’s right, title and interest in the
Licensed Patents to Develop, Commercialize, make, have made, use, offer for sale, sell and import Licensed Products. Beam hereby acknowledges and agrees that Editas’s right, title and interest in the Licensed Patents licensed by Editas pursuant
to the Cas9-I Agreement, the Cas9-II Agreement and the Cpf1 Agreement are non-exclusive with respect to the Non-Exclusive Targets. 
 2.1.2 Research License. Subject to the terms and conditions of this
Agreement, Editas hereby grants to Beam a royalty-free, non-exclusive right and license, without any right to grant sublicenses, under Editas’s right, title and interest in each Optioned Patent to perform
research activities in the Field, provided that the license granted hereunder shall expire with respect to each Family of Optioned Patents upon the expiration of the Option Period therefor. 

2.1.3 Updates to the Field. In the event that, at any time during the Term of this Agreement, Editas becomes able to grant to Beam any
additional rights in the Field [**], (a) Editas shall promptly (but in any event within [**] days) notify Beam in writing of the availability and description of all such additional rights (or, if Editas does not provide such notification, but Beam
becomes aware of the availability or such additional rights through information available to it, Beam may so notify Editas) and (b) unless Beam requests otherwise within [**] days after receiving such notice from Editas (as applicable), (i) the
definition of [**] or [**], as applicable, under this Agreement shall be deemed amended to reflect the less expansive field under which [**] or [**] has [**] rights under the Licensed Patents and (ii) the definition of “Field”
hereunder shall be deemed accordingly amended to include the applicable additional [**] rights; provided that in the event the additional rights available to Editas in the [**] or [**] permit such rights to be used for some, but not all, uses
in the Field under this Agreement, the definition of “Field” hereunder shall be deemed amended only to the extent of such rights available to Editas at such time. The Parties shall take all reasonable actions, if any,

  
 - 12 - 

 
necessary to effect or further document the amendments in clause (b) of the preceding sentence. For clarity, nothing in this Section 2.1.3 shall, or is intended to,
(i) result in any fewer or diminished rights being granted to Beam under this Agreement, (ii) conflict with [**] or (iii) permit Beam’s use of the Licensed Patents or Optioned Patents outside of the Development or
Commercialization of Base Editing Therapies. 
 2.1.4 Additional Licensed Patents. In the event that, during the Term of this
Agreement, a Party becomes aware of any issued Patent (whether such Patent issued prior to or after the Effective Date) Controlled by Editas or by an Affiliate of Editas that was an Affiliate of Editas as of the Effective Date that (a) is not
set forth on Exhibit B or Exhibit C, (b) was so Controlled as of the Effective Date and (c) Covers the development, use, manufacture or sale of a Base Editing Therapy in the Field in the Territory, such Party shall notify the
other Party and upon Beam’s request, the Parties shall, subject to Editas’s consent (such consent not to be unreasonably withheld, delayed or conditioned) and the Parties’ reasonable agreement on the Family of Patents to which such
issued Patent belongs, take all necessary actions to make such issued Patent a Licensed Patent or Optioned Patent hereunder as applicable, including amending Exhibit B or Exhibit C of this Agreement to include such issued Patent,
including the appropriate Family in Exhibit B or Exhibit C in which such issued Patent should be listed, if applicable. If the Parties are unable to agree on the Family of Patents to which a Patent belongs as provided in
the immediately preceding sentence within [**] days following Beam’s request to have such Patent be a Licensed Patent or Optioned Patent hereunder, then such matter shall be determined in accordance with Section 10.2.
For the avoidance of doubt, in the event that a Patent is made an Optioned Patent in a Family for which the applicable Option has been exercised prior to the date that such Patent is listed in such Family, such Patent shall, upon being listed in
such Family, automatically be deemed licensed hereunder with such Family without any obligation to make any additional Option Exercise Payment with respect to such Patent. 

2.2 Institutional In-Licenses. Beam acknowledges and agrees that the rights, licenses and
sublicenses granted by Editas to Beam in this Agreement (including any rights to sublicense) are subject to the terms of the Institutional In-Licenses and the rights granted to the Institutions thereunder, the
scope of the licenses granted to Editas or the applicable Affiliate thereunder and the rights retained by such Institutions and any other Third Parties (including Governmental Authorities) set forth therein, including (a) Sections 2.1, 2.2,
2.5, 2.6 2.8, 2.9, 2.10 and 10.3.1.2 of the Cas9-I Agreement, (b) Sections 2.1, 2.2, 2.5, 2.6, 2.8, 2.9, 2.10 and 10.3.1.2 of the Cas9-II Agreement,
(c) Sections 2.1, 2.2, 2.5, 2.6, 2.8, 2.9, 2.10 and 10.3.1.2 of the Cpf1 Agreement, (d) Sections 2.1(a), 2.3 and 2.4 of the 2014 MGH Agreement and (e) Sections 2.1(a), 2.3 and 2.4 of the 2016 MGH Agreement (in each case ((a) - (e)),
to the extent the Patents licensed under such Institutional In-License(s) are Subject Patents hereunder). At Editas’s request, Beam shall use Commercially Reasonable Efforts to, and cause its sublicensed
Affiliates and all sublicensees to use Commercially Reasonable Efforts to, take such actions, as may be required to assist Editas in complying with its obligations under the applicable Institutional
In-Licenses solely to the extent applicable to Beam’s rights or obligations under this Agreement, including (v) Sections 4.5.3, 8.1, 9.2.3 and 11.2 of the
Cas9-I Agreement, (w) and Sections 4.5.3, 8.1, 9.2.3 and 11.2 of the Cas9-II Agreement, (x) Sections 4.4.3, 8.1, 9.2.3 and 11.2 of the Cpf1 Agreement,
(y) Sections 10.5, 11.1, and 12.7 of the 2014 MGH Agreement and (z) Sections 10.5, 11.1, and 12.7 of the 2016 MGH Agreement (in each case ((v) – (z)), to the extent the Patents licensed under such Institutional In-License(s) are Subject Patents hereunder). 

  
 - 13 - 

 2.3 Termination of Institutional In-Licenses.

 2.3.1 Beam acknowledges and agrees that, if any of the licenses granted to Editas by Harvard and/or Broad under the Cas9-I Agreement, the Cas9-II Agreement and/or the Cpf1 Agreement is terminated, in whole or in part, including due to any failure by Editas and Beam, and their Affiliates and
sublicensees, to meet any of the diligence obligations (including any diligence milestone) set forth in any of those Institutional In-Licenses, then (a) if at the time of such termination, any Patents
licensed under such terminated license are Optioned Patents hereunder, then Beam’s Option with respect to such Optioned Patents shall immediately terminate and (b) if at the time of such termination, the Patents licensed under such
terminated license are Licensed Patents hereunder, then Beam’s license under such terminated license(s) shall automatically terminate [**] days following the effective date of termination of the Cas9-I
Agreement, the Cas9-II Agreement and/or Cpfl Agreement, as applicable, subject to Beam’s right to receive a direct license from Harvard and/or Broad pursuant to Section 10.3.1.2 of the Cas9-I Agreement, the Cas9-II Agreement and/or the Cpf1 Agreement, as applicable. 

2.3.2 Beam acknowledges and agrees that, if any of the licenses granted to Editas by MGH under the 2014 MGH Agreement or the
2016 MGH Agreement is terminated, in whole or in part, including due to any failure by Editas and Beam, and their Affiliates and sublicensees, to meet any of the diligence obligations (including any diligence milestone) set forth in any of those
Agreements, then, at the time of such termination, this Agreement shall be deemed assigned in part by Editas to MGH solely with respect to the Licensed Patents licensed under such terminated license and related rights and obligations as set forth in
Section 10.8 of the 2014 MGH Agreement and Section 10.8 of the 2016 MGH Agreement. Editas shall take all actions reasonably required to effect any assignment to MGH under this Section 2.3.2. 

2.4 Beam’s Sublicensing Rights. Beam shall have the right to grant sublicenses under the rights granted to it under
Section 2.1.1 to any of its Affiliates and Third Parties. Beam shall provide Editas with a fully-executed copy of any agreement (which Beam may redact as necessary to protect confidential or commercially sensitive
information) reflecting any such sublicense promptly after the execution thereof. If Beam grants a sublicense, the terms and conditions of this Agreement and the Institutional In-Licenses that are applicable
to sublicensees shall apply to such sublicensee to the same extent as they apply to Beam. Beam assumes full responsibility, and shall remain primarily liable, for causing the performance of all obligations of each Beam Affiliate and sublicensee to
which it grants a sublicense, and will itself pay and account to Editas for all payments due under this Agreement by reason of operation of any such sublicense. Notwithstanding the foregoing, unless and until the receipt of written agreement by the
applicable Institutions to permit further sublicensing to a Third Party, Beam shall not have the right to grant any sublicenses (other than to Affiliates of Beam and other than as may be agreed in writing by the applicable Institutions, in each case
subject to all restrictions on the granting of sublicenses herein). In the event and to the extent that an Institution does not permit further sublicensing to a Third Party by Beam without the payment of material additional consideration, then upon
Beam’s request at any time during the Term, Editas shall grant, without further consideration, a direct license to such Third Party as Beam directs, as and to the extent permitted under Editas’s obligations to the applicable Institutions
and provided such direct 

  
 - 14 - 

 
license is within the scope of Beam’s licenses granted under Section 2.1.1 and provided further, that any sale or transfer of Licensed Products by such direct
sublicensee under such direct sublicense shall be included in Net Sales hereunder, and provided even further that Editas does not incur any additional obligations or expenses under the terms of such grant. 

2.5 Option. 
 2.5.1
Grant of Option. Editas hereby grants to Beam an exclusive option to obtain the license set forth in Section 2.1.1 with respect to each Family of Optioned Patents, exercisable on a Family-by-Family basis at any time during the applicable Option Period (each, an “Option”) by providing written notice of exercise to Editas and paying the Option Exercise Payment for such
Family in accordance with Section 4.3. Upon exercise of an Option with respect to a Family of Optioned Patents, all Patents in such Family shall become Licensed Patents and shall be added to Exhibit B;
provided that, for clarity, the failure to add such Patents to Exhibit B shall not affect their status as Licensed Patents under this Agreement. Beam hereby acknowledges and agrees that Editas’s right, title and interest in the
Optioned Patents licensed by Editas pursuant to the Cas9-I Agreement, the Cas9-II Agreement and the Cpf1 Agreement are
non-exclusive with respect to the Non-Exclusive Targets. 

2.5.2 Expiration. Each of Beam’s Options hereunder shall expire on the expiration of the applicable Option Period, upon which
expiration the applicable Family of Optioned Patents shall cease to be Optioned Patents under this Agreement. 
 2.5.3 [**] Patents.
If during the Term, Editas or its Affiliates (other than any person or entity that acquires all or any part of Editas or an Affiliate of Editas, and any affiliates of such person or entity) enters into a license agreement for the license of one or
more Patents set forth on Exhibit D (collectively, the “[**] Patents”), then, Editas shall promptly provide to Beam a written description of such [**] Patents, together with a true and correct copy of the license or other
agreement pursuant to which Editas licensed such [**] Patents (each such license, an “[**] License,” and the licensor thereunder an “Additional Licensor”) (which Editas may redact as to terms not material to a
sublicensee thereunder). Editas or its applicable Affiliate will use commercially reasonable efforts to obtain sublicensing rights in any such license to any [**] Patents of a scope that would permit Beam to elect to receive a sublicense of such
rights under this Section 2.5.3. If such agreement permits the sublicensing of rights to Beam, then (a) if Beam has previously exercised its Option with respect to the Family of Optioned Patents set forth on Exhibit
C under the heading [**] Beam may elect, by written notice delivered to Editas within [**] days after Beam’s receipt of such [**] License, to receive a sublicense of rights granted under such [**] License, and thereafter (i) such [**]
License shall become an Institutional In-License hereunder, (ii) the Additional Licensor shall become an Institution hereunder and (iii) the [**] Patents shall become Licensed Patents hereunder and
shall be added to Exhibit B or (b) if Beam has not previously exercised its Option with respect to the [**] Patent Family and the Option Period for such Family has not yet expired, Beam shall have the right, exercisable if and at the
time of Beam’s exercise of its Option with respect to the [**] Patent Family, to receive a sublicense of rights granted under such [**] License, in which case upon exercise of such Option and payment of the applicable fee, (i) such [**]
License shall become an Institutional In-License hereunder, (ii) the Additional Licensor shall become an Institution hereunder and (iii) the [**] Patents shall become Licensed Patents hereunder and
shall be added to Exhibit B, provided in each case ((a) and (b)), that the [**] Patents will only be included in the Licensed Patents if Beam agrees in writing to assume and perform any pass-through financial obligations and other obligations
applicable to sublicensees under such [**] License. 

  
 - 15 - 

 2.6 No Grant of Rights to Third Parties; Inclusive Innovation Model. 

2.6.1 Except for (a) licenses to Institutions for research and education purposes or (b) subject to
Section 2.6.2, under the Cas9-I Agreement, Cas9-II Agreement and the Cpf1 Agreement, exclusive or
non-exclusive licenses granted by an Institution to a Third Party making a Bona Fide Proposal (as defined in such Institutional In-Licenses) to an Institution under
Section 2.6 of such Institutional In-Licenses, in each case of clauses (a) and (b), as required under any Institutional In-License, Editas shall not itself
exercise, nor grant to any Third Party, rights to the Subject Patents that are inconsistent with or that would interfere with the grant of the rights, Option and licenses granted or potentially to be granted to Beam hereunder. 

2.6.2 In the event that an Institution provides Editas with a Proposed Product Notice or a Proposed Broad Target Notice (each
as defined in the applicable Institutional In-License to which such Institution is a Party) for a potential product or target in the Field, Editas shall promptly notify Beam (but in any event within [**] days
after receipt of such notice) and the Parties shall discuss the matter and take such actions as the Parties mutually agree in good faith are reasonably necessary to avoid Beam’s loss of rights to such potential product or target under this
Agreement; [**]. 
 2.7 No Implied Licenses; Reservation of Rights. Except as explicitly set forth in this Agreement, neither Party
shall acquire under this Agreement any license, intellectual property interest or other rights, by implication or otherwise, under any Patents or other intellectual property rights Controlled by the other Party or its Affiliates. Any rights of
Editas not expressly granted to Beam pursuant to this Agreement shall be retained by Editas. 
 2.8 Rights Upon Bankruptcy. All rights
and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code and other similar laws in any jurisdiction outside the U.S. (collectively,
the “Bankruptcy Laws”), licenses of rights to “intellectual property” as defined under the Bankruptcy Laws. If a case is commenced during the term of this Agreement by or against a Party under Bankruptcy Laws then, unless
and until this Agreement is rejected as provided in such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns
(including a trustee) shall perform all of the obligations provided in this Agreement to be performed by such Party. If a case is commenced during the term of this Agreement by or against a Party under the Bankruptcy Laws, this Agreement is rejected
as provided in the Bankruptcy Laws and the other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including
debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall provide to the other Party copies of all information necessary for such other
Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party’s written request therefor. All rights, powers and remedies of the non-bankrupt Party as
provided herein are in addition to and not in substitution for any and all other 

  
 - 16 - 

 
rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy
Laws. All payments owed to Editas under Sections 4.5, 4.6 and 4.7 are, and shall otherwise be deemed to be, for purposes of the Bankruptcy Laws, “royalties” as defined under the Bankruptcy Laws. 

ARTICLE 3 
 DEVELOPMENT
AND COMMERCIALIZATION 
 3.1 Alliance Coordinators. Each of the Parties shall appoint one (1) representative
possessing a general understanding of this Agreement and of drug product Development to act as the primary point of contact between the Parties with respect to this Agreement (each, a “Alliance Coordinator”). Subject to the
foregoing, either Party may replace its Alliance Coordinator at any time with prior notice to the other Party. The Alliance Coordinators shall conduct quarterly in-person meetings or teleconferences, in which
the discussions may include (a) the Development, Commercialization and regulatory matters of Licensed Products, (b) general corporate updates with respect to each Party, including updates on each Party’s Patent prosecution efforts and
other developments with respect to Licensed Products or Licensed Patents (provided that, neither Party shall be required to disclose any information it considers sensitive concerning areas of its business not related to Licensed Products or Licensed
Patents) and (c) the potential for mutually-beneficial business development opportunities (including potential additional partnering and licensing arrangements), and may invite additional personnel from either Party to attend any such meetings
or teleconferences. Beam shall update Editas, through the Alliance Coordinators at the quarterly meetings described above in this Section 3.1, with any material program updates related to the Development or
Commercialization of the Licensed Products in the Field. 
 3.2 Diligence; Progress Reports. Beam shall use Commercially Reasonable
Efforts (a) to Develop one (1) Licensed Product in each of the Major Markets, including filing the first IND with respect to a Licensed Product within [**] years of the Effective Date and (b) with respect to any Licensed Product that
has received Regulatory Approval in a country in the Territory, to Commercialize such Licensed Product in such country. Beam shall provide a written report to Editas on an [**] basis beginning on the [**] anniversary of the Effective Date that
reasonably summarizes Beam’s exercise of Commercially Reasonable Efforts under this Section 3.2. In addition, Beam shall promptly notify Editas in the event that the Beam/Harvard License is terminated, which notice
shall include the underlying reason for such termination. 
 3.3 Regulatory Activities. Beam shall have the sole right and
responsibility to prepare and file for Regulatory Approval and otherwise obtain and maintain approvals from Regulatory Authorities that are necessary for Development, manufacture and Commercialization of the Licensed Products in the Field in the
Territory, and otherwise interact with Regulatory Authorities as appropriate with respect to the Licensed Products. Beam will own all such Regulatory Approvals and other Regulatory Materials for Licensed Products. 

  
 - 17 - 

 ARTICLE 4. 

COMPENSATION 
 4.1
Initial Fee. In partial consideration for the rights granted to Beam hereunder Beam shall pay Editas a one-time, non-refundable,
non-creditable payment of One Hundred Eighty Thousand Dollars ($180,000) upon execution of this Agreement (the “Initial Fee”). Such payment shall be allocated between consideration for the
rights granted to Beam hereunder and reimbursement for past Patent Costs as set forth on the Allocation Schedule. 
 4.2 Equity
Issuance. In partial consideration for the rights granted hereunder, on the date hereof, Beam shall issue to Editas (for no additional consideration), 1,833,333 shares of Series A-1 Preferred Stock and
1,222,222 shares of Series A-2 Preferred Stock (each as defined in the Stock Purchase Agreement), having an aggregate value, based on the price paid by Beam’s investors for such shares, of $3,666,666 (the
“Beam Series A Shares” and such issuance, the “Initial Equity Issuance”). Such aggregate value shall be allocated between [**] and [**]. In connection with such issuance, (a) Beam shall deliver to Editas a
certificate, signed by an executive officer of Beam, certifying that the representations and warranties set forth in Section 2 of the Stock Purchase Agreement are true and correct as of the date of such issuance (except as qualified by a
disclosure schedule that may be attached to such certificate), provided that, for purposes of such certificate, any representations and warranties regarding the “Shares” (as used in the Stock Purchase Agreement) shall be deemed to
be representations and warranties regarding the Beam Series A Shares and all other capitalized terms used in the representations and warranties shall have the definitions set forth in the Stock Purchase Agreement, (b) Editas shall deliver to
Beam a certificate, signed by an authorized officer of Editas, certifying that the representations and warranties set forth in Section 3 of the Stock Purchase Agreement are true and correct as of the date of such issuance and (c) Editas
shall become a party to the Investors’ Rights Agreement, the Right of First Refusal and Co-Sale Agreement and the Voting Agreement (each as defined in the Stock Purchase Agreement and collectively, the
“Transaction Agreements”). Beam further agrees that for so long as Editas holds some or all of the Beam Series A Shares or Beam Preferred Stock it shall not (i) amend any of the Transaction Agreements in a manner that would
diminish Editas’s rights thereunder, including, changing the definition of Major Investor in the Investors’ Rights Agreement, (ii) execute any waiver under the Transaction Agreements that would waive a right held by Editas under such
Transaction Agreements or (iii) amend or restate Beam’s Second Amended and Restated Certificate of Incorporation (as may be amended and/or restated from time to time) in a manner that would diminish any of the rights held by Editas in
connection with being a holder of Beam Series A Shares, in each case, without the written consent of Editas; provided that nothing in this sentence shall prohibit, or require Editas’s consent to, an amendment of or waiver under any of
the Transaction Agreements or an amendment or restatement of the Beam’s Amended and Restated Certificate of Incorporation that in each case would not affect Editas differently than or in a disproportional manner to other holders of Beam Series
A Shares or Beam Preferred Stock, as applicable, even if such effect was adverse. 
 4.3 Option Exercise Payment. If Beam elects to
exercise an Option with respect to a Family of Optioned Patents, Beam shall pay the amount set forth below, calculated on the date that Beam provides notice to Editas of such election (such date, the “Exercise Date” and each such
payment, an “Option Exercise Payment”). The applicable Option Exercise Payment shall 

  
 - 18 - 

 
be payable on a Family-by-Family basis, with each payment becoming payable with respect to the applicable Family
when Beam exercises its Option with respect to such Family (i.e., if Beam were to exercise as to all three Families of Optioned Patents after the [**] anniversary of the Effective Date, such exercise payments would in aggregate total [**]. Each
Option Exercise Payment shall be allocated between [**] and [**]. Each Option Exercise Payment shall be payable by Beam within [**] days after the applicable Exercise Date. Beam shall have the right, but not the obligation to settle its obligation
to make any Option Exercise Payment by issuing to Editas (for no additional consideration) a number of shares of Beam Preferred Stock (or, following an Initial Public Offering of Beam, a number of shares of Beam Common Stock) equal to the quotient
of the Option Exercise Payment being settled thereby divided by the Per Share Price, provided, that, (a) if the issuance of such shares occurs prior to the Initial Public Offering of Beam, Beam shall deliver to Editas a certificate, signed by
the Executive Officer of Beam, certifying that the representations and warranties set forth in the last stock purchase agreement entered into by Beam and a bona fide cash purchaser of preferred stock are true and correct as of the date of such
issuance (except as qualified by a disclosure schedule that may be attached to such certificate), (b) if the issuance of such shares occurs after the Initial Public Offering of Beam and Beam is eligible to file a registration statement on Form S-3, the applicable shares of Beam Common Stock so issued shall be registered by Beam for resale within [**] days after such issuance and (c) if the issuance of such shares would cause Editas to have to
consolidate Beam’s financials with its own, as determined in good faith by Editas and in accordance with GAAP, then Beam shall only be permitted to make such payment in shares to the extent that Editas would not have to consolidate Beam’s
financial statements with its own, and shall remit the remainder of such Option Exercise Payment in cash.  
  

			
	 Exercise Date
	  	Option Exercise
Payment
(in $ millions)
	 [**]
	  	[**]
	 [**]
	  	[**]
	 [**]
	  	[**]

 4.4 Institutional Payments Generally. 

4.4.1 With respect to any Institutional Milestone Payments, costs payable by Beam to Editas pursuant to Section 4.6,
any Institutional Royalty Rate and any Institutional Sublicense Income Payments, Editas shall use reasonable efforts to avail itself of all applicable reductions to such payments and costs, if any, that are available under the relevant Institutional
In-License prior to invoicing Beam for such payment or cost. In the event Beam notifies Editas of reductions to such payments or costs that are available to Editas under an Institutional In-License, Editas shall use reasonable efforts to avail itself of such applicable reductions. 

  
 - 19 - 

 4.4.2 For the avoidance of doubt, notwithstanding anything to the contrary in this
Agreement, Editas, and not Beam, shall be responsible for the payment of any Success Payment (as defined in the applicable Institutional In-License) under the 2016 MGH Agreement, the Cas9-II Agreement or the Cpf1 Agreement. 
 4.5 Institutional Milestone Payments and Institutional
Sublicense Income Payments. With respect to any Licensed Product Covered by an Institutional Patent or any payment made by Beam, its Affiliates or its sublicensees to Editas hereunder, Beam shall pay Editas the full amount of any (i) [**] plus
(ii) Institutional Sublicense Income Payment due from Editas to an Institution in connection with any payment made to Editas hereunder (including in the case of both clauses (i) and (ii) any incremental amounts to gross up Editas, such
that Editas is not required to pay the Institution any amounts in connection with such Sublicense Income Payment from Editas’s own funds), provided, that in the case of the foregoing clause (ii), Beam shall not be required to make
such payment in connection with any Option Exercise Payment, the Initial Fee or the Initial Equity Issuance. Within [**] days after achievement of an Institutional Milestone, Beam shall notify Editas of the achievement of such Institutional
Milestone, and shall pay to Editas the full amount of the applicable Institutional Milestone Payment. Beam shall pay to Editas the full amount of any applicable Institutional Sublicense Income Payment within [**] days after receipt of an invoice
from Editas therefor. 
 4.6 Institutional In-License Costs. Beam shall pay to
Editas: 
 4.6.1 [**]% of any Annual Maintenance Fees payable by Editas under any Institutional
In-License pursuant to which Editas licenses any Licensed Patents to Beam, within [**] days following receipt of an invoice from Editas therefor; provided that such invoice shall be issued to Beam no
sooner than [**] days [**] before Editas owes such Annual Maintenance Fee to the applicable Institution; and 
 4.6.2 [**]% of Patent Costs
incurred by Editas or the Institutions with respect to the Prosecution and Maintenance of the Licensed Patents (the “Annual Patent Costs”), provided however, that Beam’s share of the Annual Patent Costs for the period
beginning on the Effective Date and ending on the [**] year anniversary thereof (the “Initial Annual Patent Cost Period”) shall equal $[**]. For years beginning after the Initial Annual Patent Cost Period, Beam shall engage,
at Beam’s cost and expense, an independent accounting firm of regionally recognized standing (the “CPA”) selected by Beam and reasonably acceptable to Editas for the purpose of calculating the amount owed to Editas pursuant to
this Section 4.6.2, provided, that such calculated amount shall be subject to Editas’s review and confirmation, not to be unreasonably withheld. Such analysis shall be performed [**] per calendar year, promptly
after the end of such calendar year, and shall be conducted under appropriate confidentiality and non-use provisions, provided, that the first analysis may cover a period longer than [**] months (but in no
event, longer than [**] months) such that the subsequent analysis can begin on the January 1st immediately following the period covered by the first analysis. Editas agrees to provide the CPA with
access to relevant portions of books and records reasonably related to Patent Costs, provided, that Editas may redact such portions to the extent not required for such calculation. In addition, the CPA shall have reasonable access, on reasonable
notice and during Editas’s normal business hours, to individuals, records and responses to questions from auditors in a timely manner and have the right to make copies of relevant portions of Editas’s books and records;

  
 - 20 - 

 
provided that, any such copies shall be the Confidential Information of Editas. Prior to issuing a final calculation of the Annual Patent Costs, the CPA shall provide a preliminary
calculation thereof to Beam and Editas. Thereafter, each Party shall have a reasonable opportunity to review and comment on such preliminary calculation, and to discuss such comments with the CPA and each other. Upon resolution of any disputes
regarding such preliminary calculation, the CPA shall issue a final report detailing its calculation of the Annual Patent Costs, provided that such calculation shall be subject to dispute resolution pursuant to Sections 10.2 and
10.3 at Editas’s request. Unless disputed by Editas, Beam shall pay [**]% of the Annual Patent Costs so determined within [**] days following the CPA’s delivery of its final report. 

4.7 Royalties. Beam shall pay to Editas royalties on Licensed Products, on a Licensed Product-by-Licensed Product and country-by-country basis, in respect of Net Sales of such Licensed Product during the applicable
Royalty Term, at a royalty rate equal to the applicable Institutional Royalty Rate, plus (a) subject to the terms of this Section 4.7, if such Licensed Product is not Covered by an Editas-Owned Patent, [**]%
or (b) if such Licensed Product is Covered by an Editas-Owned Patent, the additional royalty amount set forth below. 
  

			
	 Aggregate World-Wide Net Sales of Licensed Products per calendar
year
	  	Royalty Rate Applicable
to such Net Sales
	 Net Sales up to $[**]
	  	[**]%
	 (b) Incremental Net Sales greater than $[**]
	  	[**]%

 Notwithstanding anything to the contrary in this Agreement, in the event that any license granted to Editas by an Institution
under an Institutional In-License is terminated for a reason other than Beam’s material breach of this Agreement and a direct license or assigned license to Beam from such Institution is effected as
detailed in Sections 2.3.1 or 2.3.2, if Beam’s financial obligations with respect to a Licensed Product increase under the direct or assigned license (in relation to Beam’s financial obligations with respect to such Licensed
Product under this Agreement), the Parties agree that Beam shall be entitled, as its sole and exclusive remedy and Editas’s sole and exclusive liability with respect to such termination, to offset any amount of such increased financial
obligations against any royalty owed to Editas with respect to Licensed Products Covered by such Licensed Patent under clause (a) of this Section 4.7 until the entire amount of such increased obligation has been
offset, provided, that in no event shall such royalty be reduced to less than [**] ([**]%) of what would otherwise have been due to Editas under such clause (i.e. any [**]% royalty owed may not be decreased below [**]%),
provided, further, that Beam shall have the right to carry forward as offsets any portions of such increased financial obligations that cannot be deducted due to the limitation in the immediately preceding proviso to apply against future royalties
payable to Editas under clause (a) of this Section 4.7, subject to such limitation in the immediately preceding proviso, until such amounts are fully exhausted. 

4.8 Reports and Payment. During the Royalty Term for each Licensed Product, Beam shall provide written unaudited reports to Editas
within [**] days after the end of each [**] covering sales of Licensed Products on a product-by-product,
country-by-country basis in the Territory by such Party, its Affiliates, licensees, and sublicensees during such [**]. Each such

  
 - 21 - 

 
written report shall provide (a) the Net Sales in Dollars and local currency for each Licensed Product in the Territory during the reporting period; (b) the deductions (by
deduction category) from gross amounts billed or invoiced taken in calculating such Net Sales; (c) the royalties payable, in Dollars, which shall have accrued hereunder with respect to such Net Sales and (d) to the extent
required under any applicable Institutional In-License, the number of units of such Licensed Product(s) sold during the reporting period. In addition, each such written report shall contain such additional
information as reasonably requested by Editas in order to satisfy Editas’s reporting obligations to any Institution. The information contained in each report under this Section 4.8 shall be considered Confidential Information
of Beam, provided that Editas may share such report with the Institutions as necessary to comply with its obligations under the Institutional In-Licenses, subject to confidentiality and non-use restrictions at least as strict as those that apply to Editas’s confidential information under such applicable Institutional In-License. Concurrent with the
delivery of each such report, Beam shall make the royalty payment due to Editas under Section 4.7 for the [**] covered by such report. In the case of transfers or sales of any Licensed Product between Beam and an Affiliate,
licensee or sublicensee, a royalty shall be payable only with respect to the sale of such Licensed Product to an independent Third Party that is not an Affiliate, licensee or sublicensee of Beam. Each report to be delivered by Beam pursuant to this
Section 4.8 shall be certified in writing on behalf of Beam as true, correct and complete in all material respects with respect to the information required solely to the extent Editas is required to certify in writing that such
information is true, correct and complete in a report delivered to an Institution under an Institutional In-License. In addition, during the Royalty Term for each Licensed Product, within [**] days following
the end of each [**], Beam will provide Editas a preliminary non-binding good faith report estimating the total Net Sales of, and royalties payable to Editas for, such Licensed Product projected for such [**];
provided that, Beam will have no liability as a result of any disparity between such reports and the reports delivered pursuant to the first sentence of this Section 4.8. 

4.9 Payment Method; Late Payments. Payments hereunder, other than payments made in Beam Preferred Stock or Beam Common Stock pursuant to
Section 4.3, shall be paid by wire transfer, or electronic funds transfer (EFT) in immediately available funds to a bank account designated by Editas at least [**] days in advance of such payment. Royalties and any other
payments required to be paid by Beam pursuant to this Agreement shall, if overdue, bear interest until payment at a rate per annum equal to the lesser of the prime or equivalent rate per annum quoted by The Wall Street Journal on the first
business day after such payment is due, plus [**] percent ([**]%) or, if lower, the highest rate permitted by applicable Law, calculated on the number of days such payments are paid after such payments are due and compounded [**]. The payment of
such interest shall not restrict Editas from exercising any other rights it may have because any payment is overdue. 
 4.10 Currency.
All amounts payable and calculations hereunder shall be in Dollars. Conversion of sales recorded in local currencies to Dollars will first be determined in the foreign currency of the country in which such Licensed Products are sold and then
converted to Dollars at a [**] day trailing average published by the Wall Street Journal (U.S. editions) for conversion of the foreign currency into Dollars on the last day of the quarter for which such payment is due.  

  
 - 22 - 

 4.11 Taxes and Withholding. If Beam is required to deduct or withhold from any
payment due to Editas hereunder any withholding taxes under the Laws or regulations of any jurisdiction or Governmental Authority, then Beam shall pay such withholding taxes to the applicable Governmental Authority and make the payment to Editas of
the net amount due after deduction or withholding of such taxes. Such withholding taxes shall be treated for all purposes of this Agreement as having been paid to Editas. Beam shall submit reasonable proof of payment of the withholding taxes within
a reasonable period of time after such withholding taxes are remitted to the Governmental Authority. The Parties shall reasonably cooperate to eliminate or minimize any such withholding taxes. Notwithstanding the foregoing, if Beam is required to
deduct or withhold withholding taxes from any payment due hereunder that is required to be paid to an Institution under an Institutional In-License (a “Pass-Through Amount”), then the
Pass-Through Amount shall be treated as a separate payment and such Pass-Through Amount shall be increased so that the net amount thereof payable to Editas, after the deduction of all withholding taxes directly related to such Pass-Through Amount,
equals the Pass-Through Amount; provided, however, that Editas shall take all reasonable best efforts necessary to obtain any lawful reductions or eliminations of such withholding taxes available under Law. Beam shall submit reasonable
proof of payment of any withholding taxes within a reasonable period of time after such withholding taxes are remitted to the Governmental Authority. 

4.12 Accounting. 
 4.12.1
Beam agrees to keep, and to require its Affiliates, licensees, and sublicensees to keep, full, clear and accurate records for a minimum period of [**] years after the conclusion of the calendar year in which the relevant payment is owed pursuant to
this Agreement, setting forth the sales and other disposition of Licensed Products sold or otherwise disposed of in sufficient detail to enable royalties and compensation payable to the Editas hereunder to be determined. 

4.12.2 Beam further agrees, upon not less than [**] days prior written notice, to permit, and to require its Affiliates, licensees, and
sublicensees to permit, the books and records relating to such Licensed Product to be examined by an independent accounting firm selected by Editas for the purpose of verifying reports provided by Beam under this this Agreement. Such audit shall not
be performed more frequently than once in any [**]-month period or once with respect to any reporting period, and shall be conducted under appropriate confidentiality provisions, for the sole purpose of verifying the accuracy and completeness of all
financial, accounting and numerical information and calculations provided under this Agreement. The independent accounting firm shall have reasonable access, on reasonable notice and during Beam’s normal business hours to individuals, records
and responses to questions from auditors in a timely manner and have the right to make copies of relevant portions of Beam’s books and records; provided that, any such copies shall be the Confidential Information of Beam, shall be
protected by appropriate confidentiality obligations and shall not be shared with Editas or any other Person. 
 4.12.3 Such examination is
to be made at the expense of Editas, except if the results of the audit reveal an underpayment of royalties, milestones, or other payments to Editas under this Agreement of [**] percent ([**]%) or more in any calendar year, in which case reasonable
audit fees for such examination shall be paid by Beam. 

  
 - 23 - 

 ARTICLE 5 

INTELLECTUAL PROPERTY 
 5.1
Patent Prosecution. As between the Parties, Editas shall be responsible, at its expense, and shall have the exclusive right, but not the obligation, for preparing, filing, Prosecuting and Maintaining the Subject Patents and for conducting any
opposition, reexamination request, nullity action, interference, or other attack upon the validity, title or enforceability thereof. Without limiting the foregoing, Editas shall use Commercially Reasonable Efforts to secure the right to
(x) provide Beam with a copy of each submission made to and material document received from a patent authority, court or other tribunal regarding Licensed Patents labelled as “Harvard/Liu” Patents on Exhibit B reasonably
promptly after making such filing or receiving such material document, including a copy of each application as filed together with notice of its filing date and application number; (y) keep Beam advised of the status of all material
communications, actual and prospective filings or submissions regarding such “Harvard/Liu” Patents, and shall give Beam copies of any such material communications, filings and submissions proposed to be sent to any patent authority or
judicial body; and (z) consider in good faith and reasonably incorporate Beam’s comments on material communications, filings and submissions for such “Harvard/Liu” Patents. 

5.2 Infringement by Third Parties. 

5.2.1 Beam shall promptly notify Editas of any knowledge it acquires of any actual or potential infringement of the Subject Patents by a Third
Party. Editas shall promptly notify Beam of any knowledge it acquires of any actual or potential infringement of the Licensed Patents by a Competitive Product of a Third Party. 

5.2.2 If any Licensed Patent labelled as a “Harvard/Liu” Patent on Exhibit B is infringed by the manufacture, use, offer for
sale, sale or importation of a Competitive Product by a Third Party in any country in the Territory, then Beam shall have the primary right, but not the obligation, to institute, prosecute, and control any action or proceeding with respect to such
infringement of such patent (an “Infringement Action”), by counsel of its own choice, provided that prior to initiating any such action, Beam shall notify Editas and shall provide evidence to Editas that there is a
good faith basis for such action and provided further, that (a) to the extent the Infringement Action implicates an Institutional Patent, Beam’s rights under this Section 5.2.2 shall be at all times subject to the
applicable Institutional In-License with respect to an Infringement Action and (b) Beam shall fully cooperate with Editas’s reasonable requests for information or other assistance to enable Editas to
comply with its obligations under the applicable Institutional In-License with respect to such Infringement Action. 

5.2.3 If any Licensed Patent other than a “Harvard/Liu” Patent that is licensed by Editas under an Institutional In-License is infringed by the manufacture, use, offer for sale, sale or importation of a Competitive Product by a Third Party in any country in the Territory, then Editas shall consider in good faith, but shall not
be required to grant, any reasonable request by Beam to enforce such Licensed Patent. 

  
 - 24 - 

 5.2.4 If any Editas-Owned Patent is infringed by the manufacture, use, offer for sale, sale
or importation of a Competitive Product by a Third Party in any country in the Territory, then any enforcement of such License Patent shall be subject to Editas’s approval, which Editas may withhold in its sole and absolute discretion. 

5.2.5 Notwithstanding anything to the contrary contained herein with respect to any Infringement Action, if Beam owns one or more Patents that
cover the Competitive Product (“Other IP”), Beam shall not initiate action under a Licensed Patent unless it (x) also asserts all or a portion of such Other IP or (y) obtains written consent from Editas (which consent, in
the case of Institutional Patents, shall be predicated on the consent of the applicable Institution if so required by the applicable Institutional In-License). Beam shall use the same degree of diligence in
prosecuting such Infringement Action as it uses or would use in prosecuting infringement of its own Patents. 
 5.2.6 If in any such
Infringement Action brought by Beam as permitted by this Section 5.2, Editas is required to join for standing purposes or in order for Beam to commence or continue any such Infringement Action, then Editas shall join such
Infringement Action, at Beam’s expense, and shall be represented in such Infringement Action by counsel of Editas’s choice. To the extent Editas has the right under the applicable Institutional
In-License, Editas shall cause the applicable Institution to join any such Infringement Action brought by Beam as permitted by this Section 5.2, where required for standing purposes.
The exercise by Beam of the right to bring an Infringement Action shall be subject to and consistent with the terms of all applicable Institutional In-Licenses; provided that, if, under the terms of an
applicable Institutional In-License, Editas has an applicable enforcement right as to an Infringement Action that Beam would be permitted to bring by this Section 5.2 that Editas
cannot delegate to Beam, then, at Beam’s request and expense, Editas shall exercise such rights in such Infringement Action as directed by Beam. If Beam does not take action in the prosecution, prevention, or termination of any infringement
that Beam is permitted to bring pursuant to this Section 5.2, and has not commenced negotiations with the suspected infringer for the discontinuance of said infringement, within [**] days after receipt of notice of the
existence of an infringement (or in cases where there is a relevant statutory period during which an Infringement Action must be commenced that would expire prior to the expiration of such [**]-day period and
of which Editas has notified Beam promptly after it becomes aware, [**] days prior to the expiration of such relevant statutory period), Editas and Beam shall meet and discuss Beam’s reasons for not initiating a lawsuit or otherwise making or
prosecuting an Infringement Action. If after having given due consideration to Beam’s reasons for not bringing such Infringement Action, Editas (or an Institution) desires to initiate a lawsuit or otherwise make or prosecute a claim of
infringement with respect to the Competitive Product, Editas shall so notify Beam and Editas (or an Institution) may thereafter institute, prosecute, and control such action. If in any such Infringement Action Beam is required to join for standing
purposes or in order for Editas (or an Institution) to commence or continue any such Infringement Action, then Beam shall join such Infringement Action, at Editas’s (or Institution’s), as applicable) expense, and shall be represented in
such Infringement Action by counsel of Beam’s choice. 
 5.2.7 Subject to this Section 5.2.7, the Party
prosecuting the Infringement Action shall bear all costs and expenses, including attorneys’ fees, related to such Infringement Action except for those costs and expenses incurred by the non-prosecuting
Party or other Person other than at the prosecuting Party’s request, and shall have the sole and exclusive right to elect counsel for such Infringement Action initiated by it pursuant to Section 5.2.2; provided
that such 

  
 - 25 - 

 
counsel is reasonably acceptable to the other Party. The other Party (and/or an Institution) shall have the right to participate in and be represented by counsel of its own selection and at its
own expense in any suit instituted under Section 5.2.2 by the other Party for infringement. Each Party agrees to reasonably cooperate (at the prosecuting Party’s request and expense) in any action under
Section 5.2.2 that is prosecuted by the other Party, including executing legal papers and cooperating in the prosecution as may be reasonably requested by the prosecuting Party. 

5.2.8 Unless otherwise agreed by the Parties in writing, the amount of any recovery from a proceeding brought under
Section 5.2.2 shall first be applied to the out-of-pocket costs of such action incurred by the Party, if any, prosecuting the applicable
action, then to the out-of-pocket costs, if any, of the other Party and the Institutions reasonably incurred at the prosecuting Party’s request in accordance with
this Section 5.2, and (a) if the prosecuting Party is Beam, its Affiliates or its sublicensees (or Editas as directed by Beam pursuant to Section 5.2.2), any remaining recovery amount shall be
treated as Net Sales of the Licensed Product affected by the infringing Competitive Product and Beam shall pay royalties thereon in accordance with Section 4.7 or (b) if the prosecuting party is Editas or an
Institution, any remaining recovery amount shall be allocated first to the Institution pursuant to the applicable Institutional In-License and then [**] percent ([**]%) of the remaining amount shall be
allocated to Beam and [**] percent ([**]%) to Editas. If in connection with an Infringement Action brought under Section 5.2.2, an Institution is entitled under the applicable Institutional
In-License to a portion of any recovery that is greater than the portion of the recovery payable, after costs, to Editas, the Parties will meet and agree in good faith on an alternative sharing of such
recovery to that set forth in the immediately preceding sentence that takes into account the amounts payable to the applicable Institutions and results in a consistent allocation of the amounts remaining to Beam and Editas after payment of such
amounts to the applicable Institutions. 
 5.3 Patent Challenge.  

5.3.1 Beam shall comply with Section 4.5.3 of the Cas9-I Agreement, Section 4.5.3 of the Cas9-II Agreement, Section 4.4.3 of the Cpf1 Agreement, Section 10.5 of the 2014 MGH Agreement and Section 10.5 of the 2016 MGH Agreement (in each case, to the extent the Patents licensed under such
Institutional In-License(s) are Licensed Patents hereunder) and acknowledges that any breach by Beam or its Affiliates or sublicensees of such provisions shall entitle the applicable Institution to certain
remedies which if enforced by such Institution shall be passed through to Beam with respect to the Patents licensed under such Existing In-Licenses. 

5.3.2 For any Patent Challenge with respect to a Patent that is not subject to Section 5.3.1, in the event that Beam
or any of its Affiliates, brings, assumes or participates in or knowingly, willfully or recklessly assists in bringing a Patent Challenge (except if Beam is required to participate in such Patent Challenge pursuant to a subpoena or court order or
participates in a proceeding that is initiated by a patent office and not at the instigation of Beam), then (a) Beam shall provide Editas with at least [**] days’ notice prior to taking any such action and (b) Beam shall pay all
reasonable costs, fees and expenses associated with such Patent Challenge that are incurred by Editas, either directly or under the terms of any Institutional In-License, within [**] days after receiving an
invoice from Editas for same; (c) if any fees, royalties, milestones or revenues payable under the Institutional In-Licenses increase in amount 

  
 - 26 - 

 
as a result of such Patent Challenge, Beam agrees to indemnify and hold harmless Editas from any and all such amounts; and (d) at any time after the Patent Challenge is brought, Editas may,
at its option, terminate this Agreement according to Section 9.4; provided that if any of subsections (a) through (d) are held invalid or unenforceable for any reason, such invalidity or unenforceability shall
not affect any of the other said subsections. Notwithstanding any provision of this Agreement to the contrary, Beam shall not have the right to assume or participate in the defense, settlement or other disposition of such Patent Challenge through
its status as licensee under this Agreement, but shall pay all associated costs, fees and expenses as provided in this Section 5.3.2. The Parties agree that any challenge or opposition to a Patent Right by Beam may be
detrimental to Editas, and that the above provisions shall constitute reasonable liquidated damages to reasonably compensate Editas for any loss it may incur as a result of Beam taking such action. 

ARTICLE 6 

CONFIDENTIALITY 
 6.1
Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the “Receiving Party”) shall keep confidential and shall not
publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any confidential and proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or
otherwise) which is disclosed to it by the other Party (the “Disclosing Party”) or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement,
including trade secrets, know-how, inventions or discoveries, proprietary information, formulae, processes, techniques and information relating to a Party’s past, present and future marketing, financial,
and Development activities of any product or potential product or useful technology of the Disclosing Party and the pricing thereof (collectively, “Confidential Information”), except to the extent that it can be established by the
Receiving Party that such Confidential Information: 
 6.1.1 was in the lawful knowledge and possession of the Receiving Party prior to the
time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the
Receiving Party; 
 6.1.2 was generally available to the public or otherwise part of the public domain at the time of its disclosure to the
Receiving Party; 
 6.1.3 became generally available to the public or otherwise part of the public domain after its disclosure and other than
through any act or omission of the Receiving Party in breach of this Agreement; or 
 6.1.4 was disclosed to the Receiving Party, other than
under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. 

  
 - 27 - 

 6.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement,
a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: (a) under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its obligations or
exercise of rights granted or reserved in this Agreement (including the rights to Develop and Commercialize Licensed Products and to grant sublicenses as permitted hereunder); or (b) to the extent such disclosure is reasonably necessary in
filing or prosecuting patent, copyright and trademark applications, prosecuting or defending litigation, complying with applicable governmental regulations, seeking and obtaining Regulatory Approval, conducting
non-clinical activities or clinical trials, preparing and submitting INDs to Regulatory Authorities, or is otherwise required by Law or the rules of a recognized stock exchange or automated quotation system
applicable to such Party; provided, however, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party’s Confidential Information it will, except where impracticable, give reasonable advance
notice to the Disclosing Party of such disclosure requirement and, if requested by the Disclosing Party, cooperate with the Disclosing Party to secure confidential treatment of such Confidential Information required to be disclosed; or (c) in
communication with existing or prospective investors, consultants, advisors, licensees or collaborators or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement;
or (d) to the extent mutually agreed to in writing by the Parties. 
 6.3 Publications. Beam and its Affiliates shall have the
right to publish or publicly disclose the results generated in the course of performing any research related to the rights it licenses from Editas hereunder, provided that Beam submits the proposed publication or disclosure to Editas for its
review at least [**] days prior to the scheduled submission of such proposed publication or public disclosure (including to any journal for review); provided that the review period shall be [**] days prior to presentation or disclosure for posters
and abstracts. If, during the applicable review period Editas notifies Beam that such publication or public disclosure contains the Confidential Information of Editas, Beam will remove any such Confidential Information prior to submission. For
clarity, Editas shall not have any right, and shall not grant to any other Person the right, to publish or publicly disclose any research results relating to a Licensed Product in the Field during the Term. 

6.4 Press Releases; Disclosure of Agreement. The Parties shall reasonably cooperate and mutually agree on an initial press release to be
made by Beam regarding the execution of this Agreement. Neither Party shall issue or cause the publication of any other press release or public announcement regarding the terms of this Agreement without the express prior approval of the other Party
other than as required by Law or the rules of any stock exchange, provided that if any such publication, press release or public announcement is required by Law, the Party obligated to make such publication, press release or public
announcement shall, if practicable, notify the other Party in advance thereof and reasonably consider any timely comments from such other Party, including any reasonable request to limit such publication, press release or public announcement. 

6.5 Use of Names. Neither Party shall use the name, symbol, trademark, trade name or logo of the other Party or its
Affiliates in any press release, publication or other form of public disclosure without the prior written consent of the other Party in each, except for those disclosures for which consent has already been obtained. In addition, Beam shall not, use
or 

  
 - 28 - 

 
register the name “The Broad Institute, Inc.,” “Wyss Institute for Biologically Inspired Engineering at Harvard University,” “President and Fellows of Harvard
College,” “Massachusetts Institute of Technology,” “The Rockefeller University,” “University of Tokyo,” “TODAI TLO, Ltd.,” “Wageningen University,” “Wageningen University &
Research,” “University of Iowa Research Foundation,” “University of Iowa,” “The General Hospital Corporation,” “Massachusetts General Hospital,” “MGH” or any variation, adaptation, or
abbreviation thereof (alone or as part of another name) or any logos, seals, insignia or other words, names, symbols or devices that identify such Persons or any of such Persons’ schools, units, divisions or affiliates or any trustee, director,
officer, staff member, employee, student or other agent of such Person (“Institution Names”) for any purpose except with the prior written approval of, and in accordance with restrictions required by, such Person. Without limiting
the foregoing, Beam shall cease all use of Institution Names as permitted under or in connection with this Agreement on the termination or expiration of this Agreement except as otherwise approved in writing by the applicable Institution or MIT, as
applicable. Beam shall not use or register the name “Howard Hughes Medical Institute” or any variation, adaptation, or abbreviation thereof (alone or as part of another name) or any logos, seals, insignia or other words, names, symbols or
devices that identify HHMI or any unit of HHMI (“HHMI Names”) or of any HHMI employee (including Dr. David Liu and Dr. Luciano Marraffini) in a manner that reasonably could constitute an endorsement of a
commercial product or service; but that use for other purposes, even if commercially motivated, is permitted provided that (1) the use is limited to accurately reporting factual events or occurrences, and (2) any reference to
an HHMI Name or any HHMI employees (including Dr. David Liu and Dr. Luciano Marraffini) in press releases or similar materials intended for public release is approved by HHMI in advance.  

6.6 Termination of Prior Agreement. This Agreement supersedes and replaces the Confidentiality Agreement by and between the Parties
dated as of June 28, 2017 (the “Existing Confidentiality Agreement”). All information exchanged between the Parties under the Existing Confidentiality Agreement shall be deemed Confidential Information of the respective
Disclosing Party hereunder and shall be subject to the terms of this ARTICLE 6. 
 6.7 Remedies. Each Party shall be entitled
to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of
this ARTICLE 6. 
 ARTICLE 7 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

7.1 Representations and Warranties of Both Parties. Each Party hereby represents and warrants to the other Party, as of the Effective
Date, that: 
 7.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its
incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 7.1.2 such
Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

  
 - 29 - 

 7.1.3 this Agreement has been duly executed and delivered on behalf of such Party, and
constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof; 
 7.1.4 the execution, delivery
and performance of this Agreement by such Party does not conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of
any court, governmental body or administrative or other agency having jurisdiction over such Party; and 
 7.1.5 no Governmental
Authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is
or will be necessary for, or in connection with, the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such
other agreements except as may be required to conduct clinical trials or to seek or obtain Regulatory Approvals. 
 7.2 Representations
and Warranties of Editas. Editas hereby represents and warrants to Beam, as of the Effective Date except in the case of Section 7.2.5 which is as of the date of Editas’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on or about May 4, 2018 (“Form 10-Q”), that, except as Editas has disclosed to Beam in Schedule
7.2 or the Form 10-Q: 
 7.2.1 Editas is the sole and exclusive owner of, or has Control via a
license from the Institutions to, the Subject Patents;  
 7.2.2 Editas has the right to grant all rights and licenses it purports to
grant to Beam under this Agreement; 
 7.2.3 Editas has not granted any right or license to any Third Party relating to any of the Subject
Patents that conflicts or interferes with any of the rights or licenses granted hereunder with respect to the Subject Patents; 
 7.2.4 To
its knowledge, the Subject Patents are valid and enforceable and Editas has complied (and, to its knowledge, the Institutions have complied) with all Laws and duties of candor with respect to the filing, prosecution and maintenance of the Subject
Patents. Editas has paid (with respect to Subject Patents for which it is responsible for prosecution and maintenance) and, to Editas’s knowledge, the Institutions have paid (with respect to Subject Patents for which Institutions are
responsible for prosecution and maintenance) all maintenance and annuity fees with respect to the Subject Patents due as of the Effective Date. Except as identified in Schedule 7.2, no action or proceeding regarding inventorship of a
Subject Patent has been brought or threatened in writing; 
 7.2.5 It has not received written notice of any claims, and there are no
judgments or settlements against or owed by Editas, or to the knowledge of Editas, any pending or threatened claims or litigation, in each case relating to the Subject Patents; and 

  
 - 30 - 

 7.2.6 Editas has provided to Beam true and correct partially-redacted copies of all
Institutional In-Licenses in their current form, which Institutional In-Licenses are in full force and effect; Editas is not in material breach and, to its knowledge,
none of the Institutions are in material breach of the Institutional In-Licenses, and Editas has not received any notice of breach of the Institutional In-Licenses. None
of the redactions made to the Institutional In-Licenses provided to Beam by Editas contain provisions that would be reasonably considered material to Beam’s assessment of the transaction underlying this
Agreement or the terms of this Agreement. 
 7.3 Additional Covenants. Editas agrees that, during the Term: 

7.3.1 Editas will, and will cause its Affiliates to, (i) not enter into or amend any agreement with any Third Party, including the
Institutions, which amendment or agreement materially adversely affects the rights granted to Beam hereunder or Editas’s ability to fully perform its obligations hereunder; and (ii) promptly furnish Beam with copies of all amendments to
the Institutional In-Licenses executed following the Effective Date that directly relate to (A) the rights granted to Beam under this Agreement and (B) the Field (which, in each case, Editas may
redact as necessary to protect confidential or commercially sensitive information); provided that, nothing in this Section 7.3.1 shall restrict Editas’s ability to amend, waive any right under or
terminate any Institutional In-License; and 
 7.3.2 Editas shall promptly notify Beam in the event
of the termination of any Institutional In-License and shall use Commercially Reasonable Efforts to assist Beam in obtaining a direct license from the applicable Institution if available pursuant to, and in
accordance with, the sublicense survival terms of such Institutional In-License. 
 7.4
Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE,
AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, except as otherwise expressly set forth in this Agreement, each Party
disclaims any warranties with regards to: (a) the safety or usefulness for any purpose of the technology or materials it provides or discovers under this Agreement; or (b) the validity, enforceability, or
non-infringement of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

ARTICLE 8 

INDEMNIFICATION; INSURANCE 

8.1 Indemnification by Beam. Beam shall indemnify, defend and hold harmless: 

8.1.1 Editas and its Affiliates, and its or their respective directors, officers, employees and agents, (each, an “Editas
Indemnitee”) from and against any and all liabilities, damages, losses, costs and expenses, including the reasonable fees of attorneys and other professional Third Parties (collectively, “Losses”), arising out of or
resulting from any and all Third Party suits, claims, actions, proceedings or demands (“Claims”) based upon: 
  

	 	a)	 the negligence, recklessness or wrongful intentional acts or omissions of any Beam or its Affiliates or its or
their respective directors, officers, employees and agents in connection with Beam’s performance of its obligations or exercise of its rights under this Agreement; 

  
 - 31 - 

	 	b)	 any breach of any representation or warranty or express covenant made by Beam under ARTICLE 7 or any
other provision under this Agreement; 

  

	 	c)	 failure by Beam to comply with any Law; or 

 

	 	d)	 any Development of a Licensed Product conducted by or on behalf of Beam, its Affiliates or sublicensees, and
the manufacture and Commercialization by Beam, its Affiliates, licensees or sublicensees of any Licensed Product, including (i) any product liability, personal injury, property damage or other damage and (ii) the infringement of any patent
or other intellectual property rights of any Third Party, in each case of clause (i) and (ii) resulting from any of the foregoing activities described in this Section 8.1.1(d), 

except, in each case of clauses (a) through (d) of this Section 8.1.1, to the extent any such Losses or Claims
result from (x) the gross negligence or willful misconduct of an Editas Indemnitee or (y) from the breach of any representation or warranty or obligation under this Agreement by Editas or (z) are subject to indemnification by Editas
under Section 8.2. 
 8.1.2 MGH and its Affiliates and their respective trustees, directors, officers, medical and
professional staff, employees and agents, and their respective successors, heirs and assigns (“MGH Indemnitees”) from and against any and all Losses, arising out of or resulting from any and all Actions (as defined in the 2016 MGH
Agreement) relating to (a) product liability concerning any Licensed Product made, used, sold or performed by Beam, its Affiliate or sublicensee pursuant to any right or license sublicensed by Editas to Beam under the 2014 MGH or 2016 MGH
Agreement, as applicable, or (b) the practice of any Patents and/or any right sublicensed by Editas to Beam under the 2014 MGH Agreement or 2016 MGH Agreement, as applicable, except, in each case of clause (a) and (b), to the extent such
Action results directly from the gross negligence or willful misconduct of an MGH Indemnitee. 
 8.1.3 To the extent that Patents licensed
under the Cas9-1 Agreement, Cas9-II Agreement or Cpf1 Agreement are Licensed Patents hereunder, HHMI, Harvard, Broad, MIT, UTokyo, Wageningen, Iowa, Rockefeller and each
of their current and former directors, governing board members, trustees, officers, faculty, affiliated investigators, medical and professional staff, employees, students and agents, and their respective successors, heirs and assigns
(“Institution Indemnitees”), as set forth in Section 9.1 of the Cas9-I Agreement, Section 9.1 of the Cas9-II Agreement and/or Section 9.1
of the Cpf1 Agreement, as applicable. 

  
 - 32 - 

 8.2 Indemnification by Editas. Editas shall indemnify, defend and hold harmless Beam
and its Affiliates, and its or their respective directors, officers, employees and agents (each, and “Beam Indemnitee”), from and against any and all Losses, arising out of or resulting from any and all Claims based upon: 

8.2.1 the negligence, recklessness or wrongful intentional acts or omissions of Editas or its Affiliates or its or their respective directors,
officers, employees and agents, in connection with Editas’s performance of its obligations or exercise of its rights under this Agreement; 

8.2.2 any breach of any representation or warranty or express covenant made by Editas under ARTICLE 7 or any other provision under this
Agreement; or 
 8.2.3 failure by Editas to comply with any Law, 

except, in each case of Sections 8.2.1, 8.2.2 or 8.2.3, to the extent any such Losses or Claims result from (x) the gross negligence
or willful misconduct of a Beam Indemnitee or (y) from the breach of any representation or warranty or obligation under this Agreement by Beam or (z) are subject to indemnification by Beam under Section 8.1. 

8.3 Procedure. A Person entitled to indemnification under this ARTICLE 8 (an “Indemnified Party”) shall give
prompt written notification to the Person from whom indemnification is sought (the “Indemnifying Party”) of the commencement of any action, suit or proceeding relating to a Third Party claim for which indemnification may be sought
or, if earlier, upon the assertion of any such claim by a Third Party (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Third Party claim as provided in this Section 8.3
shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of such failure to give notice). Within [**] days after
delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such action, suit, proceeding or claim with counsel reasonably satisfactory to the Indemnified Party.
If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense and, without limiting the Indemnifying Party’s indemnification obligations, the Indemnifying Party shall reimburse the
Indemnified Party for all costs and expenses, including attorney fees, reasonably incurred by the Indemnified Party in defending itself within [**] days after receipt of any invoice therefor from the Indemnified Party. The Party not controlling such
defense may participate therein at its own expense; provided that, if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and the
Indemnified Party have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the Indemnified Party in connection therewith.
The Party controlling such defense shall keep the other Party advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. The Indemnified
Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not agree
to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any
liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party without the prior written consent of the Indemnified Party. 

  
 - 33 - 

 8.4 Insurance. Beam shall maintain, at its cost, insurance against liability and
other risks associated with its activities and obligations under this Agreement, including its indemnification obligations hereunder, in such amounts, subject to such deductibles and on such terms as are customary for the activities to be conducted
by it under this Agreement and as are consistent with the requirements of the Institutional In-Licenses (to the extent the Patents licensed under such Institutional
In-License(s) are Licensed Patents hereunder). Beam shall furnish to Editas evidence of such insurance upon request and add any additional insured as may be contemplated by the Institutional In-Licenses. 
 8.5 LIMITATION OF LIABILITY. EXCEPT FOR A BREACH OF ARTICLE 6 OR FOR CLAIMS
OF A THIRD PARTY THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 8, NEITHER EDITAS NOR BEAM, NOR ANY OF THEIR RESPECTIVE AFFILIATES, LICENSEES OR SUBLICENSEES, WILL BE LIABLE TO THE OTHER PARTY TO THIS AGREEMENT, ITS AFFILIATES OR ANY OF
THEIR LICENSEES OR SUBLICENSEES FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR ROYALTIES, LOST DATA OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT
(INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR
DAMAGE. 
 ARTICLE 9 

TERM AND TERMINATION 
 9.1
Term. This Agreement is effective as of the Effective Date and shall continue in full force and effect unless earlier terminated by a Party in accordance with Section 9.2, 9.3, 9.4 or 9.5 and
shall expire on a Licensed Product-by-Licensed Product and country-by-country basis upon
the expiration of the Royalty Term with respect to such Licensed Product in such country. 
 9.2 Termination by Beam at Will. Beam
shall have the right, at its sole discretion, exercisable at any time during the Term, to terminate this Agreement [**], upon [**] days’ prior written notice to Editas. 

9.3 Termination for Material Breach. Either Party (the “Non-Breaching Party”)
may, without prejudice to any other remedies available to it under applicable Law or in equity, terminate this Agreement if the other Party (the “Breaching Party”) shall have materially breached or defaulted in the performance of
its obligations hereunder, and such default shall have continued for [**] days (or, in the case of a payment breach by Beam, [**] days) after written notice thereof was provided to the Breaching Party by the
Non-Breaching Party, such notice describing the alleged breach. Any such termination of this Agreement under this Section 9.3 shall become effective at the end of such [**]-day or [**]-day (as applicable) cure 

  
 - 34 - 

 
period, unless the Breaching Party has cured such breach or default prior to the expiration of such cure period, or if such breach is not susceptible to cure within such cure period even with the
use of Commercially Reasonable Efforts, the Non-Breaching Party’s right to termination [**]; provided that in no event shall such extension of the Breaching Party’s right to cure extend beyond
[**] days after the expiration of the original cure period. The right of either Party to terminate this Agreement as provided in this Section 9.3 shall not be affected in any way by such Party’s waiver or failure to
take action with respect to any previous default. 
 9.4 Termination for Patent Challenge by Beam. In the event of a Patent
Challenge by Beam or any of its Affiliates or sublicensees, then Editas shall be entitled to terminate this Agreement in its entirety immediately upon written notice to Beam. Notwithstanding the foregoing, if a sublicensee of Beam initiates a Patent
Challenge and the Institution licensor(s) of the Subject Patent(s) subject to such Patent Challenge has agreed or agrees that Beam, as Editas’s sublicensee under this Agreement, can terminate its sublicense with such sublicensee within a
certain period of time and thereafter not be subject to termination of this Agreement with respect to such Subject Patent(s) as a result of the relevant Patent Challenge, then Editas will not have the right to terminate this Agreement pursuant to
this Section 9.4 on account of a Patent Challenge by such Beam sublicensee if Beam terminates its sublicense with such sublicensee within such time period. For the avoidance of doubt, any participation by Beam, any of its
Affiliates or sublicensees or its or their employees in any claim, challenge or proceeding that Beam, such Affiliates or sublicensees or such employees are required to participate in pursuant to a subpoena or court order or participates in a
proceeding that is initiated by a patent office and not at the instigation of Beam, such Affiliates or sublicensees or such employees shall not constitute a Patent Challenge under this Section 9.4 and shall not give rise to
Editas’s right to terminate any license hereunder. 
 9.5 Bankruptcy. Either Party may terminate the Agreement if the other Party
makes a voluntary or involuntary general assignment of its assets for the benefit of creditors, a petition in bankruptcy is filed by or against the other Party and is not dismissed in [**] days, or a receiver or trustee is appointed for all or any
part of the other Party’s property. 
 9.6 Consequences of Termination. 

9.6.1 Accrued Obligations. Expiration or termination of this Agreement for any reason shall not release any Party of any obligation or
liability which, at the time of such expiration or termination, has already accrued or which is attributable to a period prior to such expiration or termination. 

9.6.2 Termination of Rights. 
  

	 	a)	 Upon termination of this Agreement in its entirety, all rights and licenses granted by Editas to Beam hereunder
(including the right to exercise Options and obtain such licenses) shall immediately terminate; provided that any sublicense by Beam under any sublicense or license granted by Editas to Beam under this Agreement will, at the
sublicensee’s written election delivered to Editas within [**] days of Beam being provided with written notice or having knowledge of such termination, and to the extent 

  
 - 35 - 

	 	
permitted under the Institutional In-Licenses, survive such termination on the condition that (i) the relevant sublicensee is not, at the time of such
termination, in material breach of any of its obligations under such sublicense and (ii) all amounts owed, as of the date of termination of this Agreement, by Beam to Editas or the Institutions hereunder have been paid in full. In order to
effect this provision, at the request of the sublicensee, Editas shall use Commercially Reasonable Efforts, in good faith, to enter into a direct license with the sublicensee on substantially the same terms as the sublicense to the extent such terms
relate to the sublicensed technology; provided that (1) the financial terms of such direct license will be the same terms as set forth in this Agreement with respect to the sublicensed technology (including with respect to Institutional In-License costs pursuant to Section 4.6), (2) the applicable sublicensee shall pay all amounts that, but for the termination of this Agreement, would have become payable by Beam or such sublicensee to
Editas or the Institutions pursuant to this Agreement prior to the date upon which Editas and such sublicensee enter into such direct license; provided that, in the event that more than one sublicense had been granted by Beam prior to
the date of such termination and more than one such sublicensee has elected to enter into a direct license with Editas pursuant to this Section 9.6.2(a), then the total amount payable to Editas pursuant to this clause (2) shall be
appropriately allocated among such sublicensees so that Editas does not receive from such sublicensees an aggregate amount that is more than the amount owed to it by Beam pursuant to this Agreement prior to such termination, (3) Editas will not
be required to undertake obligations in addition to those required by this Agreement and (4) Editas’s rights under such direct license will be consistent with its rights under this Agreement, taking into account the scope of the license
granted under such direct license, provided, further, that in no case shall Editas be required to negotiate with such sublicensee for a direct license for more than [**] days from the date of the sublicensee’s notice of its intent to
enter into a direct license. 

  

	 	b)	 Upon termination of this Agreement with respect to a Family of Patents under
Section 9.2, all Patents within such Family shall no longer be deemed Licensed Patents or Subject Patents hereunder as of the effective date of such partial termination, provided that any sublicense by Beam with
respect to such Family under any sublicense or license granted by Editas to Beam under this Agreement, at the sublicensee’s written election delivered to Editas within [**] days of Beam being provided with written notice or having such
knowledge of such termination, and to the extent permitted under the Institutional In-Licenses, survive such partial termination on the condition that (i) the relevant sublicensee is not, at the time of
such partial termination, in material breach of any of its obligations under such sublicense and (ii) all amounts owed with respect to such Family, as of the date of such partial termination, by Beam to Editas and/or the Institutions hereunder
have been paid in full. In order to effect this provision, at the 

  
 - 36 - 

	 	
request of the sublicensee, Editas shall use Commercially Reasonable Efforts, in good faith, to enter into a direct license with the sublicensee on substantially the same terms as the sublicense
to the extent such terms relate to the sublicensed technology; provided that (1) the financial terms of such direct license will be the same terms as set forth in this Agreement with respect to the sublicensed technology (including with
respect to Institutional In-License costs pursuant to Section 4.6), (2) the applicable sublicensee shall pay all amounts that, but for the partial termination of this Agreement, would
have become payable by Beam or such sublicensee with respect to the applicable Family to Editas or the Institutions pursuant to this Agreement prior to the date upon which Editas and such sublicensee enter into such direct license; provided
that, in the event that more than one sublicense had been granted by Beam prior to the date of such termination and more than one such sublicensee has elected to enter into a direct license with Editas pursuant to this
Section 9.6.2(b), then the total amount payable to Editas pursuant to this clause (2) shall be appropriately allocated among such sublicensees so that Editas does not receive from such sublicensees an aggregate amount
that is more than the amount owed to it by Beam pursuant to this Agreement prior to such termination, (3) Editas will not be required to undertake obligations in addition to those required by this Agreement, and (4) Editas’s rights
under such direct license will be consistent with its rights under this Agreement, taking into account the scope of the license granted under such direct license, provided, further, that in no case shall Editas be required to negotiate with
such sublicensee for a direct license for more than [**] days from the date of the sublicensee’s notice of its intent to enter into a direct license. 

9.7 Beam Option to Continue In Lieu of Termination. If Beam has the right to terminate this Agreement under
Section 9.3, but does not desire to exercise such right, Beam may elect to exercise its rights under this Section 9.7 in lieu of exercising its right to terminate the Agreement under
Section 9.3 by providing written notice of such election to Editas prior to the date that otherwise would have been the effective date of termination had Beam exercised its right under Section 9.3
to terminate this Agreement; provided that (a) Beam has provided notice to Editas asserting the alleged breach as required by Section 9.3, (b) Editas fails to cure such breach prior to the applicable cure
period and (c) Editas has not notified Beam that it (i) disputes that it is in material breach or (ii) contends that it cured such material breach within the applicable cure period. In the event of such an election, the Agreement
shall continue in full force and effect except that (x) the [**] percent ([**]%) royalty due under Section 4.7(a) with respect to Net Sales of a Licensed Product not Covered by an Editas-Owned Patent in addition
to the Institutional Royalty Rate shall be reduced from [**] percent ([**]%) to [**] percent ([**]%) of Net Sales and (y) the [**] percent ([**]%) or [**] percent ([**]%) royalty due under Section 4.7(b) with
respect to Net Sales of a Licensed Product Covered by an Editas-Owned Patent shall be reduced by [**] percent ([**]%) of the royalty otherwise due under Section 4.7(b). If Beam elects to exercise its rights
under this Section 9.7 in lieu of exercising its right to terminate the Agreement under Section 9.3, the remedy set forth in this Section 9.7 shall be Beam’s
sole and exclusive remedy and Editas’s sole and exclusive obligation with respect to any material breach giving rise to Beam’s right to terminate this Agreement under Section 9.3. For clarity, if Beam has the
right to terminate this Agreement under Section 9.3 and does not elect to exercise its rights under this Section 9.7, then, whether or not Beam terminates this Agreement, Beam may exercise any
other remedies available to it under this Agreement, at Law or in equity. 

  
 - 37 - 

 9.8 Non-Exclusive Remedy. Termination of this
Agreement by a Party shall be without prejudice to other remedies such Party may have at law or equity. 
 9.9 Survival. In addition
to this Section 9.9, the following provisions (including any definitions necessary for the interpretation thereof) shall survive expiration or termination of this Agreement and continue to be enforceable:
Section 4.2, Section 4.8 (solely with respect to accrued but unpaid amounts as of the effective date of termination and reports with respect thereto), Section 4.11 (solely
with respect to accrued but unpaid amounts as of the effective date of termination), Section 4.12, Section 9.6, Section 9.8, ARTICLE 6, ARTICLE 8 and
ARTICLE 10. 
 ARTICLE 10 

MISCELLANEOUS 
 10.1
Intended Third Party Beneficiaries. 
 10.1.1 Beam acknowledges and agrees that for so long as any Licensed Patents are licensed by
Editas from Institutions (as defined in the Cas9-I License, Cas9-II License or Cpf1 License, as applicable) or any of the Optioned Patents that are still subject to an
Option are licensed by Editas from the Institutions: 
 a) solely with respect to the
Cas9-I License, Harvard and Broad are intended third party beneficiaries of this Agreement for the purpose of enforcing all patent challenge, indemnification, and insurance provisions of this Agreement and
enforcing the right to terminate this Agreement for breach of the patent challenge, indemnification and insurance provisions of this Agreement; and HHMI, MIT and Rockefeller are intended third party beneficiaries of this Agreement for the purpose of
enforcing HHMI’s and MIT’s respective rights, including indemnification and insurance provisions, under the Cas9-I License; 

b) solely with respect to the Cas9-II License, Broad is an intended third party
beneficiary of this Agreement for the purpose of enforcing all patent challenge, indemnification, and insurance provisions of this Agreement and enforcing the right to terminate this Agreement for breach of the patent challenge, indemnification and
insurance provisions of this Agreement; and Broad, Harvard, MIT and Iowa are intended third party beneficiaries of this Agreement for the purpose of enforcing Broad’s, Harvard’s, MIT’s and Iowa’s respective rights, including
indemnification and insurance provisions, under the Cas9-II License; and 
 c) solely
with respect to the Cpf1 License, Broad is an intended third party beneficiary of this Agreement for the purpose of enforcing all patent challenge, indemnification, and insurance provisions of this Agreement and enforcing the right to terminate this
Agreement for breach of the patent challenge, indemnification and insurance provisions of this Agreement; and Broad, Harvard, MIT, UTokyo and Wageningen are intended third party beneficiaries of this Agreement for the purpose of enforcing
Broad’s, Harvard’s, MIT’s, UTokyo’s and Wageningen’s respective rights, including indemnification and insurance provisions, under the Cpf1 License. 

  
 - 38 - 

 10.1.2 Beam acknowledges and agrees that for so long as any Licensed Patents are licensed by
Editas from MGH or any of the Optioned Patents that are still subject to an Option are licensed by Editas from MGH, and solely with respect to the 2014 MGH Agreement and the 2016 MGH Agreement, MGH is an intended third party beneficiary of this
Agreement for the purpose of enforcing all patent challenge, indemnification, and insurance provisions of this Agreement. 
 10.2 Dispute
Resolution. If a dispute between the Parties arises under this Agreement, either Party shall have the right to refer such dispute in writing to the respective Executive Officers, and such Executive Officers shall attempt in good faith to resolve
such dispute. If the Parties are unable to resolve a given dispute pursuant to this Section 10.2 within [**] days after referring such dispute to the Executive Officers, either Party may have the given dispute settled by
binding arbitration pursuant to Section 10.3. 
 10.3 Arbitration Request. If a Party intends to begin an
arbitration to resolve a dispute arising under this Agreement, such Party shall provide written notice (the “Arbitration Request”) to the other Party of such intention and a statement of the issues for resolution. From the date of
the Arbitration Request and until such time as the dispute has become finally settled, the running of the time periods as to which Party must cure a breach of this Agreement becomes suspended as to any breach that is the subject matter of the
dispute. 
 10.3.1 Additional Issues. Within [**] days after the receipt of the Arbitration Request, the other Party may, by written
notice, add additional issues for resolution in a statement of counter-issues. 
 10.3.2 No Arbitration of Patent Issues. Any dispute,
controversy or claim under this Agreement relating to the scope, validity, enforceability or infringement of any Patent Covering the manufacture, use, importation, offer for sale or sale of Licensed Products shall be submitted to a court of
competent jurisdiction in the country in which such Patent was granted or arose. 
 10.3.3 Arbitration Procedure. Any arbitration
pursuant to this ARTICLE 10 will be held in Boston, MA, United States unless another location is mutually agreed by the Parties. The arbitration will be governed by the United States Arbitration Act, 9 U.S.C.
§§ 1-16, to the exclusion of any inconsistent state Law. The Parties shall mutually agree on the rules to govern discovery and the rules of evidence for the arbitration within [**] days after
the Arbitration Request. If the Parties fail to timely agree to such rules, the United States Federal Rules of Civil Procedure will govern discovery and the United States Federal Rules of Evidence will govern evidence for the arbitration. The
arbitration will be conducted by a single arbitrator knowledgeable in the subject matter at issue in the dispute and acceptable to both Parties; provided that, the Parties may by mutual agreement elect to have the arbitration conducted by a
panel of three (3) arbitrators. If the Parties fail to agree on a mutually acceptable arbitrator within [**] days after the Arbitration Request, then the arbitrator shall be selected by the Boston,

  
 - 39 - 

 
MA office of the AAA. The arbitrator may proceed to an award, notwithstanding the failure of either Party to participate in the proceedings. The arbitrator shall, within [**] days after the
conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The arbitrator shall be limited
in the scope of his or her authority to resolving only the specific matter which the Parties have referred to arbitration for resolution and shall not have authority to render any decision or award on any other issues. Subject to
Section 8.5, the arbitrator shall be authorized to award compensatory damages, but shall not be authorized to award punitive, special, consequential, or any other similar form of damages, or to reform, modify or materially
change this Agreement. The arbitrator also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief the arbitrator deems just and equitable and within the scope of this Agreement, including an injunction or
order for specific performance. The award of the arbitrator shall be the sole and exclusive remedy of the Parties, except for those remedies that are set forth in this Agreement or which apply to a Party by operation of the applicable provisions of
this Agreement, and the Parties hereby expressly agree to waive the right to appeal from the decisions of the arbitrator, and there shall be no appeal to any court or other authority (government or private) from the decision of the arbitrator.
Judgment on the award rendered by the arbitrator may be enforced in any court having competent jurisdiction thereof. 
 10.3.4 Costs.
Each Party shall bear its own attorneys’ fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrator; provided, however, that the arbitrator, in his or her
award, shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees
and expenses, transcripts, photocopy charges and travel expenses). 
 10.3.5 Preliminary Injunctions. Notwithstanding anything in this
Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the
award of the arbitrator on the ultimate merits of any dispute. 
 10.3.6 Confidentiality. All proceedings and decisions of the
arbitrator shall be deemed Confidential Information of each of the Parties, and shall be subject to ARTICLE 6. 
 10.4 Governing
Law. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the Laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles;
provided that with respect to matters involving the enforcement of intellectual property rights, the Laws of the applicable country shall apply. The provisions of the United Nations Convention on Contracts for the International Sale of Goods
shall not apply to this Agreement or any subject matter hereof. 

  
 - 40 - 

 10.5 Assignment. Neither Party may assign this Agreement without the consent of the
other Party, except as otherwise provided in Section 2.3.2 and this Section 10.5. Either Party may assign this Agreement in whole or in part to any Affiliate of such Party without the consent of
the other Party; provided that, such assigning Party provides the other Party with written notice of such assignment and the assignee agrees in writing to assume performance of all assigned obligations. Further, each Party may assign this
Agreement, and all of its rights and obligations, without the consent of the other Party to its successor in interest by way of merger, acquisition, or sale of all or substantially all of its business or assets to which this Agreement relates;
provided that, such assigning Party provides the other Party with written notice of such assignment and the assignee agrees in writing to assume performance of all assigned obligations. If any assignment of this Agreement by Beam (or one of
Beam’s Affiliates) to an Affiliate would result in withholding taxes that did not exist prior to such assignment (e.g., through a change in such assigning entity’s jurisdiction of incorporation or residence for tax purposes), then the
amount of any payment by such Affiliate hereunder shall be increased so that the net amount payable to Editas after the deduction of all incremental withholding taxes incurred as a result of such assignment equals the amount of the payment that
would otherwise have been payable but for such assignment. The terms of this Agreement shall be binding upon and shall inure to the benefit of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in
violation of this Section 10.5 shall be null and void. If a Party assigns this Agreement in whole or in part to an Affiliate or Third Party as permitted by this Section 10.5, (x) the assigning
Party shall thereafter remain liable for the performance by such assignee of all of such Party’s financial obligations hereunder and the other Party may enforce such financial obligations against the assigning Party without first seeking to
obtain performance from the assignee or exercising any other remedy or right that the enforcing Party may have and (y) the assigning Party shall thereafter remain liable for causing such assignee to perform all of the assigning Party’s non-financial obligations hereunder. 
 10.6 Performance Warranty. Each Party hereby acknowledges
and agrees that it shall be responsible for the full and timely performance as and when due under, and observance of all the covenants, terms, conditions and agreements set forth in this, Agreement by its Affiliate(s), licensees and sublicensees.

 10.7 Force Majeure. No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of
the Party so failing or delaying. For purposes of this Agreement, force majeure is defined as causes beyond the control of the Party, including acts of God; material changes in Law; war; civil commotion; destruction of production facilities or
materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or common carriers. In such event Editas or Beam, as the case may be, shall immediately notify the other Party of such inability
and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled
for up to a maximum of [**] days, after which time Editas and Beam shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by the Agreement. To the extent possible, each Party shall use reasonable
efforts to minimize the duration of any force majeure. 

  
 - 41 - 

 10.8 Notices. Any notice or request required or permitted to be given under or in
connection with this Agreement shall be deemed to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier
service (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: 
 If
to Editas, 
  

			
		
	 addressed to:
	  	Editas Medicine, Inc.
		  	11 Hurley Street
		  	Cambridge, MA 02141
		  	Attn: Chief Executive Officer
		  	Copy to: [**]
		  	Facsimile: [**]
		
	 with a copy to:
	  	Wilmer Cutler Pickering Hale and Dorr LLP
		  	60 State Street
		  	Boston, MA 02109
		  	Attention: Steven D. Barrett, Esq.
		  	E-mail: Steven.Barrett@wilmerhale.com
		  	Telephone: (617) 526-6000
		  	Facsimile: (617) 526-5000
	 If to Beam,
	  	
		
	 And prior to

October 1, 2018, addressed to:
	  	     
 Beam Therapeutics
Inc.

		  	325 Vassar St.
		  	Suite 2A
		  	Cambridge, MA 02139
		  	Attn: Chief Executive Officer
		  	E-mail: [**]
		
	 And following October
	  	
	 1, 2018, addressed to:
	  	Beam Therapeutics Inc.
		  	26 Landsdowne Street
		  	Cambridge, MA 02139
		  	Attn: Chief Executive Officer
		  	E-mail: [**]
		
	 with a copy to:
	  	Ropes & Gray LLP
		  	Prudential Tower
		  	800 Boylston Street
		  	Boston, MA 02199
		  	Telephone: (617) 951-7826
		  	Facsimile: (617) 235-0706
		  	E-mail: [**]

 or to such other address for such Party as it shall have specified by like notice to the other Parties, provided that
notices of a change of address shall be effective only upon receipt thereof. 

  
 - 42 - 

 
If delivered personally or by facsimile transmission, the date of delivery shall be deemed to be the date on which such notice or request was given. If sent by overnight express courier service,
the date of delivery shall be deemed to be the next business day after such notice or request was deposited with such service. If sent by certified mail, the date of delivery shall be deemed to be the third business day after such notice or request
was deposited with the U.S. Postal Service. 
 10.9 Export Clause. Each Party acknowledges that the Laws of the United States
restrict the export and re-export of commodities and technical data of United States origin. Each Party agrees that it will not export or re-export restricted
commodities or the technical data of the other Party in any form without the appropriate United States and foreign government licenses. 

10.10 Waiver. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of
either Party to assert a right hereunder or to insist upon compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party
of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term. 

10.11 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall
negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other
jurisdiction. 
 10.12 Entire Agreement. This Agreement, together with the Exhibits hereto and the Transaction Agreements, set forth
all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersede and terminate all prior agreements and understanding between the Parties. In particular, and without
limitation, this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date. There
are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to
this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

10.13 Independent Contractors. Nothing herein shall be construed to create any relationship of employer and employee, agent and
principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have the authority to bind
or obligate the other Party and neither Party shall represent that it has such authority. 

  
 - 43 - 

 10.14 Headings; Construction; Interpretation. Headings used herein are for
convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each
of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance
with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or
provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. 

10.15 Books and Records. Any books and records to be maintained under this Agreement by a Party or its Affiliates, licensees or
sublicensees shall be maintained in accordance with GAAP to the extent such books and records are subject to an audit right under this Agreement. 

10.16 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as may
be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 
 10.17 Parties
in Interest. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit of and be enforceable by the Parties hereto and their respective successors, heirs, administrators and permitted assigns. 

10.18 Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to
cause its Affiliates to perform such obligations. 
 10.19 Counterparts. This Agreement may be signed in counterparts, each and every
one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile signatures and
signatures transmitted via PDF shall be treated as original signatures. 
 [Signature page follows] 

  
 - 44 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representatives as of the dates set forth below. 
  

									
	 EDITAS MEDICINE, INC.
	  		  	 BEAM THERAPEUTICS INC.

					
	By:	 	 /s/ Andrew Hack
	  		  	By:	  	 /s/ John Evans

	Name:	 	Andrew Hack	  		  	Name:	  	John Evans
	Title:	 	Chief Financial Officer	  		  	Title:	  	Chief Financial Officer
					
	Date:	 	5/9/2018	  		  	Date:	  	5/9/2018

 [Signature Page to License Agreement] 

 Schedule 7.2 

[**] 

  
 A-1 

 Exhibit A 

[**] 

  
 A-2 

 Exhibit B 

Licensed Patents 
 [**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]